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CHAPTER 1-INTRODUCTION
1.1 Prostate cancer- a 2017 review
It is estimated by the Prostate Cancer Foundation that there are 3 million
American men currently living with prostate cancer (2). For the year 2017 it is
estimated that over 160,000 individuals will be newly diagnosed with prostate cancer
and there will be about 27,000 deaths associated with the disease (3). The prevalence
and risk of prostate cancer, increases with age and the average age of diagnosis is
about 66 years old (3). Despite decades of intensive efforts from researchers and
clinicians to combat this disease, it is still the most common type of cancer in men and
managing it remains a major challenge. Therefore, there is a pressing need for
identification of novel therapeutic targets and development of new drugs to treat
prostate cancer.
1.2 The normal prostate: structure and function
The human prostate is a glandular organ of the genitourinary system, located
below the bladder (4, 5). Each one of 30-50 exocrine glands of the prostate comprises
an epithelial bilayer of basal and luminal cells, supported by a fibromuscular stroma (6).
The prostate gland is thus made up of gland cells, muscle cells, and fibrous cells. The
prostate gland is part of both a man’s reproductive system and urinary system.
Testosterone is a master hormonal regulator of the prostate and plays a vital role in the
embryonic development of the prostate and male accessory organs (7). Testosterone is
also responsible for precisely regulating postnatal growth and maintenance of the adult
prostate (7). The main function of the prostate is to produce and secrete from the
glandular cells, an alkaline fluid which aids in protection, nourishment, and motility of
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sperm (8-10). The prostate surrounds the urethra and also has a role in regulating urine
flow and ejaculation, both which are controlled by muscle cells (11, 12). The urethra
runs from the bladder and directly through the prostate, this is the same path urine is
carried out of the penis (12). The fibrous cells are responsible for supporting the
structure of the gland (13).
The prostate gland is surrounded by several other structures that also play key
roles in the reproductive and urinary systems. They include (i) the seminal vesicles,
which are glands located on both sides of the prostate and produce semen (14), (ii) the
vas deferens, which are long muscular tubes that transport sperm to the urethra from
the testicles (15) and (iii) nerve bundles that aid in bladder control and erectile function
that surround the prostate (16).
1.2.1 Prostate zones
The prostate is made up of four zones: the peripheral zone, the transition zone,
the central zone, and the anterior zone (17) (Figure 1.1). The peripheral zone makes up
the majority of the prostate and is the area closest to the rectum that can be felt during a
digital rectal examination (DRE) (18). Prostate tumors are predominantly found in this
zone of the prostate(19). The transition zone is the area of the prostate that surrounds
the urethra as it passes through the gland (20, 21). As a man ages this area of the
prostate can enlarge and push the peripheral zone of the prostate towards the rectum
and also cause narrowing of the urethra, leading to a bladder outlet obstruction (22, 23).
This condition is known as benign prostatic hyperplasia or BPH. The central zone is
between the peripheral zone and the transition zone of the prostate and is located
furthest from the rectum. Therefore, tumors in this zone cannot be detected by DRE.
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Figure 1.1 Zones of the prostate gland. The prostate gland can be divided into
four zones: the anterior zone, transition zone, central zone, and peripheral zone
out of which most carcinomas arise. Reprinted from Molecular Aspects of
Medicine,
34/2-3,
M.C.Franz,P.
Anderle,M.
Bürzle,Y.
Suzuki,M.R.
Freeman,M.A.Hediger,G. Kovacs; Zinc transporters in prostate cancer:pages 735741. Copyright (2013) with permission from Elsevier.
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The anterior portion of the prostate consists of fibromuscular stroma (24).
1.2.2 Aspects of endocrine action, the androgen receptor and the prostate gland
Prostate development, function and maintenance are all regulated by the steroid
hormone androgen (25). The nuclear androgen receptor (AR) is the principal mediator
of androgen action. AR is a member of the nuclear receptor transcription factor
superfamily, categorized as a class I nuclear receptor, together with other steroid
hormone receptors (26-29). The AR gene is located on the X chromosome and has
eight exons that encode a 110kDa polypeptide (30, 31). The protein comprises four
major domains: the N-terminal (A/B) domain (amino acids 1-538), the DNA binding
domain (DBD, amino acids 539-628), the ligand binding domain (LBD, amino acids 671920) and the hinge region (amino acids 629-670) (32) (Figure 1.2).
The N-terminal domain is essential for the transactivation function of the receptor
(33). It is intrinsically disordered and presents a challenge in determining the solution
structure and for X-ray crystallography of this protein domain (34-36). This region
contains activation functional domain 1 (AF-1) with two functional entities - TAU-1
(residues 101 and 370 with a LKDIL core sequence) (37) and TAU-5 (residues 360 and
485 with a core sequence WHTLF) (38). TAU-1 has a critical role in ligand dependent
transcriptional activity whereas TAU-5 has constitutive (ligand-independent) activity (39,
40). Within the N-terminal domain there is also an FxxLP motif (residues 23-27) (39)
required for co-regulator binding and also for intermolecular interaction between N- and
C-terminal regions during ligand-induced dimerization (41). There are two zinc finger
regions within the DBD essential for dimerization and for binding to DNA at canonical
androgen responsive elements (ARE) within promoter and enhancer regions of target
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Figure 1.2 Androgen Receptor Functional domains. Schematic drawn
roughly to scale indicating the structural organization of AR, including the
positions of the major functional domains.
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genes (42). There is a second ligand-dependent activation function domain (AF-2) in the
LBD (residues 671-920) (43). This region also facilitates ligand-induced dimerization of
AR (43). Both endogenous androgens and synthetic androgen antagonists bind to the
LBD. A mutation in this region can result in androgen antagonists becoming agonists;
an example is the T877A mutation in AR in the hormone-sensitive cell line LNCaP cells
(44). In these cells the anti-androgen, bicalutamide activates transcription, rather than
antagonizing it. The hinge region plays a critical role in AR activity (44). It is a flexible
section on the receptor which contains a bipartite nuclear localization signal, RKLKKL
between amino acids 629-634 (45). This region also contributes to intranuclear mobility
of the receptor and is a target site for acetylation, ubiquitination, and methylation, which
all have contributing roles in transactivation of AR target genes (45).
AR is the principal mediator of androgen action and regulates genes to support
diverse physiological functions in various tissues (33, 46, 47). The classical mechanism
of transcriptional signaling of AR requires the presence of androgen (48). Testosterone
is the most abundant androgen in circulation and is produced in the testes.
Testosterone is converted to dihydrotestosterone (DHT) by the enzyme 5α reductase,
located at the nuclear membrane of the endoplasmic reticulum, and in prostate tissue
DHT is the primary agonist of AR (49, 50).The majority of testosterone is converted to
DHT in the stromal cells and then is transported into the epithelial cells (51-53). The
binding of DHT to AR induces a conformational change which releases the receptor
from a chaperone protein complex in the cytoplasm and also exposes the nuclear
localization signal within the receptor (54, 55). Ligand binding causes homodimerization
and phosphorylation of the receptor. This results in stabilization of AR and translocation
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of the receptor to the nucleus where it will bind to androgen-response elements (AREs)
associated with its target genes (56). The AR-homodimer then recruits co-regulator
proteins resulting in finely regulated transcription of target genes (57). The target genes
may have a variety of cellular functions in normal and malignant tissues as well as
expression of the prostate specific antigen (PSA), a well-known serum marker for
prostate cancer (58-60).
The androgen signaling axis is critical for prostate development, proliferation,
function, maintenance and oncogenesis.

AR is expressed in both the stromal and

epithelial cells of the prostate (61). The reciprocal relationship between these two cell
types is responsible for ductal morphogenesis and homeostasis of the prostate (13, 62,
63). The normal development and maintenance of the prostate epithelium depends on
paracrine signaling from the stromal cells through growth and survival factors known as
andromedins, in response to androgen signaling through AR (64-66) (Figure 1.3).
Secretions from the epithelial cells in turn signal to the stroma to maintain a supportive
environment (67) This allows for a homeostatic balance between paracrine growth
stimulation versus survival in adult prostate tissue. The development of prostate cancer
is underpinned by a breakdown of this reciprocal paracrine interaction between the
stromal and epithelial cells and an emergent autocrine mechanism within the epithelium
(64, 68, 69). In this situation the epithelial cells are no longer dependent on stromal
derived growth and survival factors but rather achieve proliferative functions due to selfstimulation. This mechanism paired with “gain of function” capability can lead to
oncogenesis of the prostate (64, 70, 71).
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Figure 1.3 Androgen receptor signaling in normal and malignant
prostate cells. (a) In normal prostate, growth and maintenance of prostate
epithelium depends on andromedins—growth (GF) and survival (SF) factors
produced by stromal cells (smooth muscle and fibroblasts). Andromedins are
produced as a result of androgen signaling through androgen receptor (AR).
Androgen signaling in prostate epithelium is required for production of
secretory proteins such as PSA and human kallikrein-2 (HK2). Basal
epithelial cells do not express AR. (b) During transformation to cancer, the
paracrine mechanism of AR action is replaced by an emergent autocrine
mechanism, whereby cancer cells are less dependent on stromal cell factors.
Androgens acting through AR can directly stimulate production of growth and
survival factors by cancer cells. (c) After hormone ablation therapy,
progression to hormone-refractory cancer occurs. The study of Chen et al.
supports a ligand-dependent, mass-action model resulting from elevated AR
expression. Elevated levels of AR sensitize cells to residual amounts of
androgen or, paradoxically, antiandrogens; cells become supersensitive to
androgen rather than independent of it. Reprinted by permission from
Macmillan Publishers Ltd: Nature Medicine,(Isaacs and Isaacs 2004)
copyright (2004)
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1.3 Prostate Disease
The precise regulation of the AR/androgen signaling axis enables maintenance
of the normal prostate. However the prostate is prone to entering disease states. There
are three major diseases that can develop in the prostate, prostatitis, BPH, and prostate
cancer.
1.3.1 Prostatitis
Prostatitis is an inflammatory disease that can cause swelling of the prostate
(72). The disease is quite common and affects about 50% of men during their lifetime
(73). The disease can be caused by common strains of bacteria and is effectively
treated with antibiotics; however the cause of infection is unknown in many cases. The
symptoms of prostatitis include difficulty in urination, and discomfort and pain in the
pelvic region. Prostatitis can be initially diagnosed using urine and blood samples that
indicate signs of infection (74). Treatments for the disease include alpha blockers that
can help relax the muscles surrounding the bladder and prostate, as well as
nonsteroidal anti-inflammatory drugs(75).
1.3.2 Benign Prostatic Hyperplasia
Benign prostatic hyperplasia or BPH is a non-malignant enlargement of the
prostate (76, 77). This condition generally occurs in older men (78). The cause of BPH
is poorly understood. Some research has indicated that as males age they produce
more dihydrotestosterone (DHT), because of an increased production of co-factors NAD
and NADH (79). The accumulation of DHT stimulates the prostate cells to grow (80, 81).
The majority of the hyperplastic cells are composed of the stroma cells while a minor
portion is composed of epithelial cells (82). It has been noted that men who do not
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produce DHT do not develop BPH (83). Since the prostate surrounds the urethra,
enlargement of the prostate from BPH can cause urine retention and lower urinary tract
symptoms. BPH is often diagnosed with a physical exam or a DRE and other medical
tests such as a urinalysis, prostate specific antigen (PSA) blood test, or a biopsy. Often
BPH is managed with alpha blockers which prevent the stimulation of adrenergic
receptors that mediate prostate muscle contraction (84). This use of such molecules
therefore relaxes the muscles and helps to improve urine flow and reduce bladder
blockage (85). Medications like 5-α reductase inhibitors are also used to inhibit the
production of DHT (86, 87).
1.3.3 Prostate Cancer
Prostate cancer is the most common cancer in American men. Prostate
carcinomas occur when there is a disruption of epithelial differentiation of luminal cells
within the gland and dysregulation of autocrine and/or paracrine mechanisms of growth
control (88). Almost all prostate cancers are adenocarcinomas meaning that these
cancers develop from glandular cells of the prostate. Certain conditions of the prostate
have been recognized as a precancerous state. They include prostatic intraepithelial
neoplasia (PIN) and atypical small acinar proliferation (ASAP) (89). These two types of
lesions are restricted to the acini and ducts and the cells show a range of atypical
morphologies (90, 91). PIN and ASAP may be identified in a biopsy of the prostate. In
prostate cancer the abnormal cells disrupt the basal cell membrane and spread beyond
these boundaries. PIN lesions are commonly found in the peripheral zone of the
prostate and high-grade PIN have more pronounced abnormalities compared to lowgrade PIN that are only slightly different compared to normal cells (92). Many studies
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have shown that there is a strong correlation between the occurrence of high-grade PIN
lesions and the diagnosis of prostate cancer (93).
The prostate gland synthesizes and secretes many unique proteins into the
seminal fluid. Among them, prostatic acid phosphatase (PAP), prostate-specific antigen
(PSA), and beta-microseminopreotien (beta-MSP) are predominant and are secreted by
both normal and malignant prostate cells (94). PSA is a serine protease capable of
cleaving peptide bonds and is responsible for regulating the liquefaction of semen (95).
Serum PSA has historically been measured as an early detection method for prostate
cancer but more recent studies have questioned its value in routine screening (96, 97).
Nevertheless, the PSA test is very useful in monitoring treatment response in patients
who have undergone surgical or chemical castration or who have been treated with
systemic therapy for prostate cancer.
As mentioned earlier, androgens are the physiological ligands required for the
transcriptional activity of AR. The AR/androgen signaling axis is necessary for
the initial growth and development of the prostate and in the differentiated
prostate this axis is required for maintenance of the differentiated state and for
the secretory function of the prostate. In the normal differentiated prostate, the
AR/androgen axis regulates both apoptosis and renewal of epithelial cells. In
prostate cancer, cellular changes affecting this signaling pathway apparently
cause the proliferative function of AR to become dominant with a simultaneous
disruption of its differentiation program. As prostate oncogenesis typically relies
on AR/androgen signaling, a major clinical approach to treating the disease is to
target this axis.
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1.4 Prostate cancer- diagnosis
In early stage prostate cancer, patients do not often experience clinical symptoms.
The cancer may be found during routine screening by DRE or by detecting elevated
serum PSA (98). The PSA test is used for early detection of a tumor and to monitor the
patient’s response to therapy throughout the course of their disease. It is generally well
accepted that PSA levels below 4ng/mL are considered to be “normal” whereas levels
over 10ng/mL are considered to be “high”; a PSA level between 4 and 10ng/mL can be
considered to be “abnormal” (98). If the PSA level is higher than “normal” most likely
the physician will repeat the test and follow up with confirmative tests including
transrectal ultrasound imaging and a biopsy (98). Proteins such as PAP are not used
for early detection but as biomarkers that provide information on response to therapy
and progression of tumors if they have spread (99).
1.4.1 Prostate Cancer Grading
When there is a definite cancer diagnosis the tumor grade is defined by the
Gleason score, which is based on histological evaluation of the tissue biopsy. This is a
system of composite grading that ranges in value from 2 to 10. A low grade cancer
grows slowly and has a lower tendency to spread. The higher scores indicate relatively
poor differentiation and a more aggressive cancer.
1.4.2 Prostate Cancer Staging
Staging of the cancer describes the location of tumor lesions and extent of spread.
Prostate cancer is staged using a system known as TNM staging (100, 101). The ‘T’
indicates how large the primary tumor is. The ‘N’ indicates whether the tumor is present
in the lymph nodes, the location of the infiltrated lymph nodes and the number
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infiltrated. The ‘M’ indicates the nature and extent of distal metastasis. The stage of the
cancer, evaluated by combining these three different parameters, enables an
appropriate treatment plan (102). The stages range from Stage I to Stage IV. In Stage I
the tumor is slow growing and confined within the prostate gland (103). In Stage II the
tumor is growing at a faster rate but is still confined. If a patient has been diagnosed
with Stage III prostate cancer, the cells would have invaded outside of the prostate into
proximal tissues (103). Stage IV is the most aggressive type of cancer and describes a
tumor that has spread from the primary site; these new locations could include distant
lymph nodes, the bladder, bone, liver, lungs, etc. (103). Recurrent prostate cancer is
also categorized as Stage IV. Thus there are many factors that contribute to a
patient’s prognosis of prostate cancer that help to guide treatment decisions.
1.5 Prostate cancer treatment
Following diagnosis of localized prostate cancer most patients have several
treatment options. The first line therapies comprise ablation of the prostate (104). This
may be accomplished by radical prostatectomy where the entire prostate gland and
some surrounding tissues including the seminal vesicles are surgically removed,
external beam radiation, internal beam radiation (brachytherapy) and cryotherapy or the
freezing of the prostate tumor (105, 106). These initial treatments could leave the
patient with many undesirable genitourinary side effects including irritation and urinary
retention (107). Moreover, prostate cancer may recur despite these treatments (108110).
1.5.1 Androgen deprivation therapy and anti-androgen therapy
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Advanced prostate cancer refers to local as well as systemic recurrence following
first line therapy. Advanced disease is commonly treated with androgen deprivation
therapy (ADT) by surgical castration or by chemical castration through the use of
luteinizing hormone-releasing hormone (LHRH) agonists (110). The goal of ADT is to
reduce the level of androgens in the body to prevent them from stimulating tumor
growth. These powerful treatments can leave the patient with both acute and chronic
side effects including fatigue, hot flashes, anemia, osteoporosis, changes in muscle and
fat mass, sexual dysfunction, and cognitive defects (107, 111, 112). Response to ADT
is generally temporary, with a median time to recurrence of 18-24 months (113).
Antagonists of AR or anti-androgens are taken orally every day and may also be
included with LHRH agonists as first-line hormone therapy. These are drug molecules
that bind to the ligand binding domain of AR, competing with androgen for binding to AR
and interfering with the transcriptional activity of AR(114). Examples of anti-androgens
currently used in the clinic are Flutamide (Eulexin), Bicalutamide (Casodex), and
Nilutamide (Nilandron) (115-117).
Despite an initial favorable tumor response to testosterone suppression by
means of ADT and the use of antiandrogens, prostate cancer frequently recurs by
progressing to an apparently hormone refractory state. At this stage the
advanced metastatic disease is referred to as castration resistant prostate cancer
(CRPC).
1.5.2 Available Treatments for CRPC
It is unclear exactly how prostate cancer progresses to CRPC, although it is believed
that ADT selects for cells that are able to grow and re-populate the tumor in the
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absence of hormone or cells that are capable of synthesizing and restoring androgen
intratumorally(118-120). CRPC is typically treated with docetaxel, an anti-mitotic
chemotherapy, usually with prednisone, a synthetic corticosteroid drug (107, 118).
However, at this point the disease is typically non-curative. Relatively new therapies
have been developed which include cabazitaxel, a chemotherapeutic agent targeting
microtubules (121) and alpharadin, which is used to treat metastatic bone cancer by
relying on alpha radiation to kill the cancer cells (122). Abiraterone acetate, an oral
androgen biosynthesis inhibitor which targets the androgen synthesis enzyme, CYP17
(123) extends the median survival to 14.8 months from 10.8 months. Enzalutamide,
which is a high affinity AR antagonist that prevents nuclear localization and
transcriptional activity of AR, extends median overall survival of CRPC patients by 5
months (124). Immunotherapies have also been FDA approved. These include
denosumab, an antibody against RANKL (125) used as a treatment to increase bone
mass in metastatic prostate cancer and also a vaccine called sipuleucel-T (126) for
metastatic CRPC.
All of the current treatments for CRPC offer limited benefit in terms of
extending median survival.
1.6 Other Major Limitations of Testosterone Suppression in Prostate Cancer –
Effects on Normal Tissues
It is evident from the discussion above that targeting the AR signaling axis has
proved to be the most effective form of treating advanced prostate cancer. However, the
conventional approaches in this treatment are severely limited due to the relatively
frequent and rapid development of drug resistance. Moreover, testosterone suppression
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has a number of acute and chronic adverse side effects due to its effect on normal
tissues, as discussed below.
1.6.1 Hot Flashes
Hot flashes are often described by patients as intense warmth and flushness of
the skin and are one of the most common acute symptoms of ADT (127). They occur
when the thermoregulatory centers in the hypothalamus are stimulated unnecessarily
(128). This results in peripheral vasodilation and inapt heating throughout the patient’s
face and neck which can last from a few seconds to several minutes (129). This is the
result of withdrawal of androgen leading to disruption of the equilibrium of
neurotransmitters. This mechanism can also lead to the feeling of anxiousness. It is
thought that selective serotonin reuptake inhibitors (SSRIs) can increase serotonin
within these centers to alleviate the intense warmth and perspiration the patient
experiences due to dysregulation of neurotransmitters within the thermoregulatory
centers (130-132).
1.6.2 Hyperlipidemia
It is well known that sex hormones such as testosterone can influence the serum
lipid profiles. Investigation in men with low testosterone levels from ADT has identified
elevated levels of total cholesterol, low-density lipoprotein, and triglycerides (133, 134).
Increasing duration of therapy has a positive correlation with further elevation of these
lipids in the serum (135). Alteration of the lipid profile due to low testosterone levels can
contribute to heart disease in prostate cancer patients (135, 136). To help manage this
severe adverse effect, patients may adjust their nutrition plan to a low-cholesterol diet,
or increase their physical activity to a manageable level without inducing intolerable
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fatigue. In addition, statin based medications may be used to control cholesterol levels
(137, 138).
1.6.3 Sexual Dysfunction
Testosterone is the major regulator for sexual function in males and therefore
one of the major adverse effects of ADT is erectile dysfunction and loss of libido (139).
This can also negatively impact quality of life. Testosterone is required to facilitate
erection by acting as a vasodilator in the penis (140). Testosterone contributes to
activation of nitric oxide synthase, which in turn activates a series of other enzymes
and results in dilation of the blood vessels of the vascular beds within the penis leading
to erection (141, 142). Therefore decreasing testosterone levels by ADT contributes to
erectile dysfunction. ADT can drop testosterone levels to below 100ng/mL (143); it is
believed that a minimum value of about 250ng/mL is needed for healthy erectile
function. Another contributing factor to erectile dysfunction from ADT is the replacement
of the muscle cells within the penis by fat tissue, leading to flaccidity (144). As a result
collagen protein deposits arise and cause venous leakage (145). It has been reported
that libido and sexual activity can improve when ADT is stopped and normal
testosterone levels are restored (146, 147). Contributing factors to sexual dysfunction
include the patient’s age, duration of hormone depletion therapy and overall health (148,
149).
1.6.4 Anemia
Androgens have an important role in the hematopoietic system. Androgens
regulate the production of red blood cells. Androgen induces the renal production of the
protein erythropoietin, which promotes the formation of red blood cells by the bone
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marrow and incorporates iron into these cells (150). The production of erythrogenesisstimulating proteins can be induced specifically by testosterone (151, 152). Patients
undergoing ADT experience a decline in hemoglobin levels and develop anemia as an
indirect effect of inhibition of erythropoiesis (153). Symptoms include fatigue, loss of
energy, dizziness, and difficulty in concentration (154). ADT-related anemia can be
temporary and correlates with the duration of the treatment.
1.6.5 Skeletal Complications
Bone fractures, osteoporosis, bone pain, and bone metastases are all associated
with men ADT (155-158). Androgens have a major role in skeletal homeostasis
throughout life (159). The difference in the size of a male’s skeleton and greater muscle
mass compared to that of a woman can be explained in part by the increase levels of
androgens in males (160). The androgen receptor is expressed in both osteoclasts
(161) and osteoblasts (162), which are the cells that facilitate bone turnover and
remodeling. Androgens stimulate osteoblast differentiation and decrease apoptosis of
osteoblasts and osteoclasts (163). Androgens also regulate growth factors and
cytokines to indirectly stimulate bone formation and downregulate factors involved in
osteoclastogenesis (164). Because androgens are essential for bone turnover and
development, several skeletal complications result from ADT. It is estimated that there
is a six-fold increase in the rate of bone fracture in men undergoing ADT as well as a
greater risk for development of osteoporosis (165-167). Both of these conditions are
due to the bones becoming brittle and fragile as a result of withdrawal of androgens.
Bone metastasis of prostate cancer also interferes with normal maintenance of the
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healthy bone and strength of the bone, again leading to increase fracture rate and bone
pain.
There are several lifestyle modifications, such as light exercise and calcium
supplementation, to help manage skeletal complications due to ADT. In recent past
years there has been much focus on supplemental therapies for patients experiencing
skeletal-related events. Bisphosphonates such as zoledronic acid are the most
commonly prescribed drug for osteoporosis as they induce osteoclasts to undergo
apoptosis (168). Inhibition of osteoclast activity can help improve bone mineral density;
this slows bone loss and reduces fracture and bone pain. Denosumab is a human
monoclonal antibody which is a receptor activator for nuclear factor kB ligand (RANKL)
inhibitor (169). RANKL is expressed on osteoclasts and is the key mediator for bone
destruction (170). Densoumab neutralizes this activity to increase bone mineral density
and reduce bone brittleness and fracture (171). Densoumab has also been shown to be
effective in delaying bone metastasis and increased bone metastasis-free survival in
men with non-metastatic advanced prostate cancer (125).
1.6.6 Effects on the cardiovascular system
ADT has been linked to major adverse effects related to cardiovascular disease
(172-174). These effects can go unnoticed but can be fatal. Heart attacks, strokes, and
peripheral vascular disease together can be categorized as cardiovascular disease.
ADT can cause these cardiovascular events by causing metabolic changes. These
changes can include an increase in high density lipoprotein cholesterol, development of
hyperglycemia and obesity (136, 175, 176). These conditions are all risk factors that
contribute to the progression of atherosclerosis, which leads to cardiovascular disease
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(136). Androgens have also been shown to inhibit local inflammatory responses that
contribute to atherosclerotic plaque development. The positive effects of androgens
allow for normal blood flow and therefore have a role in promoting cardiovascular health
(177). Due to the high risk of development of cardiovascular disease in patients on ADT,
careful monitoring of the patient’s overall health is essential. Precautions and certain
alterations to the patient’s lifestyle such as reducing caloric intake and increasing
physical activity can contribute to lowering the risk of cardiovascular complications as a
result of ADT.
1.6.7 Cognitive and Psychological Impairment
AR is endogenously expressed throughout the brain including the hippocampus,
parietal lobe, and prefrontal cortex (178-180). These areas are critical for cognitive
functions and memory (181). Processes involved in how people think, perceive, and
remember can all be categorized as cognitive functions. Patients receiving ADT have
reported memory problems while on therapy and cognitive side effects are almost
immediate after initiation of treatment (182). Evidence from neuropathological studies
has shown an association with low levels of testosterone in older men with depression
(183). These symptoms have been shown to decrease with the use of testosterone
replacement therapy. Depression is commonly reported in men with prostate cancer
(184, 185). Depression reported by these patients is often linked with anxiety and is
exacerbated by ADT(186).
As discussed above, adverse effects associated with ADT are both acute
(fatigue, hot flashes, flares) and long-term (hyperlipidemia, cardiovascular
disease, anemia, osteoporosis, sexual dysfunction and cognitive defects) and
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include loss of the feeling of well-being (107, 111, 112). Although these effects are
somewhat mitigated by routine monitoring, medications and changes in diet and
lifestyle, the side effects of ADT remain a major challenge in the treatment of
advanced prostate cancer.
1.7 Mechanisms of restoration of AR signaling in CRPC
It is clear from the cumulative pre-clinical and clinical evidence that the
progression of prostate cancer is reliant on the AR/androgen signaling axis. Hormonedeprivation therapy has proven effective in patients; however a major limitation is that
the cancer progresses to CRPC. An interesting aspect of CRPC is that the cancers
typically remain dependent on AR for growth stimulation. Treatment-naive prostate
cancer is typically dependent on androgen for growth and is therefore sensitive to ADT
and anti-androgen drugs; however as the cancer progresses further, it still remains
dependent on AR for growth but acts independent of androgen or could thrive on
androgen produced within the tumor. Therefore these advanced cancers are insensitive
to ADT and anti-androgen drugs. Although it is difficult to elucidate the precise
molecular mechanisms underlying clinical cases of CRPC, evidence based
studies of in vitro and in vivo models, clinical response to newer drugs as well as
well substantiated theoretical notions have indicated several possible molecular
and cellular mechanisms driving CRPC. Notably, almost all of these mechanisms
restore functional AR signaling.
1.7.1 Intratumoral Androgen Synthesis
One adaptive response to ADT that restores AR signaling is the synthesis of
intratumoral androgens from different androgen precursors such as cholesterol and
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adrenal dehydroepiandrosterone (DHEA) (187). It has been reported that there is a
correlation between the expression of cholesterol and the increase in the expression of
an enzyme required for de novo androgen synthesis, CYP17A, in CRPC tumor tissue
(137). Tumors may thus produce testostosterone or DHT through the classical or a
“backdoor” androgen biosynthesis pathway at levels thought to be sufficient to support
progression of the disease (188). However, enzyme inhibitors to circumvent restoration
of testosterone have only shown modest clinical benefit (189).
1.7.2 Overexpression of AR
One way in which prostate cancer can overcome the ability to grow in castrate
levels of androgen is through the overexpression of AR (190). In these cells that
overexpress the receptor, sensitivity to androgen or to hormone-independent
autocrine/paracrine signaling may be enhanced (191). The overexpression of AR could
be the result of selective pressure of the androgen depleted environment, causing the
cells which express more AR to flourish (192).
1.7.3 Imbalance of AR co-regulator expression
The androgen/AR signaling axis is directed and finely regulated by many protein
factors. Once AR is bound to the DNA, the composition of proteins that are co-recruited
to that site determine if transcriptional activity will occur (193). These proteins are
known as coregulators of AR and they could be either coactivators or corepressors
(194). Coactivators are preferentially recruited by agonist-bound AR (195). Coactivators
enhance transcription, through various mechanisms that either directly modulate the
pre-initiation complex or do so indirectly through chromatin remodeling (193, 196).
Corepressors are preferentially recruited by antagonist-bound AR and act through
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similar mechanisms to repress transcription (197). Therefore the cellular complement of
coactivators and corepressors can determine the biological response and functional
activity of AR (198, 199). It has been shown that CRPC could be supported by an
imbalance of AR co-regulator expression. In these situations there is a higher
expression of coactivators in relation to corepressors(200). This disproportionality in the
coregulator complement could enable AR to be activated by lower levels of androgen or
even by anti-androgens (57, 201).
1.7.4 Dysregulation of growth factors and crosstalk with other signaling pathways
AR may support growth through activation of the receptor by crosstalk with other
pathways resulting in the activation of the androgen receptor by ligand independent
mechanisms. The dysregulation of growth factors in prostate cancer such as insulin-like
growth factor and cytokine IL-6 contributes to an increase in the activation of MAPK
pathways, PI3K/AKT pathways, and the PKC pathway (37, 202-204). This leads to
direct phosphorylation of AR (205). Therefore the deregulation of multiple growth factors
and the crosstalk between the nuclear receptor pathway and these MAPK signaling
pathways can contribute to the development of androgen independent prostate cancer.
1.7.5 Mutations in AR and Splice Variants of AR
Increases in somatic mutations within AR have been reported in advanced
prostate cancer samples (206, 207). As a result of these gain-of-function mutations, the
malignant cells acquire a proliferative advantage. For example, the widely used
hormone-sensitive prostate cancer cell line, LNCaP cells, contain a missense mutation
at amino acid 877, converting the amino acid from threonine to alanine within the ligand
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binding domain of the receptor(44). This mutation permits anti-androgens to bind as
agonists and confers a growth-gain-of-function for the receptor (44).
More recent studies have established a role of the AR splice variants (AR-V) in
acquired resistance to hormonal therapies in prostate cancer. AR splice variants are
alternatively spliced variants of the androgen receptor and more than twenty different
splice variants of AR have been identified (208). Almost all of the splice variants that
have been identified have carboxyl-terminal truncations that eliminate the ligand binding
domain of the receptor (208). The AR splice variants retain their amino-terminal domain
which harbors two transactivation domains Tau-1 and Tau-5 which confer constitutive
activity (209). This is significant because it allows for the activation of AR signaling in
the absence of hormone ligand. Therefore ADT and antiandrogens, which both target
the ligand binding domain of native AR are ineffective against AR-V expressing tumors
(210-212). AR-V7 and ARv567es are the most common and abundant AR variants found
in clinical prostate tumors (213-215). Studies have shown that the expression of AR-V7
and ARv567es correlates with disease progression to CRPC and are the most commonly
found splice variants associated with tumor metastasis and decrease in patient survival
(216, 217).
The binding of agonist is an essential event in the classical (ARE-mediated)
mode of target gene activation by AR. Full length AR requires ligand binding to initiate
homodimerization (33). In the process of dimerization, intramolecular interaction
between the carboxyl- and amino-terminal regions of AR leads to a D-box-dimerization
transition(218). The homodimer can then directly bind to ARE enriched DNA sequences
and activate target gene transcription. It has been shown by studying D-box-D-box
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interactions that dimerization of AR-V7 also must occur to transactivate target genes
(219). Deletions or mutations in the D-box prevent dimerization in both the full length
receptor and AR-V7 resulting in loss of their ability to activate target genes. This results
in loss of their ability to support CRPC cell growth. Therefore it has been proposed that
targeting the D-box interface might be an effective therapeutic approach to treating ARV7 dependent tumors (219).
An important question is whether the splice variants of AR can activate the
same set of canonical target genes as the full length receptor (AR-FL). It has been
shown in several studies that AR-Vs localize to the nucleus in the absence of ligand to
activate target genes. The AR-Vs can also facilitate AR-FL to localize in the nucleus in
the absence of androgen (220, 221). When co-expressed, AR-V7 and AR-FL co-localize
at the canonical ARE enhancer in the PSA gene promoter. Interestingly, in contrast to
full length AR alone, co-occupancy of the full length and variant forms of AR at this site
is not enhanced or diminished in the presence of androgen or in the presence of the
potent anti-androgen, enzalutamide (220). Ubiquitin-conjugating enzyme E2C (UBE2C)
is as an AR-V specific target gene; the promoter of this gene can only be occupied by
an AR-V7 homodimer or by an AR-V7/ ARv567es heterodimer but not by AR-FL (213,
215, 220). This indicates that most likely, there is a separate subset of direct target
genes that are activated by AR-Vs alone. There is cumulative evidence to support the
idea that there is a set of genes that are upregulated by AR-Vs alone and that they
comprise genes that support CRPC cell growth (219, 222-224).
Following castration, the molecular changes in the tumor AR signaling axis
discussed above overcome or minimize the need for systemic androgen to
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activate AR. In these situations the tumors may themselves synthesize androgen
to near pre-castration levels but, more often, AR is localized in the nucleus in the
absence of androgen or in the presence of extremely low levels of androgen.
Future

studies

may

reveal

additional

mechanisms

contributing

to

the

development of CRPC. Presumably, even within a tumor, several mechanisms
contribute to the ability of AR to activate transcriptional growth in the absence of
hormone because of the heterogeneity of this type of cancer. Several newer
approaches have attempted to disrupt ligand-independent activity of AR in
prostate cancer.
1.8 Targeting the amino-terminal domain of AR
Despite the more recent development of enzalutamide and abiraterone acetate to
treat CRPC, tumor escape and resistant mechanisms that restore AR signaling, as
mentioned above, still remain a major challenge for treatment of the disease. Although
there is a modest benefit and a gain in median overall survival of less than 6 months
with these current agents for the treatment of CRPC, the majority of CRPC cases will
develop resistance and the therapy will essentially become ineffective. As with all other
current therapies, the functional action of these molecules targets the carboxyl ligand
binding domain of AR. However, it is the amino-terminal domain of AR which harbors
the region that drives constitutive hormone-independent transcriptional activity of AR or
its splice variants in CRPC. It has been shown that deletions within this region of the
receptor result in a transcriptionally inactive protein (40). Because the N-terminal
domain of the receptor has not been crystallized due to the intrinsically disordered
nature of the protein, it has made it difficult to develop targetable therapies to this
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region by means of structure-based design. Despite these challenges, efforts have
been made to use high-throughput screening methods to discover drug candidates that
block recruitment of coactivators to the N-terminal domain. An advantage of such drugs
is their expected ability to inactivate AR splice variants that pose a major problem in
prostate cancer progression. Notable developments in studies of small molecules
targeting interactions of the N-terminal domain of AR as well as very early conceptual
studies of cell penetrating antibodies with similar effects are discussed below.
1.8.1 Bromodomain inhibitors
As mentioned earlier, the transcriptional activity of AR is precisely regulated by a
complex network of proteins and epigenetic mechanisms that enable its entry into the
nuclear compartment and localization to the chromatin. Therefore these mediators of
transcription propose an alternative strategy for disrupting AR signaling in CRPC
patients. Bromodomain and Extra-terminal motif (BET) proteins have a wide variety of
functions in regulating transcription including histone acetyltransferase activity,
chromatin remodeling and recruitment of co-regulators (225). BRD4 is a conserved BET
family member that associates with acetylated chromatin and has a critical role in
recruitment of the positive transcription elongation factor, P-TEFb, which in turn
enhances the activity of RNA polymerase II by stimulating phosphorylation of its
carboxyl-terminal domain (226-228). It was shown using co-immunoprecipitation studies
that BRD4 directly interacts through its two conserved bromodomains, BD1 and BD2,
with the N-terminal domain of AR to facilitate transcriptional activity (229). Inhibition of
BRD4 decreases recruitment of full length AR and splice variants of AR to target loci in
the chromatin to an extent that is comparable to the effect of enzalutamide on full length
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AR (229). BRD4 inhibition is selective for AR-positive prostate cancer cell lines in
promoting the induction of apoptosis and cell cycle arrest. Blockade of BRD4 in vivo
resulted in inhibition of CRPC tumor growth (229). An interesting study that was done in
parallel with the tumor xenograft models was observing the effect bromodomain
inhibition of BRD4 had on metastasis. This was of interest because other studies have
described enzalutamide to have a pro-metastatic effect in pre-clinical models (230) .
There was evidence of metastases in the femur and liver of enzalutamide treated VCaP
tumor-bearing mice in contrast to no evidence of metastasis in mice bearing the same
tumors treated with BRD4 inhibitors(229). By functioning downstream in the AR
signaling pathway, BET inhibitors are likely to circumvent resistance mechanisms that
restore functional AR. There are at least four compounds currently being

studied

as

BRD4 inhibitors. One of them, JQ1, is still in preclinical evaluation (231-233). BRD4
inhibitors currently in Phase 1 clinical trials are GSK525762 (NCT01587703), GS5829(NCT0207228), and OTX015 (NCT02259114).
1.8.2 EPI family small molecules
The EPI family of small molecules compounds was initially discovered by
screening a library of marine sponge extracts (234). The screen was performed to
identify molecules that blocked the transactivation of the N-terminal domain of AR (234).
This family of compounds binds to AF-1 of AR, specifically tau-5, blocking proteinprotein interactions in this region (235). The binding of the EPI to this region also blocks
the amino and carboxyl terminal interaction required for ligand activity of AR (234, 236).
As a consequence they inhibit transactivation of the AR N-terminal domain. EPI seems
to be specific for AR and does not inhibit transcriptional activities of the progesterone
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and glucocorticoid receptors (234). EPI suppresses activation of the classical androgen
responsive genes, PSA and TMPRSS2 (234). It does not compete for the ligand binding
domain like other current AR targeted therapies and is effective in blocking
transcriptional activity of the major AR splice variants. It has been demonstrated in a
number of different prostate cancer cells lines that EPI is able to inhibit AR-dependent
growth but has no effect on cells that do not rely on AR signaling for proliferation and
survival (234). It was shown to be effective in blocking tumor growth in xenograft models
that express full length AR and those that express splice variant AR in castrated male
mice (234, 236, 237). There was no toxicity to internal organs of animals treated with
EPI systemically; this along with the selective antitumor activity observed in preclinical
models suggests potential for EPI as a new class of therapeutic drugs for CRPC (234,
236).
Further investigations of EPI compounds have led to the development of EPI506. This is the first AR N-terminal domain inhibitor to enter into clinical trials. The
original EPI compound that was discovered through screening was compound EPI-001.
When detailed preclinical studies were conducted on this compound along with four of
its isomers, EPI-002 was found to be the most potent (234, 236, 237). Compound EPI506, which is the clinical drug candidate, is a prodrug form of EPI-002. Currently, EPI506 is under investigation in Phase I/II clinical trials. Patients with metastatic CPRC who
have failed on enzalutamide and abiraterone are eligible for this trial. The study is
currently enrolling in both the United States and Canada (NCT02606123). EPI-506 has
the potential to circumvent major AR-related resistance mechanisms and is the first
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drug to enter clinical trials that has the ability to inhibit both the classical AR
transcriptional signaling and also AR-V dependent signaling.
1.8.3 Sintokamides
Sintokamide A (SINT1) has also shown novel effects on the N-terminal domain of
the androgen receptor. This is a natural compound (238) isolated from the marine
sponge Dysidea sp. This natural product was able to block transactivation by the Nterminal domain and inhibit AR-dependent proliferation in prostate cancer cells in vitro
and of CRPC xenografts in vivo (238). SINT1 was able to selectively block the
transcriptional activity of both full length AR and AR splice variants by binding to AF-1,
without interfering with other nuclear receptors with similar structures (239). SINT1 was
unable to prevent the interaction between AR and STAT3, which is a necessary
transcription factor in AR signaling, unlike EPI indicating that STINT1 binds to a different
region of AF1 than EP1 (238, 239). These studies imply that most likely there are
multiple

regions

within

AF-1

that

can

be

targeted

independently.

Further

characterization of these sponge extracts may provide the foundation for further
development of AR N-terminal targeted therapies.
1.8.4 Bispecific antibodies to inhibit N-terminal AR activity
Although still in the early stages of preclinical development, the synthesis and use of
the bispecific antibody (bsAb), 3E10-AR44, to penetrate prostate cancer cells and
simultaneously bind to the N-terminal domain of the AR is noteworthy. Treatment with
the bsAb in the androgen sensitive PC cell line LNCaPs, resulted in accumulation in
the nuclear compartment with AR (240). 3E10-AR44 was able to co-immunoprecipitate
with AR as well as mutant AR or AR-V7, and inhibited AR activity in promoter-reporter
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based assays (240). Data on 3E10-AR44 was presented in 2015 at the annual
American Association for Cancer Research meeting and are currently unpublished.
Data on the effects of 3E10-AR44 on tumor growth are unavailable. Nevertheless,
3E10-AR44 may represent an interesting alternative approach to inhibiting AR function
in a manner that does not rely on the ligand binding domain of the receptor (240).
Clearly, drugs that inhibit the transcriptional activity of AR by preventing coactivator recruitment by the N-terminal domain of AR hold promise in
overcoming the limitations of ADT and anti-androgens in that they are effective
against AR splice variants that lack the ligand binding domain. Nevertheless, this
approach is still limited by its lack of selectivity for androgen signaling in
prostate cancer cells vs. normal tissues and may cause many of the side effects
associated with ADT and androgen antagonists. In the following sections, this
thesis advances a new concept to address this problem.
1.9 Targeting AR tethering proteins
Currently major efforts are underway to discover/develop new therapeutics for
CRPC tumors including those resistant to enzalutamide and abiraterone. The idea of
targeting the N-terminal transcriptionally active domain of AR is a novel approach that
is suitable for disruption of canonical AR signaling pathways as well as AR-V
transcriptional pathways. However, in all cases, the current clinical paradigm remains
as total and ubiquitous attenuation of AR signaling. Disrupting the androgen signaling
axis is clinically validated and the best available treatment for prostate cancer but is
seriously limited by side effects of depriving the patient of testosterone or its receptor
function in all tissues (107, 111, 112). It is therefore desirable to selectively disrupt a
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functional arm of AR that is critical for prostate tumor growth at all stages but not for
the normal role of androgen or AR in various normal tissues. Such an approach would
obviate the need for testosterone suppression while enabling improved therapy
outcome for the spectrum of prostate tumors including CRPC.
The precise mechanisms by which prostate cancer cells reprogram AR signaling
to primarily support growth have not been well understood. Recent work from our lab
and others [reviewed in (241)] has strongly supported the general premise that the
pattern of expression of proteins that tether AR to chromatin during development,
differentiation and malignant transformation of the prostate could redirect AR signaling
according to the physiological context. This may be exemplified by the ability of several
well established AR tethering proteins to profoundly influence the pattern of gene
activation by androgen/AR. Those proteins include HoxB13 (involved in development)
(242), C/EBPalpha (involved in terminal differentiation) shown in our lab (243-245) and
ELK1 (required for growth signaling by AR) shown in our lab (246).
1.9.1 HoxB13
HoxB13 is a transcription factor that belongs to the homeodomain family of
proteins and plays a vital role in prostate development (247, 248). HoxB13 can
associate with the DNA binding domain of AR (242). It can associate with AR bound to
a canonical ARE and act as a co-repressor of AR gene transcriptional activity (242,
249). HoxB13 can also act as a tether for AR at homeobox elements in the chromatin.
In the presence of androgen, HoxB13 can recruit AR and support transcriptional activity
at those sites (242). HoxB13 and AR may also interact by binding at adjacent sites on
the chromatin (242). It has been suggested that in addition to supporting prostate
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development, the cooperative actions of HoxB13 and AR may have a regulatory role in
growth and migration of prostate cancer cells (242).
1.9.2 C/EBPα
The CCAAT enhancer binding protein, C/EBPα, is a member of dimeric basic
leucine zipper family of transcription factors and is involved in differentiation of several
different types of tissues (250). C/EBPα is also a tumor suppressor and exerts antiproliferative effects through protein-protein interactions including stabilization of p21 and
disruption of E2F complexes (251-253) (254, 255). Activation of the phosphatidylinositol
3 kinase/AKT pathway can lead to dephosphorylation, causing C/EBPα to stimulate
proliferation by sequestering the tumor suppressor protein, retinoblastoma (256) (257).
Our lab has shown that coincident with differentiation of prostate epithelial cells,
C/EBPα enters the nuclear compartment, suggesting a role for the protein in prostate
differentiation(244) Previously it was reported that C/EBPα associates with AR bound to
classical androgen response elements and acts as a co-repressor to suppress ARmediated gene transcriptional activity (258). Studies from our laboratory following this
finding revealed the action of C/EBPα as a tethering protein for AR at C/EBP-binding
sites that could enable AR to activate a different set of genes possibly contributing to
prostate differentiation and other functions of AR in the prostate (245). Although in the
normal prostate, androgen is needed for nuclear localization of AR, the mechanism of
recruitment of AR by C/EBPα per se was found to be ligand-independent and without a
need for dimerization of AR (245). The interaction of C/EBPα with AR involves multiple
domains of AR (245).
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1.9.3 ELK1 and other TCF subfamily members
The E twenty six (ETS) domain transcription factors have distinct roles in
differentiation, development, transformation, and cellular proliferation (259). Within this
large family of proteins exists a subfamily of three members, the ternary complex factors
(TCF), ELK1, ELK3 (Net), and ELK4 (Sap-1). The TCF subfamily members are
characterized by the presence of the ETS DNA-binding domain of about 85 amino acids
and like all ETS proteins; they bind to cis elements in the DNA containing a GGA core
sequence. TCF proteins characteristically also interact with serum response factor
(SRF) at serum response elements (SREs) as a ternary complex. The formation of this
nuclear ternary complex is required for transient induction of immediate early genes
such as c-fos and Egr-1 (260, 261) in response to hyperphosphorylation of ELK1 by
activated mitogen-activated protein (MAP) kinase pathways (262).
The TCF subfamily polypeptides contain four domains (A, B, D, and C domains) that
are conserved among ELK1, ELK3, and ELK4 (Figure 1.4). The N-terminal region
comprises the A domain which encompasses the ets DNA binding domain (263). The B
domain interacts with SRF and allows for the formation of the ternary complex (264).
The C domain resides at the C-terminus of the protein and regulates activation through
phosphorylation by MAPK. The D domain is a docking site (D box) for MAPK. There is
an additional MAPK docking site within the C domain, known as the FXFP motif or F
box. The three TCF subfamily members also contain domains that distinguish them
from each other. ELK1 contains a repressor (R) domain that diminishes the activity of
the C-terminal which has similar activity to the CID domain of ELK3. ELK3 contains an
additional inhibitory domain, NID domain, which inhibits transactivation and DNA
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binding. ELK4 also has an NID domain with similar function. ELK3 has an additional
phosphorylation regulatory J domain (259).
ELK1 is primarily regulated through phosphorylation by the MAP kinase pathway
protein ERK at serine 383; however it can also be phosphorylated by the MAP kinases
JNK and p38.

There have been several studies of ELK1’s role in neuronal cell

differentiation; however ELK1 knockout mice are viable and phenotypically normal (265)
suggesting functional redundancy within the TCF subfamily members. ELK1 is
expressed in the clinical spectrum of prostate tumors (266). ELK4 plays a role in
regulating the proliferation of T cells after targeted activation by the ERK and p38
pathways. ERK and p38 target ELK3 through the D domain; in addition ELK3 can also
be targeted through the JNK pathway at the J domain. ELK3 is expressed at sites of
angiogenesis and vasculogenesis. Knockout of ELK3 results in the most severe
phenotypic effect of all the TCF subfamily members. ELK3 most closely resembles
ELK1 in structure and DNA binding specificity most likely causing a large part of the
redundancy of ELK1 in normal tissues (259, 264).
1.9.4 ELK1 as an AR tethering protein essential for PC/CRPC growth
Our lab has reported that, in a PC cell line model capable of growing robustly in the
complete absence of hormone, AR was localized in the nucleus without the need for
hormone and that AR expression was obligatory for cell growth (267). In these same
cells, replacement of endogenous AR with a DNA binding domain mutant of AR that
could not bind directly to DNA, did not impair cell growth (267). The mutant AR was able
to associate with the chromatin and activate the required genes to support cell growth
(267). In the same cells, the direct binding of endogenous AR to DNA required
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Figure 1.4 Schematic of the structural domains of ELK1, ELK4, and
ELK3, the three TCF subfamily members. The A box represents the
conserved ETS DNA binding domain. The B box is the SRF interaction
domain. ELK4 contains one inhibitory domain and ELK3 contains two
inhibitory domains represented by NID (net inhibitory domain) and CID
(CtBP interaction domain). Docking sites for MAP kinases are represented
by J, and D. The black box represents an additional secondary MAPK
docking site known as the FXFP motif. The C box is responsible for
transcriptional activation and contains phosphorylation sites targeted by
MAPK.
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androgen (267). These findings suggested that hormone-independent growth of
prostate cancer cells could be supported by AR by associating with chromatin through
DNA bound tethering proteins.
Systematic studies of a large number of candidate AR tethering proteins led our lab
to the discovery that ELK1 is an AR tethering protein that is obligatory for androgen/ARdependent malignant growth in a variety of the well-established PC/CRPC models
(246). Both hormone sensitive PC and CRPC cell line models are absolutely addicted to
ELK1 for AR-dependent growth, anchorage-dependent and –independent colony
formation, and tumorigenicity (246, 268). ELK1 was at least partially required for
activation by AR of approximately 27% of AR target genes in prostate cancer cells;
these genes were primarily and heavily enriched for cell growth functions (246). The
tethering of AR by ELK1 to ELK1 binding sites allows for constitutive activation of these
genes. This dependence of prostate cancer cells on ELK1-dependent AR signaling is
independent of known ets1-TMPRSS2 gene fusions (246). The cooperative action of
ELK1 and AR is hormone-independent, unless hormone is needed for nuclear
localization of AR and is mediated through the N-terminal A/B domain of AR. ELK1 is
not required for growth of AR-negative cancer cell lines where it may be substituted by
other proteins (e.g. ELK3) that do not interact with AR. In the normal differentiated
prostate epithelium and in other normal differentiated AR+ tissues, where growth genes
are not activated, it is possible that ELK1 is displaced in the chromatin by related
members of the large ETS family that do not associate with AR. Alternatively, at the
relatively low AR levels in normal tissues, the receptor could be sequestered by
preferential binding to AREs associated with genes unrelated to growth. AR binding
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sites in the chromatin are enriched for ELK1 binding elements (269) which are among
the most enriched motifs at these sites (270).
1.10

The ELK1-AR complex as a critical and selective therapeutic target in

prostate cancer
Both early stage and advanced prostate tumors are generally dependent on the
androgen receptor (AR) for growth (271-274).Tumor growth could be driven by
physiological levels of androgen, post ablation levels of androgen or by the androgen
receptor (AR) acting completely independent of androgen. Hence, the disease is
managed clinically by disrupting the AR signaling in the tumors via the use of androgen
deprivation therapy (ADT) through androgen ablation and the use of androgen
antagonists. However, these options present major drawbacks including limited efficacy
in advanced disease, progression to castrate resistant prostate cancer (CRPC), and
many undesirable acute and chronic side effects on non-target tissues including the
central nervous system, cardiovascular system, bone, muscle, and adipose tissue.
Therefore a more strategic approach is one that could disrupt a functional arm of AR
signaling that is critical for prostate tumor growth at all stages but not for the essential
roles of AR in normal adult tissues.
AR regulates genes to support diverse physiological functions in various tissues but
in prostate cancer (PC) cells AR is redirected to gene targets that primarily support
growth. The specificity of AR tethering interactions could be critical for AR-dependent
growth signaling in both early stage prostate cancer and CRPC. If such tethering
mechanisms are not required for the adult normal physiology they could then act as a
functionally selective therapeutic target in prostate tumors. It has been previously shown
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in our lab that ELK1, an ETS family transcription factor, tethers AR to the chromatin
leading to the sustained activation of a critical set of growth genes in prostate cancer
cells (246). ELK1 is genetically redundant in normal tissues (110). Moreover, our lab
has shown that in a variety of prostate cancer cell lines both androgen and ARdependent are addicted to ELK1 for cell growth, colony formation, and tumorgenicity
(246).
The ELK1-AR synergy is independent of the classical mechanism of activation of
ELK1 by ERK-dependent phosphorylation (246). The unique role of ELK1 in prostate
cancer cells is underscored by the fact that ELK3, the closest functional substitute for
ELK1, does not bind AR (246). Moreover, in contrast to ELK1, ELK3 is expressed at
higher levels in normal prostate epithelial cells and tissues compared to standard
models of both early stage PC and CRPC (266). Targeting the ELK1-AR complex for
disruption would obviate the need for androgen ablation and reduce adverse effects
associated with current AR targeted therapies. Because the synergy between the two
proteins is a downstream event in the AR signaling axis, this approach would also
evade resistance mechanisms to current therapies as these mechanisms typically
restore functional AR. Therefore targeting the ELK1-AR complex should be effective
against both hormone-dependent PC, as well as CRPC. The focus of this dissertation is
to prove this concept and also discover a functional class of small molecules that could
be

developed

as

drugs

that

target

the

ELK1-AR

complex.
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CHAPTER 2-THESIS OUTLINE
This thesis describes our efforts to develop small molecule drugs using two different
mechanistic approaches.
Chapters 3 and 4 describe the first approach. Here, the central premise was to
avoid global attenuation of androgen/AR signaling, by only targeting a critical growth
signaling arm of AR, specifically, the interaction of AR with ELK1 which has previously
been reported by this laboratory. In order to accomplish this, we first mapped the
docking sites for AR on ELK1 (Chapter 3). Next we designed and developed a high
throughput small molecule screening system which we then used to discover and
develop a lead drug candidate that would selectively disrupt the ELK1-AR complex
(Chapter 4).
Chapter 5 describes the second approach. Here we developed hybrid molecules
that incorporate scaffolds of a high affinity AR antagonist (enzalutamide) and a histone
deacetylase (HDAC) inhibitor, suberoylanilide hydroxamic acid (SAHA). The hybrid
molecules possess weak HDAC inhibitor activity compared with SAHA. Our premise
was that the weak activity of the hybrid molecule would minimize the pan-HDAC
inhibitor activity of SAHA. At the same time the enzalutamide moiety should redirect the
HDAC inhibitor activity to client proteins of HDAC6 within the AR chaperone complex,
resulting in cell growth inhibition in enzalutamide resistant cells expressing full length
AR.
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CHAPTER 3- THE AMINO-TERMINAL DOMAIN OF THE ANDROGEN RECEPTOR
CO-OPTS ERK DOCKING SITES IN ELK1 TO INDUCE SUSTAINED GENE
ACTIVATION THAT SUPPORTS PROSTATE CANCER CELL GROWTH
Reprinted by permission from Journal of Biological Chemistry Copyright 2016
3.1 Introduction
The androgen receptor (AR) and other members of the nuclear receptor (NR)
superfamily mediate the transcriptional activities of their ligands as well as some of their
non-genomic actions (60, 275-278). NRs in the cytosol, in the nucleus or in association
with plasma membrane proteins are known to interact with a variety of signaling
pathway proteins, either as protein kinase substrates or as regulators of transcription or
signal transduction. Although some of the client proteins of NRs in these pathways have
been identified, including those shared by different NRs, there is paucity of information
on the structural elements that enable the mutual recognition of NRs and signaling
proteins in both normal physiology and in pathogenesis.
Most early stage and advanced prostate tumors depend on AR for growth (272274, 279-281). The human AR is a 919 amino acid polypeptide with a basic structural
organization typical of NRs (282). In the classical model of gene regulation by AR,
ligand binding is critical for several events including release of AR from a cytosolic
chaperone complex as well as phosphorylation, stabilization, dimerization and nuclear
import of AR (282-284). Ligand binding is also needed for optimal binding of AR to DNA
at well-characterized response elements associated with target genes (267, 285).
However, advanced prostate cancer (PCa) cells may acquire the ability to localize
adequate AR to the nucleus where it is transcriptionally active through mechanisms that
include AR amplification, hormone-independent phosphorylation of AR through hyperactivated signaling pathways or overexpression of ligand-independent AR splice
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variants (221, 286-288). Splice variants of AR have carboxyl-terminal truncations that
lack the ligand binding domain (289). The above cellular changes in advanced PCa
cells, as well as intratumoral androgen biosynthesis, could render the tumors resistant
to conventional AR-targeted therapies, including surgical or chemical castration and
androgen antagonists (120, 192, 211, 214, 290, 291). Normal and malignant prostate
epithelial cells appear to redirect androgen/AR signaling to regulate different sets of
genes via tethering proteins that bind AR to chromatin (241, 242, 245, 246, 267).
Therefore, developing drugs that disrupt interactions of AR with a tethering protein
required exclusively for growth is an attractive approach to overcoming resistance to
current AR-targeted therapies and would also obviate the need for androgen ablation.
We have previously reported that the ETS family transcription factor ELK1 is
essential for growth in PCa cells that are either dependent on androgen or independent
of hormone but still dependent on AR (246). In contrast, ELK1 was not required for
growth in AR-negative PCa cells. In PCa cells, ELK1 is required wholly or in part for
activation by androgen/AR of approximately 27 percent of target genes and these genes
are enriched for clusters supporting cell cycle progression and mitosis (246). Promoter
activation analyses, mammalian two-hybrid assays and chromatin immunoprecipitation
studies have indicated that ELK1 recruits AR as a transcriptional co-activator (246).
Other investigators have extended these studies to demonstrate that ELK1 is similarly
required for androgen-dependent growth of bladder cancer (292, 293). Moreover,
chromatin sites of AR binding are highly enriched for ELK1 binding DNA cis-elements
(294).
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ELK1 belongs to the ternary complex factor (TCF) sub-family of ETS proteins
that characteristically bind to purine-rich GGA core sequences (295). ELK1 is activated
through hyper-phosphorylation by ERK to transiently activate immediate early genes in
association with the serum response factor (SRF) (261, 262, 295-297). Accordingly,
ELK1 is one of many substrates of ERK1/2 that have variable types and combinations
of recognition motifs for ERK (298-300). In the absence of hyper-phosphorylation, ELK1
is in a repressive association with many genes (301). However, ELK1 is expressed in
the clinical spectrum of prostate tumors (266) and in PCa cells the activation of AR
target growth genes through ELK1 was constitutive and did not entail hyperphosphorylation or activation of immediate early genes (246). In this study, we now
elucidate the physical basis for the interaction between ELK1 and AR in the context of
growth dependency of PCa cells on ELK1.
3.2 Experimental Procedures
3.2.1 Cell culture and reagents
LNCaP, CWR22Rv1 cells and HeLa cell lines were from the American Type
Culture Collection (Manassas, VA); 293FT cells were from Invitrogen. HeLa cells with a
stably integrated minimal promoter-luciferase reporter containing five upstream Gal4
elements (Gal4-TATA-Luc) and expressing a Gal4-ELK1fusion protein in which the Gal4
DNA binding domain was substituted for the ETS DNA binding domain of ELK1 were
kindly provided by Dr. Johann Hofman (Innsbruck Medical University). These cells were
then stably transduced with a vector expressing the full-length AR. Recombinant HeLa
cells were also generated by stably transducing Gal4-TATA-Luc and a vector
expressing the AR (A/B) domain fused to the VP16 transactivation domain [AR(A/B)-
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VP16]. LNCaP cells were routinely grown at 37°C in 5% CO 2 in RPMI 1640 medium
supplemented with 10% FBS (Invitrogen), 100 units/ml penicillin, 100 µg/ml
streptomycin, 2mM L-glutamine mixture (Invitrogen); and sodium pyruvate (1mM)
(Invitrogen). CWR22Rv1 cells were grown in phenol-red free RPMI 1640 medium
supplemented with 10% FBS (Invitrogen), 100 units/ml penicillin, 100 µg/ml
streptomycin, and 2mM L-glutamine mixture (Invitrogen). Parental and recombinant
HeLa cells were grown in DMEM supplemented with 10% FBS and 100 units/ml
penicillin, 100µg/ml streptomycin, 2mM L-glutamine mixture (Invitrogen). Additionally,
the culture media for the recombinant HeLa cells included one or more of the following
selection antibiotics: 100µg/ml Hygromycin (Invitrogen) (for Gal4-ELK1), 100µg /ml or
400ug/ml Geneticin (Invitrogen) (for Gal4-TATA-Luc) and 2 µg /ml Puromycin (SigmaAldrich) [for AR or AR(A/B)-VP16]. For hormone depletion, LNCaP cells were grown in
phenol-red free RPMI 1640 medium supplemented with 10% heat-inactivated and
charcoal-stripped FBS (Sigma) and 100 units/ml penicillin, 100µg/ml streptomycin, and
2mM L-glutamine mixture for 96 hours before each experiment. For hormone depletion,
parental and recombinant HeLa cells were grown in phenol-red free DMEM
supplemented with 5% heat-inactivated and charcoal-stripped FBS (Sigma) and 2mM Lglutamine for 48 hours before each experiment. Affinity-purified rabbit anti-human
antibody to AR (sc-7305) and mouse antibodies to Gal4 (sc-510) and GAPDH (sc47724) were purchased from Santa Cruz Biotechnology (Santa Cruz, CA). Rabbit
monoclonal anti-human antibody to ERK1/ERK2 (ab17942), rabbit monoclonal antihuman to androgen receptor-ChIP grade antibody (ab74272), rabbit monoclonal antihuman antibody to ELK1 (ab32106) and Mouse monoclonal anti-human antibodies to
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the Androgen Receptor (ab77557) and ELK1 (ab7712) were from Abcam (Cambridge,
MA).

R1881

was

kindly

provided

by

Dr.

Steve

Patrick

(Wayne

State

University/Karmanos Cancer Institute, Detroit, MI). Testosterone was from SigmaAldrich. Lipofectamine

TM

2000 was purchased from Thermo Scientific (product number

78410). Trametinib was purchased from Selleckchem. AKTi-1/2 was purchased from
EMD Millipore (Darmstadt, Germany). esiRNAs were purchased from Sigma-Aldrich.
3.2.2 Purified proteins
Full length human AR expressed in insect cells and purified to >95% by affinity
chromatography and FPLC chromatography (ab82609) was purchased from Abcam
(Cambridge MA). Recombinant his-tagged ELK1 as well as his-tagged ELK1 mutated in
both the D-box (∆308-321) and the DEF motif (F397L, P398A) expressed from
baculovirus

infected

Sf9

cells

were

purified

using

nickel

agarose

affinity

chromatography. The proteins were eluted with 200mM imidazole and dialysed against
20 mM HEPES, pH 7.9 containing 10% glycerol, 20mM KCl, 2mM MgCl2, 0.2 mM
EDTA, 0.5mM benzamidine and 0.5mM DTT. Purity of the proteins was estimated to be
> 85% by SDS-polyacrylamide gel electrophoresis.
3.2.3 Surface plasmon resonance
Amine Coupling Kit, CM5 sensor chip and HBS-N buffer (GE Healthcare) were
used for surface plasmon resonance (SPR) analysis. The rate and equilibrium binding
constants of the interaction of AR with ELK1 or mutant ELK1 were determined using a
Biacore 3000 (Biacore, Piscataway, NJ). Affinity-purified AR polypeptide (ligand) was
immobilized on a CM5 research grade sensor chip by an amine coupling method (302).
The immobilization involved activation of carboxymethyl groups on a dextran-coated
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chip by reaction with N-hydroxysuccinimide, followed by covalent bonding of the ligand
to the chip surface via amide linkages. Reference surfaces were prepared in the same
manner but blocked with ethanolamine and thus contained no ligand. Kinetic binding
analysis was carried out by injecting affinity-purified ELK1 polypeptide at different
concentrations (0-160 nM) or mutant ELK1 (100 nM) into the flow cells (ligand and
reference cell), and the interaction (response units, RU) between analyte and ligand
was recorded as the ligand RU minus the reference RU. Kinetic values were determined
using BIAevaluation software (Biacore), and the data were fitted with the model showing
closest match (303, 304). A 1:1 Langmuir binding model was generally selected, in
which all the sensorgrams representing the different analyte concentrations were fitted
simultaneously with the wide window of association and dissociation phases. Individual
concentration curves were also evaluated to confirm the fitting data. The equilibrium
dissociation constant (Kd) was calculated by Kd = koff/kon.
3.2.4 Plasmids
The expression plasmid for human full length ELK1 in the pCMV plasmid was
purchased from OriGene (Rockville, MD). The pLenti-GIII-CMV-hELK1 Lentiviral Vector
was from Applied Biological Materials Inc. The Gal4-TATA-luc plasmid (pG5lucPromega) and expression plasmid for VP16 and Gal4 were purchased from Promega
(Madison, WI) (CheckMate Mammalian Two-hybrid System). The pRL plasmid encoding
Renilla luciferase was purchased from Promega. The PatheDetect pFC-MEK1 transReporter plasmid with a S218/222E point mutation and internal deletion between amino
acid residues 32-51 rendering it constitutively active was from Stratagene. The pLVXAR-V7 plasmid and pLVX control plasmid were a kind gift from Dr.Yan Dong from
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Tulane University (New Orleans, LA). Construction of the (ELK1)2-TATA-Luc plasmid
and the ARE-TATA-Luc plasmid has been previously described (246). The Gal4-ELK1
fusion construct in which the DNA binding domain of ELK1 (amino acid residues 1-86)
was deleted and replaced with the Gal4 DNA binding domain was constructed by PCR
by using the ELK1-pCMV expression plasmid (Origene, Rockville, MD) as the template.
The appropriate PCR primers were custom synthesized to generate the various aminoterminal and carboxyl-terminal deletion constructs of Gal4-ELK1 using the ELK1-pCMV
expression plasmid as the PCR template and subcloned at BamHI (upstream) and NotI
(downstream) sites in the pBind vector expressing Gal4 fusions. The following ELK1
deletions reported previously (305) (i.e., pCMV5L ELK1 ∆31, pCMV5L ELK1 ∆D,
pCMV5L ELK1 ∆32, pCMV5L ELK1 ∆32, pCMV5L ELK1 ∆24, pCMV5L ELK1 ∆19,
pCMV5L ELK1 FxLa) were subcloned into the appropriate vectors. PCR primers were
designed to subclone each of the ELK1 deletions into the pBind vector at BamHI
(upstream) and NotI (downstream) sites. All other ELK1 internal deletion and mutant
constructs were generated using the The QuickChange II XL Site-Directed Mutagenesis
kit (Agilent Technologies) according to the manufacturer’s protocol. They include:
Lentiviral ELK1 ∆308-321 and Lentiviral ELK1 FxLa, Gal4-ELK1∆287-306, Gal4ELK1∆307-313, Gal4-ELK1∆307-315, Gal4ELK1∆400-407, Gal4-ELK1∆331-340, and
Gal4-ELK1∆340-350.
The AR(A/B)-VP16 fusion construct was initially constructed using the VP16
expression plasmid from Promega. Using this plasmid as the PCR template, custom
synthesized PCR primers were then used to amplify the AR(A/B)-VP16 sequence which
was cloned into the pCDH-CMV-MCS-EF1-Puro cDNA Cloning and Expression Vector
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(System Biosciences) at NheI (upstream) and BamHI (downstream) sites. The full
length AR was subcloned from the pCMV expression vector (Origene) into the pCDHCMV-MCS-EF1-Puro cDNA Cloning and Expression Vector (System Biosciences) at
NheI (upstream) and BamHI (downstream) sites. Generation of the AR(A/B) expression
plasmid in the pCDH vector has been described (246). Custom synthesized PCR
primers were used to amplify and clone the five tandem Gal4 elements from the pG5luc
vector into the pGreenFire1TM-mCMV-EF1-Neo (Plasmid) at SpeI (upstream) and
BamHI (downstream) sites.
All of the plasmid constructs generated above were sent to either the PlantMicrobe Genomics Facility for DNA Sequencing at The Ohio State University
(Columbus, OH) or to Genewiz (South Plainfield, NJ) to verify DNA sequences before
the constructs were used in the studies.
3.2.5 siRNA mediated gene knockdown
The appropriate recombinant HeLa cells were plated in a 6-well plate (CytoOne,
from USA Scientific) in DMEM media supplemented with 10% FBS and 2mM Lglutamine 24 hours before transfection. The following day cells were transfected with
esiRNAs against ERK1 (MAPK3, 1ug) and ERK2 (MAPK1, 1ug) or 2µg of control siRNA
using LipofectamineTM 2000.
3.2.6 Co-Immunoprecipitation
HeLa cells were transfected with the expression plasmid for AR and cotransfected with expression plasmid for wtELK1, ELK1∆308-321 or ELK1 FxLa. Cells
were harvested in radioimmune precipitation assay lysis buffer and 1X protease inhibitor
mixture 48h post-transfection. Whole cell lysates (500µg) were pre-cleared for 2h using
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protein A-agarose beads (Calbiochem). Immunoprecipitation was performed by first
incubating 100 µl of the protein A-agarose beads with 20µg of the anti-rabbit androgen
receptor antibody (ab74272) or negative control for 4h. After washing the antibody
bound beads three times, 500 ug of the cell lysate was added and incubated at 4°C
overnight under rotary agitation. At the end of the incubation, the complexes were
washed five times with the radioimmune precipitation assay buffer. The western blot
was probed with mouse monoclonal AR antibody (ab77557) and mouse monoclonal
ELK1 antibody (ab7712).
3.2.7 Other experimental methods
Transient transfection and luciferase reporter assays, Checkmate mammalian
two hybrid assay, Lentivirus mediated gene knockdown and gene expression, cell
proliferation assay, western blot analysis, RNA isolation, reverse transcription, and real
time PCR have been described in (246).
3.2.8 Statistical analysis
All experiments were performed in triplicate and repeated at least three times.
The error bars in all graphs represent the standard deviation. Statistical analysis was
performed using one-way ANOVA with post-hoc and LSD (Least Square Differences)
and/or T-test using GraphPad v.6.0 software. The P values are indicated in the figure
legends.
3.3 Results
3.3.1 Role of the amino-terminal A/B domain of AR in functional interactions with
ELK1
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AR includes (i) an amino-terminal A/B domain containing ligand-independent
transcriptional activation functions (AF1 and AF5), (ii) a carboxyl-terminal region (E and
F domains) containing the ligand binding pocket and a ligand-dependent activation
function (AF2) and (iii) internal DNA-binding and hinge domains (C and D domains)
(Figure 3.1A). Typically, (e.g., in LNCaP cells) the binding of androgen is necessary for
AR to localize in the nucleus, to associate with classical androgen response elements
(AREs) and activate its gene targets. However AR has splice variants with carboxylterminal truncations that remove the ligand binding pocket; such variants are known to
activate growth genes and support growth of PCa cells in a hormone-independent
manner. Therefore we tested the ability of the A/B domain of AR to induce ELK1dependent gene activation. In contrast to full-length AR the AR A/B domain does not
require bound hormone for nuclear localization.
We first used a minimal TATA-dependent promoter luciferase construct in which
two ELK1 binding cis-elements were placed upstream of the TATA box [(ELK1) 2-TATAluc]. This construct was transfected along with an expression plasmid for either the fulllength AR or the N-terminal A/B domain of AR into AR-negative HeLa cells. The fulllength AR was able to activate the promoter in an androgen-dependent manner (Figure
3.1B). In contrast, the A/B domain activated the promoter to a comparable extent both in
the presence and in the absence of hormone (Figure 3.1B). On the other hand, when
the cells were transfected with the minimal promoter construct in which the ELK1
binding elements were substituted with a canonical androgen response element (ARE),
promoter activation only occurred through the full-length AR and in the presence of
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Figure 3.1 Adequacy of the A/B domain of AR for functional interactions of AR with
ELK1. A shows a schematic for the organization of functional domains in AR. The A/B
domain is the amino-terminal domain (NTD), which contains the ligand-independent
activation functions AF1 and AF5. The C domain comprises the DNA binding domain
(DBD) adjacent to a hinge region (D). The E domain encompasses the ligand binding
domain (LBD) and the ligand-dependent activation function, AF2. The F domain
represents the carboxyl-terminal domain. B and C, hormone-depleted HeLa cells were
transfected with an ELK1-driven minimal promoter-luciferase reporter ((ELK1)2-TATALUC) (B) or with an androgen-response element-driven minimal promoter-luciferase
reporter (ARE-TATA-Luc) (C) and co-transfected with expression plasmids for the AR A/B
domain, full-length AR, or the plasmid vector control. The cells were treated with either
testosterone (10 nm) or vehicle at the time of transfection. Luciferase activity was
measured in the cell lysates 48 h post-transfection. D shows a Western blot of lysates
from cells transfected with expression plasmids for either the full-length AR or the AR A/B
domain and treated with either testosterone (10 nm) or vehicle for 48 h and probed using
an antibody to the amino-terminal domain of AR or with antibody to GAPDH (loading
control). E, hormone-depleted LNCaP cells were treated with R1881 (1 nm) or vehicle for
48 h. Total RNA from the cells was used to quantify mRNA levels for the indicated genes
that were known to be either ELK1-dependent or ARE-dependent for activation by AR. F,
hormone-depleted LNCaP cells transduced using lentivirus expressing either the AR A/B
domain or with control lentivirus. Cells were harvested 72 h after infection. Total RNA
from the cells was used to quantify mRNA levels for the indicated genes that were known
to be either ELK1-dependent or ARE-dependent for activation by AR. The inset shows
cell lysates probed by Western blotting using an antibody to the amino-terminal domain
of AR or with antibody to GAPDH (loading control). G, hormone-depleted LNCaP cells
transduced using lentivirus expressing either the AR A/B domain or with control
lentivirus. After 72 h, cells were plated in 96-well plates, and cell growth was monitored
by the MTT assay. The vector control cells were treated with R1881 (1 nm) or vehicle 24
h after plating. The inset shows Western blotting analysis of cell lysates, 72 h postinfection, using antibody to the amino-terminal domain of AR or with antibody to GAPDH
(loading control). For all transfections, a Renilla luciferase reporter was used as the
control for transfection efficiency. In all panels, the error bars represent standard
deviation of experimental triplicates. *, p < 0.001. Reprinted by permission from Journal
of Biological Chemistry Copyright 2016 (1).
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androgen (Figure 3.1C). Western blot analysis confirmed expression of both the fulllength AR and AR(A/B) in the transfected cells (Figure 3.1D).
Next, we compared the abilities of AR(A/B) and the full-length AR to activate
genes (CDCA3, CDCA5, CDC6 and DTL) previously shown to be activated by AR in an
ELK1-dependent manner (246). We also tested for activation of genes (PRKCA,
TMPRSS2 and KLK3) known to be activated by androgen (R1881) in an AREdependent manner. Androgen activated both classes of target genes in LNCaP cells,
which express full-length AR (Figure 3.1E). However, when AR(A/B) was ectopically
expressed in LNCaP cells in the absence of androgen (Figure 3.1F, inset), only the
ELK1-dependent target genes were activated (Figure 3.1F). This result demonstrates
that the A/B domain of AR is able to recapitulate ELK1-dependent gene activation by
androgen plus AR.
Next, we tested whether the A/B domain of AR could support hormoneindependent growth in LNCaP cells. AR(A/B) was ectopically expressed in LNCaP cells
by lentiviral transduction and control cells were infected with non-expressing lentivirus
(Figure 3.1G, inset). Growth of the control cells was dependent on androgen (Figure
3.1G). The A/B domain of AR was capable of supporting androgen-independent cell
growth, albeit less robustly than androgen (Figure 3.1G).
Collectively, the data in Figure 3.1 demonstrate that the amino-terminal A/B
Domain of AR is adequate for cooperation with ELK1 and for ELK1-dependent
transcriptional activation. This hormone-independent action of the A/B domain is
associated with partial recapitulation of androgen-dependent growth induced by full-
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length AR. The A/B domain may represent the minimal structural unit of AR that is
required for synergizing with ELK1.
3.3.2 Mapping the region(s) in ELK1 required for association with AR(A/B)
ELK1 consists of several functional domains. The amino-terminus comprises the
A domain, encompassing the ETS DNA binding domain (263). The B domain interacts
with SRF and directs ternary complex formation (264). The C domain resides at the Cterminus of the protein and regulates activation through phosphorylation by mitogenactivated protein kinases (MAPKs). The D domain is a docking site for MAPKs. There is
also an additional MAPK docking site within the C domain, known as the DEF (Docking
site for ERK, FXFP) motif (259, 306, 307). Segments of ELK1 that are required for
association with the AR A/B domain were mapped using a mammalian two-hybrid
assay. For the two-hybrid assay, we used HeLa cells in which a minimal promoterluciferase reporter construct with Gal4 elements upstream of the TATA box (Gal4TATA-Luc) was stably integrated. These cells also stably expressed the AR(A/B)-VP16
fusion protein. The recombinant HeLa cells were transfected with Gal4-ELK1 fusion
constructs in which the DNA binding domain (amino acids 1-86) was replaced by that of
Gal4. The reporter readout was used to assess the ability of the Gal4-ELK1 fusion
proteins to associate with AR(A/B)-VP16. In parallel, HeLa cells stably expressing Gal4TATA-Luc alone were co-transfected with each one of the Gal4-ELK1 constructs and an
expression plasmid for a constitutively active mutant of MEK1 (CA-MEK1). Activation of
Gal4-TATA-Luc by CA-MEK1 entails phosphorylation and functional association of
ERK1/2 with Gal4-ELK1; therefore this parallel test probes the ability of each Gal4ELK1 deletion/mutation construct to associate with and become activated by ERK1/2.
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Figure 3.2 Mapping ELK1 polypeptide segments required for co-activation by
AR(A/B) by amino-terminal deletion analysis. A shows data obtained using
recombinant HeLa cells generated by stably transducing a minimal promoter-luciferase
reporter containing upstream Gal4 elements (GAL4-TATA-LUC) and also with a vector
expressing the AR A/B domain fused to the VP16 transactivation domain. Cells were
transfected with plasmids expressing Gal4 fusion proteins of ELK1. The fusion
constructs substituted the Gal4 DNA binding domain (Gal4-DBD) for the ETS DNA
binding domain of ELK1. Within this fusion construct, a series of amino-terminal
deletions were made, as indicated in the schematic in A. Forty eight hours after
transfection with the various Gal4-ELK1fusion constructs, cells were harvested by
preparing lysates for measurement of luciferase activity. The promoter activity shown on
the y axis required the presence of the AR A/B domain as knocking down AR(A/B)
expression in the same cells transfected with full-length Gal4-ELK1 decreased the
promoter activity to the basal value shown in the figure for Gal4-DBD alone. The inset
shows cell lysates probed by Western blotting with antibodies against Gal4 or GAPDH
(loading control). B shows data obtained using recombinant HeLa cells generated by
stably transducing only GAL4-TATA-LUC. The cells were transfected with each of the
Gal4-ELK1 fusion constructs used in A and co-transfected with an expression plasmid for
a constitutively active mutant of MEK1 or with the vector control. Forty eight hours after
transfection with the various Gal4-ELK1 fusion constructs, cells were harvested by
preparing lysates for measurement of luciferase activity. The inset shows cell lysates
probed by Western blotting with antibodies against Gal4 or GAPDH (loading control). C
shows a schematic of the domain organization of ELK1; here, the amino-terminal
deletion mapping of an ELK1 polypeptide segment encompassing residues required for
association with AR(A/B) (data from A) is represented by gray shading. For all
transfections, a Renilla luciferase reporter was used as the control for transfection
efficiency. In all panels, the error bars represent standard deviation of experimental
triplicates. *, p < 0.001. Reprinted by permission from Journal of Biological Chemistry
Copyright 2016 (1)
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First, Gal4-ELK1 constructs containing progressive deletions beginning from the aminoterminus were tested in the two-hybrid assay (Figure 3.2A). Expression of the
transfected constructs was confirmed by western blot, using antibody to the Gal4 DNA
binding domain (Figure 3.2A, inset). The reporter assay values were similar to the full
length construct for deletions to positions 187, 261, 287 and 297. However, there was
virtually a complete loss of reporter activity for deletions to positions 317, 327, 337, 367
and 397. These results map an element required for association of AR(A/B) to the
region downstream of amino acid residue 297 of ELK1 (Figure 3.2A and schematic in
Figure 3.2C). The parallel experiment testing activation of the Gal4-ELK1 constructs by
CA-MEK1, showed a virtually identical pattern of activity (Figure 3.2B and inset), a
result that is consistent with the position of the D-box region beginning at residue 312
(schematic in Figure 3.2C).
Next, Gal4-ELK1 constructs containing progressive deletions beginning from the
carboxyl-terminus were tested in the two-hybrid assay (Figure 3.3A). Again, expression
of the transfected constructs was confirmed by western blot (Figure 3.3A, inset). The
reporter assay values were similar to the full length construct for the deletion made at
position 397, but was lost for deletions to positions 387, 377 and 367. These results
map an element required for association of AR(A/B) to the region upstream of amino
acid residue 397 of ELK1 (Figure 3.3A and schematic in Figure 3.3C). The parallel
experiment testing activation of the Gal4-ELK1 constructs by CA-MEK1 again showed
the same pattern (Figure 3.3B and inset). This result is consistent with the position of
the DEF motif, which serves as an additional ERK docking site (schematic in Figure
3.3C).
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Figure 3.3 Mapping ELK1 polypeptide segments required for co-activation by
AR(A/B) by carboxyl-terminal deletion analysis. A shows data obtained using
recombinant HeLa cells generated by stably transducing a minimal promoter-luciferase
reporter containing upstream Gal4 elements (GAL4-TATA-LUC) and also with a vector
expressing the AR A/B domain fused to the VP16 transactivation domain. Cells were
transfected with plasmids expressing Gal4 fusion proteins of ELK1. The fusion
constructs substituted the Gal4 DNA binding domain (Gal4-DBD) for the ETS DNA
binding domain of ELK1. Within this fusion construct, a series of carboxyl-terminal
deletions were made, as indicated in the schematic in A. Forty eight hours after
transfection with the various Gal4-ELK1 fusion constructs, cells were harvested by
preparing lysates for measurement of luciferase activity. The promoter activity shown on
the y axis required the presence of the AR A/B domain because knocking down AR(A/B)
expression in the same cells transfected with full-length Gal4-ELK1 decreased the
promoter activity to the basal value shown in the figure for Gal4-DBD alone.
The inset shows cell lysates probed by Western blotting with antibodies against Gal4 or
GAPDH (loading control). B shows data obtained using recombinant HeLa cells
generated by stably transducing only GAL4-TATA-LUC. The cells were transfected with
each of the Gal4-ELK1 fusion constructs used in A and co-transfected with an
expression plasmid for a constitutively active mutant of MEK1 or with the vector control.
Forty eight hours after transfection with the various Gal4-ELK1 fusion constructs, cells
were harvested by preparing lysates for measurement of luciferase activity.
The inset shows cell lysates probed by Western blotting with antibodies against Gal4 or
GAPDH (loading control). C shows a schematic of the domain organization of ELK1;
here, the carboxyl-terminal deletion mapping of an ELK1 polypeptide segment
encompassing residues required for association with AR(A/B) (data from A) is
represented by gray shading. For all transfections, a Renilla luciferase reporter was used
as the control for transfection efficiency. In all panels, the error bars represent standard
deviation of experimental triplicates. *, p < 0.001. Reprinted by permission from Journal
of Biological Chemistry Copyright 2016 (1).
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Additionally, we made and tested the effects of a series of short, overlapping
internal deletions within Gal4-ELK1 (Figure 3.4A) using the two-hybrid assay. The
internal deletions covered segments flanking and within the region mapped above by
amino- and carboxyl-terminal deletion analyses. Expression of the Gal4-ELK1
constructs was confirmed by western blotting (Figure 3.4A, inset). As shown in Figure
3.4A, the reporter assay values for the constructs clearly fell into two groups – those
corresponding to the activity of the full length construct and those approaching the
background value obtained by transfecting the Gal4 DNA binding domain alone. Based
on this data, we were able to confirm and further bracket peptide motifs required for
association of AR(A/B) to within the amino acid sequences 307-350 and 372-397.
Activation of the Gal4-ELK1 internal deletion constructs by CA-MEK1 followed a similar
pattern except for the deletion 351-371 which reduced activation by CA-MEK1 but not
association with AR(A/B)-VP16 (Figure 3.4B and inset). These results are again
consistent with the locations of the ERK docking sites in ELK1 (D box and DEF motif)
(schematic in Figure 3.4C). As residues 351-371 lie within the transactivation domain
(domain C, residues 351-399) of ELK1 (schematic in Figure 4C) and includes two ERK
phosphorylation sites (297) its requirement for optimal activation of ELK1 by CA-MEK1
was anticipated.
To further refine the mapping data for the motif required for association of
AR(A/B) within the ELK1 polypeptide segment 307-350, we made additional deletions of
residues 331-340 and 341-350 (Figure 3. 5A). Western blotting confirmed expression of
the constructs (Figure 3.5B, inset). Neither deletion reduced the reporter activity in the
two-hybrid assay (Figure 3. 5B), thus further bracketing the upstream element required
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Figure 3.4 Mapping ELK1 polypeptide segments required for co-activation by
AR(A/B) by internal deletion analysis. A shows data obtained using recombinant HeLa
cells generated by stably transducing a minimal promoter-luciferase reporter containing
upstream Gal4 elements (GAL4-TATA-LUC) and also with a vector expressing the AR
A/B domain fused to the VP16 transactivation domain. Cells were transfected with
plasmids expressing Gal4 fusion proteins of ELK1. The fusion constructs substituted the
Gal4 DNA binding domain (Gal4-DBD) for the ETS DNA binding domain of ELK1. Within
this fusion construct, a series of internal deletions were made, as indicated in the
schematic in A. Forty eight hours after transfection with the various Gal4-ELK1 fusion
constructs, cells were harvested by preparing lysates for measurement of luciferase
activity. The promoter activity shown on the y axis required the presence of the AR A/B
domain because knocking down AR(A/B) expression in the same cells transfected with
full-length Gal4-ELK1 decreased the promoter activity to the basal value shown in the
figure for Gal4-DBD alone. The inset shows cell lysates probed by Western blotting with
antibodies against Gal4 or GAPDH (loading control). B shows data obtained using
recombinant HeLa cells generated by stably transducing only GAL4-TATA-LUC. The cells
were transfected with each of the Gal4-ELK1 fusion constructs used in A and cotransfected with an expression plasmid for a constitutively active mutant of MEK1 or with
the vector control. Forty eight hours after transfection with the various Gal4-ELK1 fusion
constructs, cells were harvested by preparing lysates for measurement of luciferase
activity. The inset shows cell lysates probed by Western blotting with antibodies against
Gal4 or GAPDH (loading control). C shows a schematic of the domain organization of
ELK1; here, the deletion mapping of two ELK1 polypeptide segments encompassing
residues required for association with AR(A/B) (data from Figs. 3A, ,44A, and and55A) is
represented by gray shading of the two segments. For all transfections, a Renilla
luciferase reporter was used as the control for transfection efficiency. In all panels, the
error bars represent standard deviation of experimental triplicates. *, p < 0.001.
Reprinted by permission from Journal of Biological Chemistry Copyright 2016 (1)
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Figure 3.5 Further refinement of the mapping of ELK1 motifs required for coactivation by AR(A/B). A shows the ELK1 polypeptide sequence. The bracketed
segments indicate the two segments that were mapped from the deletion analyses in
Figs. 33–5 as regions containing residues essential for the association of ELK1 with
AR(A/B). The boxed segments denote the D-domain of ELK1 and the FXFP motif of
ELK1. The segments in bold font represent peptides that were deleted for further
mapping in B and C. B and D show data obtained using recombinant HeLa cells
generated by stably transducing a minimal promoter-luciferase reporter containing
upstream Gal4 elements (GAL4-TATA-LUC) and also with a vector expressing the AR
A/B domain fused to the VP16 transactivation domain. Cells were transfected with
plasmids expressing Gal4 fusion proteins of ELK1. The fusion constructs substituted the
Gal4 DNA binding domain (Gal4-DBD) for the ETS DNA binding domain of ELK1. Within
this fusion construct, the indicated internal deletions or mutations were made, as
indicated in the schematics in B and D. Forty eight hours after transfection with the
various Gal4-ELK1 fusion constructs, cells were harvested by preparing lysates for
measurement of luciferase activity. The promoter activity shown on the y axis required
the presence of the AR A/B domain as knocking down AR(A/B) expression in the same
cells transfected with full-length Gal4-ELK1 decreased the promoter activity to the basal
value shown in the figure for Gal4-DBD alone. The insets in B and D show cell lysates
probed by Western blotting with antibodies against Gal4 or GAPDH (loading control). C
and E show data obtained using recombinant HeLa cells generated by stably
transducing only GAL4-TATA-LUC. The cells were transfected with each of the Gal4ELK1 fusion constructs used in B and D, respectively, and co-transfected with an
expression plasmid for a constitutively active mutant of MEK1 or with the vector control.
Forty eight hours after transfection with the various Gal4-ELK1fusion constructs, cells
were harvested by preparing lysates for measurement of luciferase activity. The insets in
C and E show cell lysates probed by Western blotting with antibodies against Gal4 or
GAPDH (loading control). For all transfections, a Renilla luciferase reporter was used as
the control for transfection efficiency. In all panels, the error bars represent standard
deviation of experimental triplicates. *, p < 0.001. Reprinted by permission from Journal
of Biological Chemistry Copyright 2016 (1)
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for association of AR(A/B) to within amino acid residues 307-330. These internal
deletions also had no effect on activation of Gal4-ELK1 by CA-MEK1 (Figure 3.5C and
inset). Finally, we tested whether the FQFP motif (FXFP motif) and the D-box region
(residues 308-321), both of which direct ERK docking to ELK1, were also required for
the association of AR(A/B) to ELK1. We tested a Gal4-ELK1 construct in which the
FQFP motif was mutated to FQLA, a Gal4-ELK1 construct in which the D-box region
(ELK1 residues 308-321) was deleted and a Gal4-ELK1 construct with both lesions. All
three
resulted in loss of function of AR(A/B)-VP16 in the two-hybrid assay (Figure 3.5D and
inset), mirroring the loss of activation by CA-MEK1 (Figure 3.5E left and right).
Collectively, the data from Figures 3.2-3.5 identify two peptide motifs in ELK1
that are both essential for its association with the A/B domain of AR. The pattern of
retention or loss of association with AR(A/B) due to the various deletions/mutations in
ELK1 mirrored the pattern for activation by ERK with one exception, i.e., a deletion
within the transactivation domain of ELK1, which disrupted activation by ERK but did not
affect association with AR(A/B). The two ELK1 motifs required for association with
AR(A/B) equate to the two ERK docking sites in ELK1.
3.3.3 ELK1 motifs required for association with the AR A/B domain participate in
hormone-induced activation of ELK1 by full-length AR
To further validate the mapping of ELK1 motifs required for association with AR,
it was necessary to confirm that the mapping data obtained above by the mammalian
two-hybrid assay using AR(A/B)-VP16 applies to the full-length AR. For this purpose we
tested Gal4-ELK1 fusion constructs with deletions and mutations that were indicative for
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bracketing the binding sites for AR(A/B) (Figure 3.6A). Each of these constructs, as well
as control constructs, were co-transfected with full-length AR into recombinant HeLa
cells in which the Gal4-TATA-Luc promoter-reporter was stably integrated. The cells
were treated with testosterone or the vehicle control beginning at the time of
transfection. Androgen activated the promoter only in cells transfected with Gal4-ELK1
constructs that were found in the preceding sections to have the ability to bind AR(A/B)
(Figure 3.6A). It was confirmed that both AR and the appropriate Gal4-ELK1 construct
were expressed in the transfected cells, as observed by western blot using antibody to
either Gal4 or AR (Figure 3.6B).
To complement the above data we co-expressed in HeLa cells, AR and wtELK1
or AR and a mutant of ELK1 in which either one of the two ERK docking sites was
disrupted. AR and wtELK1 co- immunoprecipitated in these cells; however, when ELK1
was mutated at either one of its two ERK docking sites, it was unable to coimmunoprecipitate with AR (Figure 3.6C).
These results demonstrate that functional association of the full-length AR with
ELK1 (or transcriptional co-activation of ELK1 by AR) requires the same ELK1 motifs as
those mapped for the binding of AR(A/B) to ELK1.
3.3.4 Influence of SRF on the interaction of AR with ELK1
Functional interactions between AR and ELK1 could be influenced by the
association of ELK1 with its DNA binding partner, SRF. To explore this possibility we
first used recombinant HeLa cells in which a minimal promoter-luciferase reporter
construct with Gal4 elements upstream of the TATA box (Gal4-TATA-Luc) was stably
integrated in the chromatin. The cells also stably expressed full-length AR and the Gal4-
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Figure 3.6 ELK1 motifs required for co-activation by full-length AR. A shows data
obtained using recombinant HeLa cells generated by stably transducing a minimal
promoter-luciferase reporter containing upstream Gal4 elements (GAL4-TATA-LUC).
Cells were plated in hormone-depleted media and co-transfected with expression
plasmids for the indicated Gal4-ELK1 fusion proteins and an expression plasmid for fulllength AR. The fusion constructs substituted the Gal4 DNA binding domain (Gal4-DBD)
for the ETS DNA binding domain of ELK1. At the time of transfection, the cells were
treated with testosterone (10 nm) or vehicle control. Forty eight hours after transfection,
cells were harvested by preparing lysates for measurement of luciferase activity. B
shows cell lysates probed by Western blotting with antibodies against Gal4, AR, or
GAPDH (loading control). C shows data on co-immunoprecipitation of ectopic AR and
ectopic ELK1 or ELK1 mutants from HeLa cell lysates. HeLa cells were transfected with
the expression plasmid for AR and co-transfected with an expression plasmid for
WTELK1 or one of two ELK1 mutants, ELK1Δ308–321 and ELK1 FxLa. The lysates
were immunoprecipitated (IP) using either antibody to AR or a negative control. The
immunoprecipitates were probed by Western blotting using antibody to either AR or
ELK1 as indicated. *, p < 0.01. . Reprinted by permission from Journal of Biological
Chemistry Copyright 2016 (1)
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ELK1 (87-428) fusion protein. Induction of reporter luciferase activity by testosterone
was measured to quantify the binding of AR to ELK1. In these cells, lentiviral
transduction with shRNA against SRF resulted in knocking down SRF at both the
mRNA and protein levels compared to control shRNA (Figure 3.7A and inset).
Knockdown of SRF significantly increased testosterone-induced luciferase activity
(Figure 3.7B).
As a complementary approach, we used recombinant HeLa cells that stably
expressed the AR(A/B) domain fused to the VP16 transactivation domain [AR(A/B)VP16]. Additionally, the Gal4-TATA-Luc promoter-reporter was stably integrated in the
chromatin. In these cells, we examined the effect of SRF knockdown on the hormoneindependent activation of ELK1 by AR(A/B)-VP16. Cells were transduced with shRNA
against SRF or with control shRNA followed by transfection with the Gal4-ELK1 fusion
construct or with the Gal4 control vector. SRF shRNA substantially decreased both SRF
mRNA and protein (Figure 3.7C and inset) and increased the luciferase reporter activity
three-fold compared to cells transduced with control shRNA (Figure 3.7D). Taken
together, these results demonstrate that SRF is not required for activation of ELK1 by
AR; rather, SRF may hinder optimal ELK1-dependent transcriptional activation by AR.
3.3.5 Influence of ERK1/2 on the interaction of AR with ELK1
The requirement for MAPK docking motifs in ELK1 suggested the possibility that
the functional association of AR with ELK1 could involve ERKs, the classical ELK1
activating protein kinases, as an essential component of the ELK1-AR complex. As a
first test we used recombinant HeLa cells stably expressing AR(A/B)-VP16 in which the
Gal4-TATA-Luc promoter-reporter was also stably integrated. These cells were co-
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transfected with siRNAs against ERK1 and ERK2 or transfected with control siRNA.
ERK mRNAs and proteins were depleted within 48 hours of siRNA transfection
compared with the control siRNA (Figure 3.7E, top and bottom). Following knockdown
of ERKs, the cells were transfected again, this time with expression plasmid for the
Gal4-ELK1 fusion protein or the control Gal4 vector. In parallel, cells were also cotransfected with Gal4-ELK1 and the expression plasmid for CA-MEK1. The reporter
luciferase activity was measured 24 hours following the second transfection (72 hours
following the first transfection) while the knockdown of ERKs persisted (Figure 3.7E, top
and bottom). The synergistic activation of the promoter-reporter by AR and ELK1 was
unaffected by the combined depletion of ERK1 and ERK2 (Figure 3.7F). In contrast, the
CA-MEK-induced hyper-activation of the promoter was abrogated by depletion of ERK1
and ERK2, decreasing the promoter activation to the level observed for cells only
expressing AR(A/B) and Gal4-ELK1 (Figure 3.7F).
Next we tested whether AR(A/B) would compete with ERKs as activators of
ELK1. We used recombinant HeLa cells in which the Gal4-TATA-Luc promoter-reporter
was stably integrated and which also stably expressed the Gal4-ELK1 fusion protein. As
expected, in these cells ectopic expression of CA-MEK1 strongly stimulated expression
of the luciferase reporter (Figure 3.7G). However, co-expression of AR(A/B) decreased
the promoter activation (Figure 3.7G), indicating that AR interferes with hyper-activation
of ELK1 by ERKs.
In a third approach, the effect of ERK activity on the interaction ELK1 and AR
was tested using HeLa cells co-transfected with the (ELK1)2-TATA-luc reporter and an
expression plasmid for either AR(A/B) or CA-MEK1. The (ELK1)2-TATA-luc promoter is
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Figure 3.7 Effect of depleting SRF or ERK1/2 on the interactions of AR with ELK1.
A and B show data obtained using recombinant HeLa cells generated by stably
transducing a minimal promoter-luciferase reporter containing upstream Gal4 elements
(GAL4-TATA-LUC) and also with vectors expressing AR and a Gal4-ELK1 fusion
construct in which the Gal4 DNA binding domain was substituted for the ETS DNA
binding domain of ELK1. The cells were depleted of hormone and then transduced with
shRNA against SRF or a non-targeted control shRNA using lentivirus. Seventy two hours
after infection, cells were treated with testosterone (10 nm) or vehicle for a further 48 h.
The cells were then harvested to quantify SRF mRNA (A) or for Western blotting analysis
using antibody to SRF or to GAPDH (loading control) (A, inset) or for luciferase activity
(B). C and D show data obtained using recombinant HeLa cells generated by stably
transducing GAL4-TATA-LUC and also a vector expressing the AR A/B domain fused to
the VP16 transactivation domain (AR(A/B)-VP16). The cells were transduced with
shRNA against SRF or a non-targeted control shRNA using lentivirus. Seventy two hours
after infection, the cells were transfected with expression plasmid for the Gal4-ELK1
fusion protein. Forty eight hours later, the cells were harvested to quantify SRF mRNA
(C) or for Western blotting analysis using antibody to SRF or to GAPDH (loading control)
(C, inset) or to measure luciferase activity (D). E–G show data obtained using the
recombinant HeLa cells with stably incorporated GAL4-TATA-LUC and stably expressing
the AR(A/B)-VP16 fusion protein. Cells were transfected with a mixture of siRNA against
ERK1 and ERK2 or with control non-targeted siRNA. After 48 h of transfection, the cells
were harvested to quantify mRNAs for ERK1 and ERK2 (E) or for Western blotting
analysis using antibody to ERK1/2 or to GAPDH (loading control) (E, below); the
remaining cells were transfected for a second time with the Gal-4ELK1 expression
plasmid or the control vector plasmid or the plasmid for constitutively active mutant of
MEK1 (F). After a further 24 h, the cells were harvested to quantify mRNAs for ERK1
and ERK2 (E) or for Western blotting analysis using antibody to ERK1/2 or to GAPDH
(loading control) (E, below) or to measure luciferase activity (F). H, HeLa cells were cotransfected with an ELK1-driven minimal promoter-luciferase reporter ((ELK1)2-TATALUC) and expression plasmid for either AR(A/B) or constitutively active MEK1 or control
vector plasmid. The cells were treated with trametinib (1 μm) or vehicle for 48 h
beginning with the time of transfection. Luciferase activity was measured in the cell
lysates. For all transfections, a Renilla luciferase reporter was used as the control for
transfection efficiency. In all panels, the error bars represent standard deviation of
experimental triplicates. *, p < 0.001; **, p < 0.001. Reprinted by permission from Journal
of Biological Chemistry Copyright 2016 (1)
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responsive to the endogenous ELK1 in the cells. Following the transfections, the cells
were treated with the MEK inhibitor, trametinib. As expected, MEK-induced activation of
the promoter was inhibited by trametinib (Figure 3.7H). In contrast, trametinib did not
affect activation of the promoter by AR(A/B). The results from the complementary
approaches of depletion and inhibition of ERK1/2 and competition between MEK1 and
AR(A/B) as activators of ELK1 all demonstrate that the functional interaction of AR and
ELK1 is insensitive to the expression or activation status of ERKs. The data indicates
that the association of AR with ELK1 occurs independently of ERK1 and ERK2.
3.3.6 Direct binding of AR and ELK1
The studies above indicate that the classical binding partners of ELK1, i.e. SRF
and ERK1/2, interfere with rather facilitate functional association of AR with ELK1.
Therefore, to test whether the association of AR with ELK1 could be due to direct
binding, we used surface plasmon resonance (SPR). Purified AR (Abcam, Cambridge,
MA) was immobilized as the “ligand”. His-tagged ELK1 and his-tagged mutant ELK1 in
which both the D-box and the DEF motif were disrupted (∆308-321, F397L, P398A)
were affinity purified to >85% percent (Figure 3.8A) and used as the analyte. The
binding kinetics for ELK1 was determined at concentrations of 0, 5, 10, 20, 40, 80, and
160 nM (Figure 3.8B). Bovine serum albumin was used as the negative control. Kinetic
constants were evaluated using the BIAevaluation software. The equilibrium
dissociation constant for the AR-ELK1 interaction was determined to be 1.9 × 10 -8 M.
When the mutant ELK1 was used as the analyte at a concentration of 100nM the
average response from triplicate measurements was reduced by ~90 percent compared
with 100nM ELK1 (Figure 3.8C). The relatively high affinity of binding of purified
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preparations of AR and ELK1 strongly supports the concept that the in situ interactions
of the two proteins are due to direct binding. Moreover, loss of this binding due to
disruption of the ERK docking sites in ELK1, strongly indicate that these are also the
docking sites for AR.
3.3.7 Relevance of the physical association of ELK1 and AR to androgendependent cell growth
Previous studies using ELK1 depletion methods have demonstrated that both
prostate and bladder cancer cells require ELK1 for androgen-dependent growth (246,
292, 293). However, they did not test the physiological effect of disrupting the
association of ELK1 with AR. To disrupt the hormone-dependent association of AR and
ELK1 in situ without disrupting the ability of ELK1 to bind to DNA, we used an ELK1
mutant lacking the D-box region (amino acids 308-321) that should compete with
endogenous ELK1 for binding to chromatin. We tested whether the mutant ELK1 would
produce a dominant-negative effect on androgen-dependent growth. LNCaP cells were
transduced with lentiviral expression vectors for either ELK1 or the ELK1Δ308-321
mutant (Figure 3.8D, inset). Ectopic overexpression of ELK1 did not appreciably
influence androgen (R1881)-dependent growth compared with the vector-transduced
control (Figure 3.8D). In contrast, ectopic overexpression of the ELK1Δ308-321 mutant
showed a dominant-negative effect by inhibiting hormone-dependent growth.

To

confirm that the dominant-negative effect of this ELK1Δ308-321 on androgendependent growth was not due to dependence on activation of ELK1 by ERK, we
demonstrate that LNCaP growth is insensitive to inhibition of MEK by trametinab (Figure
3.8E); as a control in Figure 3.8E, the AKT inhibitor AKTi-1/2 completely inhibited
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Figure 3.8 Direct binding of ELK1 and AR and the effect of disrupting docking
sites in ELK1 on AR binding and androgen-dependent cell growth. A shows SDSPAGE of purified His-tagged ELK1 protein and His-tagged ELK1 protein mutated (ELK1
mut) in both D-box (Δ308–321) and DEF motif. The protein bands were visualized by
Coomassie Blue staining and estimated to be >85% pure and used in the SPR
experiments below together with purified AR obtained commercially. B shows SPR
kinetic curves for quantitative analyses of AR binding to His-tagged ELK1. AR was
immobilized on a CM5 sensor chip, and ELK1 was diluted in a series of concentrations
(0, 5, 10, 20, 40, 80, and 160 nm). The results were normalized by subtracting the SPR
response (RU) for buffer alone or BSA and performed in duplicate. C shows SPR kinetic
curves for quantitative analyses of AR binding to His-tagged mutant ELK1. AR was
immobilized as in B, and ELK1 or mutant ELK1 was used at 100 nm. The kinetic curves
for triplicate determinations are shown. D, hormone-depleted LNCaP cells were
transduced using lentivirus expressing either the WTELK1, or ELK1(Δ308–321), or with
control lentivirus. After 72 h, cells were plated in 96-well plates, and cell growth was
monitored by the MTT assay. Twenty four hours after plating, the cells were treated with
R1881 (1 nm) or vehicle for a further 72 h. The inset in D shows Western blotting
analysis of cell lysates, 72 h post-infection, using antibody to ELK1 or with antibody to
GAPDH (loading control). The error bars represent standard deviation of experimental
triplicates. *, p < 0.001. E, hormone-depleted LNCaP cells were plated in 96-well plates
in the presence of R1881 (1 nm) together with vehicle, trametinib (1 μm), or AKTi-1/2 (2
μm). MTT assay was performed 72 h later. The error bars represent standard deviation
of experimental triplicates. *, p < 0.001. Reprinted by permission from Journal of
Biological Chemistry Copyright 2016 (1)
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androgen-dependent growth. These results further validate the model that docking of
AR on ELK1 is an essential component of growth signaling by androgen/AR in prostate
cancer cells.
3.3.8 Synergy between the splice variant AR-V7 and ELK1 and AR-V7 dependent
cell growth
The ability of the amino-terminal A/B domain of AR to synergize with ELK1
suggested that AR-V7, the major splice variant of AR, would most likely also synergize
with ELK1. To test this possibility we co-transfected the (ELK1)2-TATA-luc promoterreporter construct with an expression plasmid for AR-V7 and wtELK1 into the ARnegative HeLa cells. Ectopic AR-V7 activated the promoter driven luciferase activity well
above the basal level presumably associated with endogenous ELK1 (Figure 3.9A).
Similarly, when the Gal4-TATA-luc promoter was co-transfected with Gal4-ELK1 and
AR-V7, there was strong induction of promoter activity (Figure 3.9B). Western blot
analysis confirmed expression of the AR-V7 construct in both cases (Figure 3.9C).
We have previously demonstrated that ELK1 is necessary for androgen/ARdependent growth of prostate cancer cells. To test whether prostate cancer cells that
are dependent on AR-V7 also depend on ELK1, we used shRNA to deplete ELK1 in
CWR22Rv1 cells, which depend on endogenous AR-V7. Partial depletion of ELK1
prevented the growth of these cells (Figure 3.9D, top and bottom panels).
These results confirm that the AR-V7 splice variant cooperates with ELK1 as a
transcriptional co-activator in the same manner as AR(A/B) and that ELK1 is also
necessary for AR-V7 dependent growth of prostate cancer cells.
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Figure 3.9 Functional association of ELK1 and AR-V7 and effect on cell growth. A,
HeLa cells were co-transfected with an ELK1-driven minimal promoter-luciferase
reporter ((ELK1)2-TATA-LUC) and expression plasmid for either AR-V7 or WTELK1 or
control vector plasmid for 48 h. Luciferase activity was measured in the cell lysates. For
all transfections, a Renilla luciferase reporter was used as the control for transfection
efficiency. B, HeLa cells were co-transfected with a Gal4-driven minimal promoterluciferase reporter (Gal4-TATA-Luc) and expression plasmid for either AR-V7 or Gal4ELK1 or control vector plasmid for 48 h. Luciferase activity was measured in the cell
lysates. For all transfections, a Renilla luciferase reporter was used as the control for
transfection efficiency. C shows a Western blot of HeLa cell lysates corresponding to all
of the transfections in A and B, which was probed using an antibody to the aminoterminal domain of AR or with antibody to GAPDH (loading control). D, top panel shows
the effect of depleting ELK1 by lentiviral shRNA transduction on the growth of
CWR22Rv1 cells monitored by the MTT assay compared with control shRNA. The
Western blot in the bottom panel shows ELK1 shRNA-induced depletion of ELK1
compared with control shRNA; GAPDH was probed as the loading control. Reprinted by
permission from Journal of Biological Chemistry Copyright 2016 (1)
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3.4 Discussion
The results of this study elucidate the nature of the interaction of the ligandindependent A/B domain of AR with ELK1 that accounts for the ELK1-dependent
transcriptional activity of AR in PCa cells. Systematic mapping using a mammalian twohybrid assay and an extensive series of ELK1 deletion and point mutants, and
confirmatory co-immunoprecipitation experiments, identified the two ERK docking motifs
(D-box and DEF motif) in ELK1 as the elements essential for co-activation by AR.
Nonetheless, the AR synergy with ELK1 is independent of ERKs and involves AR
binding directly to ELK1. Interactions with ELK1 are required for hormone-dependent
growth of PCa cells and also account for the ability of the AR A/B domain, as well as the
major AR splice variant AR-V7, to support their hormone-independent growth. Indeed
the results strongly support the view that synergy with ELK1, via AR docking on ELK1,
is a critical component of growth signaling by AR and AR-V7.
The mammalian two-hybrid mapping data with Gal4ELK1 mutants were clear-cut.
Parallel studies using a constitutively active form of MEK to activate ELK1 demonstrated
that the regions required for co-activation by AR(A/B) precisely coincided with the D-box
and DEF motifs in ELK1 (298-300). Activation was hormone independent as, in contrast
to full length AR, the A/B domain is not constrained by the need for ligand binding to
enter the nuclear compartment. Importantly, mapping data for the sites of interaction of
the AR A/B domain with ELK1 were entirely recapitulated with full length AR and
confirmed by co-immunoprecipitation. There were two notable differences between coactivation of ELK1 by AR and activation by MEK. First, the level of ELK1 transcriptional
activity induced by MEK was substantially higher than that induced by AR. This
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difference in magnitude is associated with the transient nature of ELK1 activation
through the MAPK pathway in contrast to the constitutive ELK1-dependent activation of
growth genes by AR (246). Second, an intact ELK1 transactivation domain was
essential for activation by MEK but not for co-activation of ELK1 by AR. This finding
indicates that AR only utilizes ELK1 for recruitment to regulatory sites in chromatin to
activate growth genes and that the transcriptional activity per se of ELK1 is unimportant
for the ELK1-AR synergy.
Complementary approaches, including one- and two-hybrid assays, promoter
assays, gene knockdown, MEK inhibition and competition assays demonstrated that the
classical binding partners of ELK1 in the TCF complex, i.e. SRF and ERKs (307), are
not required for co-activation of ELK1 by AR. Indeed, SRF and ERKs both appeared to
interfere with the interaction of AR with ELK1. SRF knockdown may release ELK1 from
immediate early gene promoters, which are unresponsive to androgen (246). Similarly,
ELK1 recruits ERKs directly to a subset of target genes (308) suggesting that ERK
competes directly with AR for ELK1 binding. Indeed SPR confirmed binding between
ELK1 and AR with a relatively high affinity (Kd, 1.9 x 10-8 M), strongly supporting the
premise that the transcriptional synergy between ELK1 and AR is due to direct binding.
Loss of this binding upon mutational disruption of the ERK docking sites in ELK1
equates the ELK1 motifs required for functional association with AR with those required
for direct binding of AR to ELK1.
ETS elements are commonly enriched at or in the vicinity of AR binding sites in
the chromatin (269, 309) and indeed physical association of AR has been suggested
with ETV1 (310) and ETS1 (309). However, in neither case has the structural binding
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elements in either AR or the ETS protein been elucidated. Among the known DNA
binding proteins that have been suggested to recruit AR, the interactions of AR with
HoxB13 and C/EBPa are perhaps the best studied. HoxB13 interacts with the DNA
binding domain of AR (242) whereas C/EBPa did not show a strong AR domain
selectivity for interaction and its association with AR involved multiple AR domains
(245). Relatively little is known about the structural basis for non-genomic interactions of
AR and other nuclear receptors with signaling pathways involving MAPK, PI3K/Akt,
PKC, PLC and GPCR (275). Notable exceptions include the direct or indirect
associations of NRs with the Src SH2 or SH3 domains where proline-rich motifs in AR
and the progesterone receptor or LXXL motifs in the estrogen receptor are required
(311-314). The relatively large size and multi-domain structure of NRs appears to offer a
diversity of binding motifs for interactions with co-activators and DNA binding
transcription factors.
To our knowledge the functional interaction of AR with ELK1 is the first
demonstration of a nuclear receptor co-opting protein kinase docking sites to regulate or
constitutively activate a signaling pathway. The finding that ERK docking motifs can
recruit AR suggests that AR may adopt similar modes of interaction in its crosstalk with
other signaling molecules. Certainly, by mimicking ERK interactions with docking motifs,
AR may interact with additional substrates of ERK, of which there are over fifty (298).
There is much crosstalk between AR genomic and non-genomic pathways in prostate
cancer. The canonical pathway for AR signaling requires nuclear translocation of the
ligand bound receptor to activate transcription and induce proliferation in PCa cells.
Activation of the MAPK phosphorylation cascade can be induced through non-genomic
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pathways of AR signaling and stimulate cell proliferation. Activated ERK can
phosphorylate AR and its coactivators, and therefore this feedback loop of the nongenomic AR signaling may induce genomic AR signaling in prostate cancer (315, 316).
These are pathways that are well known in the literature pertaining to PCa; however
these classical genomic and non-genomic AR signaling pathways are independent of
the AR tethering mechanism and the ability of AR to co-opt the ERK docking sites in
ELK1 to activate transcription.
Overexpression of an ELK1 docking site mutant in which the ability to associate
with AR was disrupted without disrupting the DNA binding domain, had a dominantnegative effect on androgen-stimulated growth in PCa cells. This was unrelated to loss
of ERK binding in the mutant ELK1 as the cells were insensitive to MEK inhibition. As
the discrete DNA binding domain in the mutant ELK1 was not compromised, the mutant
presumably still bound to ELK1 elements in the DNA; however, because the D-box was
deleted in the mutant ELK1, our mapping data would predict that AR would not bind to
it. The dominant-negative effect of the mutant ELK1 on androgen-stimulated growth is
therefore consistent with this prediction. These observations provide an additional
functional link between recruitment of AR by ELK1 and growth signaling by AR in PCa
cells. The characterization of such discrete AR interacting motifs should enable
development of small molecule drugs that bind to those sites and selectively target
dysregulated growth signaling in prostate cancer, while avoiding the global side effects
of androgen ablation.
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CHAPTER 4- Tumor Selective Disruption of Androgen Receptor function in
Prostate Cancer
The information on the high throughput screening methodology and small
molecule inhibitors of ELK1-AR interactions described in this chapter comprise
intellectual property of Wayne State University and is covered by provisional patents
filed by the university.

4.1 Introduction
A unique feature of prostate oncogenesis is its dependence on androgen, which
acts by binding to and activating transcriptional signaling by the androgen receptor
(AR). Both early stage and advanced prostate tumors are generally dependent on AR
for growth (272-274, 279-281). Following initial surgery or radiation treatment, residual
or recurrent prostate cancer (PC) is commonly treated by suppressing testicular
androgen synthesis, typically by disruption of the pituitary hypothalamus axis (chemical
castration) (107, 110). In addition, androgen antagonists or an androgen synthesis
inhibitor may be used to inhibit AR activation via intratumoral testosterone synthesis
(317). Unfortunately, the initial responders to androgen deprivation therapy (ADT) tend
to develop hormone refractory disease, referred to as castration resistant PC (CRPC),
which nevertheless continues to depend on AR (192, 214, 290, 291, 318, 319). Growth
signaling may be sustained in CRPC largely through amplification of AR (291) or
expression of its spice variants. Splice variants of AR lack the ligand binding domain but
are localized in the nucleus of CRPC cells (289). AR splice variants are frequently coexpressed with full length AR with which they heterodimerize and translocate to the
nuclear compartment in a ligand-independent manner (220). AR splice variants, in
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collaboration with full length AR, confer optimal hormone-independent growth and
insensitivity to anti-androgens and their expression is both functionally and clinically
linked to tumor progression (210, 221, 319, 320). Resistance mechanisms also include
hormone-independent cross-talk between AR and certain signaling pathways and
alterations in the AR co-regulator complement or mutation of AR (291).
Adverse effects associated with ADT are both acute (fatigue, hot flashes, flares)
and long-term (hyperlipidemia, insulin resistance, cardiovascular disease, anemia,
osteoporosis, sexual dysfunction and cognitive defects) and include loss of the feeling
of well-being (107, 111, 112). The high affinity androgen antagonist enzalutamide, used
to treat CRPC, inactivates AR by blocking its nuclear entry and impairing its
transcriptional activity (321) but it necessarily also abrogates AR signaling in normal
tissues (322) and is ineffective against AR splice variants or highly overexpressed AR
(221, 323-325). The recurrent and metastatic disease is then treated by chemotherapy,
which is typically non-curative and has adverse side effects. Newer types of
chemotherapy, immunotherapy and radiation therapy offer valuable, but limited,
improvements (112, 121-123, 125, 126, 321, 322). Experimental drugs that block coactivator protein binding to AR have been developed via high throughput small molecule
screening. They are effective against AR splice variants (234, 236, 326, 327) but they
may also be expected to impair AR function in normal tissues.
Thus the current clinical paradigm for long-term treatment of advanced PC is
ubiquitous attenuation of AR signaling (328). However, these approaches have two
major limitations: 1. ineffectiveness against advanced tumors in which functional AR has
been restored through any of the aforementioned mechanisms; and 2. the need to
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deprive the patient of androgen or AR function in all tissues and the consequent multiple
long-term side effects noted above. A strategic approach to addressing the dual
limitation of ADT is to identify and disrupt a functional arm of AR that (i) is preserved as
a crucial mechanism for supporting growth in CRPC and (ii) is necessary for tumor
growth, but not for the physiological role of androgen in differentiated normal tissues.
Mechanisms of growth signaling by AR that are tumor-specific could potentially offer a
highly sensitive point of attack, even in cells that have acquired resistance to ADT and
anti-androgen therapies.
As androgen plays a major role in all physiological aspects of the normal prostate
epithelium including development, differentiation, maintenance and function (329),
malignant prostate epithelial cells must selectively support mechanisms that redirect
androgen/AR signaling to strongly support growth. In the classical model of gene
regulation by AR the receptor requires bound ligand to homo-dimerize, enter the
nucleus and bind to DNA at well-characterized androgen response elements (AREs)
associated with target genes (58-60, 284, 285). When the bound ligand is an agonist,
AR then recruits co-activators; in contrast, when bound to antagonists, co-repressors
are preferentially recruited (59, 60). AR contains sites of co-regulator binding that are
either ligand-dependent or -independent. However, in PC cells that are adapted to grow
in the absence of hormone, the AR apo-protein is localized in the nucleus, where it is
transcriptionally active even in the absence of hormone (210, 221, 245, 267, 289). AR
cannot optimally bind to AREs without androgen; nevertheless, both ligand-bound and unbound AR will still activate a large set of growth supporting genes and support growth
through associations with chromatin via putative tethering proteins (267). We have
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previously reported that ELK1 is an AR tethering protein that is obligatory for
androgen/AR-dependent malignant growth in a variety of well-established PC/CRPC
models (246, 268).
ELK1 is a downstream effector of the MAPK signaling pathway and belongs to
the ternary complex factor (TCF) sub-family of the ETS family of transcription factors.
ELK1 characteristically binds to purine-rich GGA core sequences (295) and is in a
repressive association with many cell growth genes. Phosphorylation by ERK transiently
stimulates ELK1 to activate its target genes including association with serum response
factor (SRF) for activation of immediate early genes (261, 262, 295-297, 308). ELK1
was at least partially required for a substantial proportion (~ 27 percent) of all gene
activation by androgen in PC cells (246). The activation of AR target growth genes
through ELK1 is mechanistically distinct from the mode of activation of immediate early
genes by ELK1 in that it does not require hyper-phosphorylation by ERK; the
phosphorylation state of ELK1 is unaltered in the context of the ELK1-AR synergy (246).
Tethering of AR by ELK1 in PC/CRPC cells enables constitutive activation of a crucial
set of growth genes by AR. In the normal differentiated prostate epithelium and in other
normal differentiated AR+ tissues, where growth genes are not activated, it is possible
that ELK1 is displaced in the chromatin by related members of the large ETS family that
do not associate with AR. Alternatively, at the relatively low AR levels in normal tissues,
the receptor could be sequestered by preferential binding to AREs associated with
genes unrelated to growth. The N-terminal A/B domain of AR [AR(A/B)], which lacks the
ligand binding site, is adequate for interaction with ELK1 (246), in contrast to other
known AR tethering proteins (242, 245). AR splice variants, which have C-terminal
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deletions and lack the ligand binding domain (LBD), also synergize with ELK1 and
support growth (268).
The goal of this study is to establish the feasibility of developing a new class of
small molecule drugs that could selectively suppress growth signaling by AR or its
variants required by PC/CRPC without affecting other actions of the receptor. To
accomplish this, we undertook an unbiased cell-based screen to search for small
molecules that could block the association of AR with ELK1 and further derived a lead
molecule from an initial hit. Here we report on this small molecule discovery including a
detailed evaluation of its mechanism of action and selectivity and efficacy as an inhibitor
of the growth of PC/CRPC cells and tumors.
4.2 Materials and Methods
4.2.1 Cell Culture and Reagents
LNCaP, CWR22Rv1, VCaP, DU145, HEK293, H1650 and HeLa cell lines were
from the American Type Culture Collection (Manassas, VA); 293FT cells were from
Invitrogen. LNCaP, CWR22Rv1 and H1650 cells cells were routinely grown at 37°C in
5% CO2 in RPMI 1640 medium supplemented with 10% FBS (Invitrogen), 100 units/ml
penicillin, 100 µg/ml streptomycin, 2mM L-glutamine mixture (Invitrogen), with the
exception that sodium pyruvate (1mM) (Invitrogen) was included in the LNCaP culture
media alone. VCaP, HEK293, DU145 and HeLa cells were grown in DMEM medium
supplemented with 10% FBS (Invitrogen), 100 units/ml penicillin, 100 µg/ml
streptomycin, 2mM L-glutamine mixture (Invitrogen) or for hormone depletion, LNCaP
cells were grown in phenol-red free RPMI 1640 medium supplemented with 10% heatinactivated and charcoal-stripped FBS (Sigma) and 100 units/ml penicillin, 100µg/ml
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streptomycin, and 2mM L-glutamine mixture for 96 hours before each experiment.
Affinity-purified rabbit anti-human antibody to AR (sc-7305) and mouse antibody to
GAPDH (sc-47724) were purchased from Santa Cruz Biotechnology (Santa Cruz, CA).
Rabbit monoclonal anti-human antibody to ELK1 (ab32106) was from Abcam
(Cambridge, MA). Testosterone was from Sigma-Aldrich. Lipofectamine
purchased

from

Thermo

Scientific

(product

number

TM

78410).

2000 was
5,7,3’,4’-

Tetrahydroxyflavone was from Selleckchem (S2320); 5,7,3’,4’-Tetrahydroxyisoflavone
was from BOC Sciences (480-23-9). The following compounds were from INDOFINE
Chemical

Company:

5,7,3’,4’-Tetrahydroxyflavanone

(021111S);

5,3’,4’-

Tetrahydroxyflavone (T-406); 5,3’-Dihydroxyflavone (D-409); 7,4’-Dihydroxyflavone (D412); 5-Hydroxyflavone (H-025); 3’-Hydroxyflavone (H-410); 5,3’-Dihydroxy-6,7,4’trimethoxyflavone (D-123). The following compounds were from Extrasynthase: 3’,4’,7Trihydroxyflavone (1223); 5,7-Dihydroxyflavone (1362S); 3’,4’-Dihydroxyflavone (1204);
4’,5,7-Trihydroxy-3’-methoxyflavone

(1104S);

3’,4’,5,7-Tetrahydroxyflavone-3-

methoxyflavone (1342); and 3’,4’,5,7-Tetramethoxyflavone (1204). The following
compounds were from Cayman Chemical: 4’,5,7-Trihydroxyflavone (10010275) and
5,7,3’-Trihydroxy-4’-methoxyflavone (18649). 7,3’-Dihydroxyflavone was from SigmaAldrich (CDS06791). 4’,5-Dihdyroxyflavone was from Sana Cruz (sc-267859). shRNAs
targeting AR and ELK1 and non-targeting control shRNA in the lentiviral expression
vector pLKO.1-puro were purchased from Sigma-Aldrich. The pLVX-AR-V7 plasmid and
pLVX control plasmid were a kind gift from Dr.Yan Dong from Tulane University (New
Orleans, LA).
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4.2.2 Generation of recombinant cell lines for high throughput screening and
counter screening of small molecule libraries
The recombinant cells used for primary screening were generated from HeLa
HLR cells, kindly provided by Dr. Johann Hofman (Innsbruck Medical University), which
were originally designed to serve as a cell-based assay system to measure modulation
of MAPK activity. HeLa HLR cells have a stably integrated minimal promoter-luciferase
reporter containing five upstream Gal4 elements (Gal4-TATA-Luc) and also
constitutively express a Gal4-ELK1fusion protein in which the Gal4 DNA binding domain
is substituted for the ETS DNA binding domain of ELK1. We stably transduced these
cells with a vector expressing the full-length AR. The full length AR was subcloned from
the pCMV expression vector (Origene) into the pCDH-CMV-MCS-EF1-Puro cDNA
Cloning and Expression Vector (System Biosciences) at NheI (upstream) and BamHI
(downstream) sites. The lentiviral vector expressing full length AR was then packaged in
lentivirus and the HeLa HLR cells were infected as described below in the sub-section
‘Lentivirus-mediated-Transduction’. After 72h of infection, 2 ug/mL of puromycin was
added to the culture media to select for the transduced cells. The cells were plated at
low density for colony formation (20 -40 colonies) in a 100 mm dish. Clonal cells were
isolated using cloning cylinders from CORNING (Cat. #3166-8). The selected clones
were further expanded and then tested for luciferase induction by testosterone. The
clone that gave the greatest luciferase signal to noise ratio in response to testosterone
treatment was then chosen for use in the primary screening assay for high throughput
small molecule screening.
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The cells generated for counter screening comprise HeLa cells stably transduced
with a lentiviral plasmid construct containing a minimal promoter-luciferase reporter and
an upstream androgen response element (ARE) sequence. The cells were also
transduced with a lentiviral expression plasmid for the full-length AR. These constructs
were made as follows. Custom synthesized PCR primers were used to amplify and
clone the ARE sequence from the pG5luc vector into the pGreenFire1TM -mCMV-EF1Neo (Plasmid) at SpeI (upstream) and BamHI (downstream) sites. The lentiviral vector
expressing ARE-luciferase reporter was then packaged in lentivirus and parental HeLa
cells were infected as described below under the sub-section ‘Lentivirus-mediatedTransduction’. After 72h of infection, 400 ug/mL of Geneticin was added to the culture
media to select for the transduced cells. These cells were then infected with the
lentivirus containing the full length AR expression plasmid described above. After 72h of
infection, 2 ug/mL of Puromycin was added to the culture media to select for the
transduced cells. Clonal cells harboring both the ARE-promoter-luciferase reporter and
also stably expressing AR were then isolated using cloning cylinders as described
above. The selected clones were further expanded and then tested for luciferase
induction by testosterone. The clone that gave the greatest luciferase signal to noise
ratio in response to testosterone treatment was then chosen for use in the counter
screening assay for high throughput small molecule screening. All of the plasmid
constructs generated above were sent to either the Plant-Microbe Genomics Facility for
DNA Sequencing at The Ohio State University (Columbus, OH) or to Genewiz (South
Plainfield, NJ) to verify DNA sequences before the constructs were used in the studies.
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The recombinant HeLa cells generated above were routinely grown in DMEM
supplemented with 10% FBS and 100 units/ml penicillin, 100µg/ml streptomycin, 2mM
L-glutamine mixture (Invitrogen) and the appropriate selection antibiotics. The
antibiotics used in the culture media for the primary screening cells included 100µg/ml
Hygromycin (Invitrogen) (to maintain Gal4-ELK1), 100µg /ml Geneticin (Invitrogen) (to
maintain Gal4-TATA-Luc) and 2 µg /ml Puromycin (Sigma-Aldrich) (to maintain AR).
The antibiotics used in the culture media for the counter screening cells included 400
µg/ml Geneticin (Invitrogen) (to maintain ARE-TATA-Luc) 2 µg /ml Puromycin (SigmaAldrich) (to maintain AR).
4.2.3 High Throughput Screening
The high throughput screening was conducted at University of Michigan’s Center
for Chemical Genomics Screening facility under the guidance of its Director, Martha
Larsen.

Recombinant primary screening cells were first depleted of hormone by

growing them for 24h in media in which the serum used was heat-inactivated and
charcoal-stripped. The cells were then plated in 384-well white flat bottom plates (5,000
cells/well) (Corning Product #3570) using a Multidrop (Thermo Fisher Scientific,
Waltham, MA). The plates were then incubated for 24h prior to adding compounds. The
following day compounds from the LOPAC, Prestwick, or Maybridge Hitfinder libraries
were added precisely in a 0.2 µL volume in the test wells using a Biomek FX liquid
handler (Beckman Coutler, Break, CA) to achieve final media concentration of 10 µM of
each compound. Using the same technique, testosterone was added in addition to the
compounds to achieve a final media concentration of 10 nM. As the compounds were
re-constituted from powder stocks using dimethyl sulfoxide (DMSO) as the solvent, the
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final media concentration of DMSO was 0.4% v/v. For the assay negative control on
each plate, one row of wells on each plate contained 10 nM testosterone and 0.4% v/v
of DMSO. For the assay positive control on each plate, one row of wells on each plate
contained 10 nM testosterone and 10 uM enzalutamide dissolved in DMSO (0.4% v/v of
DMSO in the wells). The plates were incubated for 24h at 37°C in 5% CO 2. The medium
was then aspirated leaving a residual volume 10µl using an Elx 405-plate washer (Bio
Tek U.S.). Then, 10 uL of the assay reagent Bright-Glo (Promega Corp., Madison WI)
was added to each well. Luciferase activities in the wells were then measured using a
Biomek FX dual head (Beckman) plate reader. A total of 18,270 compounds were
tested in the primary screen. A ‘hit’ was initially defined using relatively low stringency
criteria as a compound able to reduce luciferase activity in the test well ≥ 3 standard
deviations below the negative control wells or to a level ≥ 40% of the enzalutamide
control wells. For the primary assay this definition produced 1613 hits for an overall hit
rate of 8.8%. The 1613 compounds were then tested again in the primary screening
assay in parallel with the counter screening assay in triplicate. A hit was now redefined
as a compound able to reduce luciferase activity in the test wells ≥ 3 standard
deviations below the negative control wells and that was unable to reduce luciferase
activity ≥ 50% in the counter screen. By this definition, 92 hits were obtained.
Compounds were further triaged based on their ability to inhibit in the primary screen by
≥ 80% and produced no inhibition in the counter screen. One of the top hits was
prioritized for this study.
4.2.4 Purified Proteins
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Full length human AR expressed in insect cells and purified to >95% by affinity
chromatography and FPLC chromatography (ab82609) was purchased from Abcam
(Cambridge MA). Recombinant his-tagged ELK1 expressed from baculovirus infected
Sf9 cells was purified using nickel agarose affinity chromatography as previously
described by us (268). The proteins were eluted with 200mM imidazole and dialysed
against 20 mM HEPES, pH 7.9 containing 10% glycerol, 20mM KCl, 2mM MgCl2, 0.2
mM EDTA, 0.5mM benzamidine and 0.5mM DTT. Purity of the proteins was estimated
to be > 85% by SDS-polyacrylamide gel electrophoresis.
4.2.5 Surface Plasmon Resonance
Amine Coupling Kit, CM5 sensor chip and HBS-N buffer (GE Healthcare) were
used for surface plasmon resonance (SPR) analysis. The rate and equilibrium binding
constants of the interaction of AR with KCI807 was determined using Biacore 3000
(Biacore, Piscataway, NJ). Depending on the experimental plan, affinity-purified AR or
ELK1 polypeptide (ligand) was immobilized on a CM5 research grade sensor chip by an
amine coupling method (302). The immobilization involved activation of carboxymethyl
groups on a dextran-coated chip by reaction with N-hydroxysuccinimide, followed by
covalent bonding of the ligand (AR) to the chip surface via amide linkages. Reference
surfaces were prepared in the same manner but blocked with ethanolamine and thus
contained no ligand. To examine binding of KCI807 or enzalutamide, kinetic binding
analysis was carried out, by injecting the compound (analyte) at different concentrations
(0-320 nM for KCI807 or 0-200 nM for enzalutamide) into the flow cells (ligand and
reference cell). The interaction (response units, RU) between analyte and ligand was
recorded as the ligand RU minus the reference RU. Kinetic values were determined
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using BIAevaluation software (Biacore), and the data were fitted with the model showing
closest match (303, 304). A 1:1 Langmuir binding model was generally selected, in
which all the sensorgrams representing the different analyte concentrations were fitted
simultaneously with the wide window of association and dissociation phases. Individual
concentration curves were also evaluated to confirm the fitting data. The equilibrium
dissociation constant (Kd) was calculated by Kd = koff/kon. In all cases, baseline was
established in the presence of the vehicle used for the compounds (DMSO)
appropriately diluted in HBS-N buffer.
Competition binding experiments were executed on the Biacore 3000 system at a
flow rate of 5-10 µl/min in HBS-N buffer (330, 331). A fixed concentration (200 nM) of
AR in the presence of increasing concentrations of KCI807 or enzalutamide was passed
over a covalently stabilized ELK1 sensor surface for 5 min at 50 µl min -1. The sensor
surface was regenerated between experiments by dissociating any formed complex in
HBS-N buffer for 30 min, followed by a further 30-min stabilization period. After
regeneration, the SPR signal returned to the original level (baseline). In all cases,
baseline was established in the presence of the vehicle used for the compounds
(DMSO) appropriately diluted in HBS-N buffer. The binding curves were analyzed using
the heterogeneous analyte competition model. The kinetic curves were analyzed for a
one-to-one Langmuir fitting model provided by with the Biacore 3000 instrument
software.
4.2.6 Transfections and Reporter Luciferase Assays
Hela Cells were plated in a 24-well plate at a concentration of 75,000 cells/well in
antibiotic-free red DMEM. The following day the cells were transfected with a total of
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300 ng of plasmid DNA/well using Lipofectamine 2000. The cells were incubated for 24h
then lysed using luciferase assay lysis buffer 5X (REF: E291A) from Promega. The
luciferase activity of the cell lysates were measured using firefly substrate from
Promega and a luminometer (Lumat LB9501, Berthold, Wildbad, Germany).
4.2.7 Lentivirus-mediated-Transduction
shRNAs for ELK1, AR, and non-targeting control shRNA were packaged in
293FT cells. The lentiviral particles were generated using lipofectamine and three
plasmids, pMD2G, pMDLg/RRE, and pRSV/Rev which all code for essential elements of
the virus. The virus containing supernatant was harvested at 48 and 72 h after
transfection. Cells were plated in 6-well poly-D-lysine coated plates (BD Falcon) in
phenol red-free medium supplemented with 10% heat-inactivated charcoal-stripped
FBS and 2mM L-glutamine. The following day cells were infected with control shRNA,
ELK1 shRNA, or AR shRNA lentivirus with Polybrene (8µg/ml) for a 5 h duration,
followed by an additional 5h. After infection, the virus was replaced with fresh phenol
red-free growth medium.
4.2.8 Colony Growth Assay
Cells were trypsinized, and 1000 cells/well were seeded in poly-D-lysine coated
6-well plates in phenol red-free regular growth media. The cells were treated with the
indicated concentration of KCI807, which was replenished every 48h. The cells were
grown at 37°C in 5 % CO2 for 10 days until colonies grew to the desired size in the
untreated control wells. Colonies were fixed with methanol and stained with crystal
violet. Each treatment was conducted in triplicate and the number of colonies was
counted using the GelCountTM colony counter and a 350 size cutoff.
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4.2.9 Cell Monolayer Growth Assay
Cells were trypsinized and 3000-4000 cells/well were seeded in 96-well plates
coated with poly-D-lysine. The cells were seeded in phenol red-free medium
supplemented with 10% FBS, 100units/ml penicillin, 100 µg/ml streptomycin, 2mM Lglutamine mixture and sodium pyruvate (1mM) for LNCaP cells and phenol red-free
medium supplemented with 10% FBS, 100units/ml penicillin, 100 µg/ml streptomycin
and 2mM L-glutamine mixture for VCaP, 22Rv1, DU145, HeLa, HEK293 and H1650
cells. The cells were grown at 37°C in 5% CO2. Twenty four hours after seeding in the
96-well plates, the cells were treated with the indicated concentration of KCI807 or
DMSO (vehicle). The cells were re-treated on Day 3 by removing half the volume of
medium and replacing it with fresh treated medium. Cell viability was determined using
the MTT assay from day zero until day five. MTT (10µL, 5mg/mL) was added to each
well and incubated for 2h at 37°C. The formazan crystal sediments were dissolved in
100µL of DMSO, and the absorbance at 570nm was measured using the BioTek
Synergy 2 Microplate Reader (BioTek, Winooski, VT). The assay was conducted in
sextuplicate wells and values were normalized to day zero.
4.2.10 Western Blot Analysis
The treated cells were washed once with phosphate buffered saline (PBS) and
then lysed with RIPA buffer (150mM NaCl, 1% Nonidet P-40, 0.5% sodium
deoxycholate, 0.1% SDS, 50mM Tris of pH 8.0) containing a protease inhibitor cocktail
(Pierce, Thermo Fisher Scientific). The cell lysates were then incubated on ice for 40
minutes and vortexed every 10 minutes. Total protein concentrations were estimated
using the Bradford Assay (Bio-Rad). Ten micrograms of each protein sample was
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heated at 95°C for 5 minutes and resolved by electrophoresis on 8% polyacrylamideSDS gels and electrophoretically transferred to PVDF membranes (Millipore, Billerica,
MA). The membranes were then probed overnight at 4°C with the appropriate primary
antibody followed by the appropriate horseradish peroxidase-conjugated secondary
antibody. The blots were then developed to visualize the protein bands using the
HyGLO Chemiluminescent HRP Antibody Detection Reagent (Denville Scientific,
Metuchen, NI) (332) (332) (332) (332) (331) (331) (331) (75) (74).
4.2.11 RNA isolation, Reverse Transcription, and Real Time PCR.
Total RNA was isolated from cells using the RNeasy Mini Kit (Qiagen). Reverse
transcription PCR was then performed using 500 ng of total RNA with random primers
and using the high-capacity complementary DNA Archive kit (Applied Biosystems). The
complementary DNA from this reaction was measured using quantitative real time PCR
using the StepONE Plus Real Time PCR system (Life Technologies Corporation,
Carlsbad, CA). All reactions were performed in triplicate and normalized to
glyceraldehyde-3-phosphate-dehydrogenase values in the same samples. All primers
and Taqman probes were purchased from the applied Biosystems inventory (Invitrogen)
4.2.12 Measurement of intracellular and serum levels of compounds
4.2.12.1 Chromatographic and mass-spectrometric conditions
Instrumentation
All LC-MS/MS analyses were performed on an AB SCIEX (Foster City, CA) QTRAP
6500 LC-MS/MS system, which consists of a SHIMADZU (Kyoto, Japan) Nexera ultrahigh performance liquid chromatography (UPLC) coupled with a hybrid triple quadrupole
/ linear ion trap mass spectrometer. The UPLC system is equipped with two X2 LC-
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30AD pumps, an X2 SIL-30AC autosampler, a CBM-20A communication bus module,
an X2 CTO-30A column oven, and two DGU-20A degassing units.

Analyst®1.6

software was used for system control and data acquisition, and MultiQuant 3.0 software
was used for data processing and quantitation.
Liquid chromatography
Chromatographic separation was achieved on a Waters XBridge C18 (2.1 × 50 mm,
3.5 µm) column using an optimized gradient elution consisting of mobile phase A (0.1%
formic acid in water) and mobile phase B (0.1% formic acid in acetonitrile), at a flow rate
of 0.3 mL/min. The elution gradient program was as follows [shown as the time (min),
(% mobile phase B): 0 – 2.5 min, 40%; 2.5 – 4.5 min, 40 – 55%; 4.5 – 5 min, 55 –
100%; 5 – 6 min, 100%; 6 – 6.5 min, 100 - 40%; and 6.5 – 10 min, 40%. Column oven
temperature was maintained at 40°C. To minimize the carryover, external and internal
washes were implemented prior to and post the injection for both the auto-sampler
syringe and injection port, as follows: 50% methanol (for R3) was used for external
wash with one second rinse dip and 500 µL volume, and the mixture of
IPA:MeOH:Acetonitrile:H2O 1:1:1:1 (for R1) and 40% acetonitrile (R0) was used in the
internal wash with sequence R1 to R0.
Mass spectrometry (MS)
The QTRAP 6500 mass spectrometer was operated in electrospray positive
ionization using multiple reaction monitoring mode (MRM). The MS parameters were
optimized to obtain the most sensitive and specific MS transitions for 5, 3’dihydroxyflavone, 5, 3’, 4’-trihydroxyflavone, and 5, 7, 3’, 4’- tetrahydroxyflavone by
direct infusion 0.5 µM of the standard solutions into the ion source with a syringe pump.
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The Turbo ion-spray voltage was set at 4500 V and the source temperature was set at
500 C. Collision gas was optimized at medium level with curtain gas, ion source gas 1
and ion source gas 2 delivered at 20, 30 and 30 psi, respectively. The dwell time was
set for 50 ms. For each compound, four most sensitive MS transitions were selected
and the corresponding decluttering potential, collision energy, collision cell exit potential,
and entrance potential were optimized as shown in table below.
Q1

Q3

Time

DP

CE

CXP

(m/z)

(m/z) (ms)

ID

(Voltage)

(Voltage)

(Voltage)

255

137.1 50

5,3-dihydroxyflavone_1

130

41.5

23.3

255

152

50

5,3-dihydroxyflavone_2

130

61.9

25.8

255

181

50

5,3-dihydroxyflavone_3

130

43.5

16.9

255

155

50

5,3-dihydroxyflavone_4

130

54.1

25

271.3 117.1 50

5, 3’, 4’-trihydroxyflavone_1

99.7

46.2

13.8

271.3 135

50

5, 3’, 4’-trihydroxyflavone_2

99.1

39.1

11.9

271.3 137.1 50

5, 3’, 4’-trihydroxyflavone_3
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39.7

12.3

271.3 225.1 50

5, 3’, 4’-trihydroxyflavone_4

97.4

41.8

13.6

287.5 135

50

5, 7, 3’, 4’-tetrahydroxyflavone_1

118.9

39.2

15.7

287.5 153

50

5, 7, 3’, 4’-tetrahydroxyflavone_2

120

41.8

13.9

287.5 160.9 50

5, 7, 3’, 4’-tetrahydroxyflavone_3

112.4

44.9

22.1

287.5 241

5, 7, 3’, 4’-tetrahydroxyflavone_4

82.3

41

13.9

50

DP: Decluttering Potential
CE: Collision Energy
CXP: Collision Cell Exit Potential
4.2.12.2 Sample Preparation
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Stock solutions, calibration standards, and quality control (QC) samples
The stock solutions were prepared in DMSO at a final concentration of 5 mM, and
stored in brown glass vials at –20 ºC. The working solutions were prepared freshly by
serial dilutions of the stock solution with DMSO on each day of analysis.

For the

concentration determination in mouse serum or cell samples, the calibration standards
were prepared by spiking 5 µL of working solution into 95 µL of blank human plasma or
untreated cell lysate, respectively. All standards were prepared fresh daily.
Mouse serum samples for the determination of serum concentrations of 5,3dihydroxyflavone
Frozen serum samples were thawed at room temperature. An aliquot of 100 µL
serum was transferred into a micro centrifuge tube, and 1000 µL ethyl acetate was
added. The mixture was vortex-mixed for 15 minutes and centrifuged at 14000 rpm at
40C for 15 min, 950 uL of the supernatant was transferred to a new 1.7 mL centrifuge
tube, and dried under a steam of nitrogen at room temperature. The sample was then
reconstituted with 100 µL 40% acetonitrile, and 5 µL was injected into the LC-MS/MS
system.
Cell

samples

for

the

determination

of

intracellular

concentrations

of

5,3-

dihydroxyflavone, 5, 3’, 4’-trihydroxyflavone, or 5, 7, 3’, 4’-tetrahydroxyflavone
The suspended cells were sonicated to generate a cell lysate, and then 1000 µL
ethyl acetate was added. The mixture was vortex-mixed for 15 minutes and centrifuged
at 14000 rpm at 40C for 15 min, 950 uL of the supernatant was transferred to a new 1.7
mL centrifuge tube, and dried under a steam of nitrogen at room temperature. The
sample was then reconstituted with 100 µL 40% acetonitrile, and 5 µL was injected into
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the LC-MS/MS system.

Measured concentrations were normalized to cell protein

concentrations.
4.2.13 Tumor xenograft model studies
The 22Rv1 human CRPC xenograft model was established subcutaneous
implant of 22Rv1 cells (10,000,000 cells) and serial passaging of the tumors in male
SCID mice. 5,3’-Dihydroxyflavone was administered by ip injection (formulation: 1%
carboxymethyl cellulose, 5% DMSO, and 0.5% NaHCO3). For preliminary dose
determinations, mice were tested for immediate post-injection toxicity by monitoring
weight and behavior following daily ip injection of 3 doses of the compound (100, 150
and 250 mg/kg body weight) for a duration of 7 days. As the mice were asymptomatic at
all doses, the highest dose of 250mg/kg body weight was used for anti-tumor efficacy
studies of the compound. Plasma levels of unmetabolized compound for this dose
regimen were determined by LCMS at our institutional Pharmacology Core Services as
described in a separate sub-section. Male SCID mice were implanted bilaterally SC
with 30-50 mg tumor fragments by 12 gauge trocar, and randomly distributed to various
treatment and vehicle control groups. Treatment typically began 5 days post-implant
(early stage disease) to determine antitumor efficacies and to further evaluate potential
cumulative toxicities. Tumors were measured with a caliper 3 times/week and tumor
masses (in mg) estimated by the formula, mg = (a x b2)/2, where “a” and “b” are tumor
length and width in mm, respectively. Mice were sacrificed when cumulative tumor
burdens reached 5-10% of body weight (1-2g).
4.3 Results
4.3.1 Discovery of the lead compound
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For initial discovery of small molecules that selectively blocked the binding of
ELK1 and AR, we developed a stringent and methodical system for high throughput
screening (HTS) of a high diversity compound library. We expected a relatively high
probability of success because we were screening for molecules that could bind at any
one of a minimum of four target sites, considering the two AR docking sites on ELK1
and the corresponding binding sites in AR. Therefore, we screened a diversity library of
~ 20,000 small molecules based on conventional wisdom at our facility that the primary
hit rate for a single target in cell-based HTS by moderately stringent criteria is 1-2 %.
For the primary screen, we used recombinant AR+ HeLa cells harboring a Gal4
promoter-luciferase reporter as well as a Gal4-ELK1 fusion protein gene. When these
cells are treated with testosterone AR translocates to the nucleus where it binds to
Gal4-ELK1 and activates the reporter gene. The cells for counter screening were
identical to the primary screening cells with the exception that an androgen response
element (ARE) sequence replaced Gal4 in the promoter and Gal4-ELK1 was absent.
Compounds of interest should only suppress the signal in the primary screening assay,
as the only difference between these two assays is AR recruitment to the promoter via
ELK1 binding vs. direct DNA binding (Illustrative schematic in Figure 4.1). The Z-factor
for the primary screening assay was 0.734 and for the counter screening assay it was
0.711. In both assays enzalutamide, which does not allow nuclear translocation of AR,
completely suppressed the signal (Figure 4.2a, 4.2b). We initially screened two pilot
sets of compound libraries, LOPAC and Prestwick, and then the Maybridge Hit Finder
library, all of which are diversity sets, at a compound concentration of 10 µM. A hit in the
primary screen was defined as a compound able to reduce luciferase reporter activity ≥
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a.
Primary Screen
Nucleus

ELK1

b.

Counter Screen
Nucleus

Figure 4.1 Schematic of HTS screening system (a) Schematic of the reporter
system for the primary screening assay. Recombinant HeLa cells used in this
assay harbor the Gal4-TATA-luc promoter-reporter, and express a Gal4-ELK1
fusion protein as well as the androgen receptor (AR). Gal4-ELK1 is bound to the
Gal4 elements in the promoter. In the absence of testosterone (red circle), AR is
localized in the cytoplasm. When testosterone is present it binds to AR causing
AR to translocate to the nucleus where it then binds to Gal4-ELK1 and activates
the downstream luciferase reporter. (b) Schematic of the reporter system for the
counter screening assay. Recombinant HeLa cells used in this assay are
identical to the primary screening cells except for the absence of Gal4-ELK1 and
substitution of the Gal4 elements in the promoter with a canonical ARE. In this
case, testosterone causes cytosolic AR to translocate to the nucleus and bind as
a dimer to the ARE in the promoter resulting in activation of the luciferase
reporter.

104

Primary Screen

Promoter Activity
(RLU X 10^5)

30
25
20
15
10
5
0

Vehicle
Testosterone

b.

Counter Screen

25
Promoter Activity
(RLU X 10^6)

a.

20

Vehicle
Testosterone

15
10
5
0

Figure 4.2 Testing recombinant Hela cells for HTS.
Recombinant HeLa cells used in the primary screen (a) and
in the counter screen (b) were treated with either vehicle
(ethanol) or 10 nM testosterone together with 10uM of
Enzalutamide or vehicle (DMSO) control. Cells were
harvested and luciferase assay was performed 24 h posttreatment.
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3 standard deviations below the negative control or to a level ≥ 40% of the enzalutamide
control. This definition produced 1613 hits. Elimination of false positives by counterscreening resulted in 15 compounds with variable potencies (40% - 100% inhibition) in
the primary screen. We chose 5,7,3’,4’-tetrahydroxyflavone (Hit 1), one of our top hits in
terms of potency of inhibition in the primary screen (80% - 100% in < 6 hours) and
virtual absence of an effect in the counter screen (Figure 4.3a). This hit was prioritized
for further studies because it is a natural dietary product and could potentially be
introduced relatively rapidly in the clinic in an appropriately modified form.
Hit1 is itself highly unstable (easily oxidized) in vitro and rapidly metabolized in
vivo because of its multiple phenolic hydroxyl groups including hydroxyls on adjacent
carbon atoms (333, 334); hence its reported anti-inflammatory, neuroprotective and
other physiological effects (335, 336) may be related to its metabolites rather than its
original structure. In order to identify the essential structural elements required for
selective activity against the ELK1-AR complex, we conducted structure-activity
analysis using the same in vitro assay as in the primary screening. First, we tested the
effect of substituting the flavone scaffold in Hit 1 with the closely related flavanone and
isoflavone scaffolds. Hit 1 was unable to affect either ELK1-dependent or AREdependent promoter activation by AR upon scaffold substitution (Figure 4.3b, 4.3c).
Further structure-activity analysis using derivatives of Hit 1 in which individual or pairs of
hydroxyl groups were substituted by hydrogen indicated that only the hydroxyls at the 5
and 3’ positions are necessary for inhibition of the ELK1-AR synergy (Table 4.1).
However, the hydroxyl group at either position alone had no activity (Table 4.1).
Substitution of all four hydroxyl groups with methoxy groups or substitution at the 3’
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Figure 4.3 Hit1 (5,7,3’,4’-Tetrahydroxyflavone) selectively inhibits ELK1-dependent
promoter activation by AR and the compound scaffold is obligatory. Dose response
curve for (a) 5,7,3’,4’-Tetrahydroxyflavone (b) 5,7,3’,4’-Tetrahydroxyisoflavone (c)
5,7,3’,4’-Tetrahydroxyflavanone for inhibition of promoter activation by testosterone in the
primary screening assay (ELK1-dependent promoter activation by AR) compared with
the counter screening assay (ARE-dependent promoter activation by AR). The cells were
simultaneously treated with compound and testosterone for 6h and promoter activity was
measured in terms of reporter luciferase activity.
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Table 4.1 Structure-activity relationships for inhibition of ELK1-dependent
promoter activation by AR. The primary screening assay (ELK1-dependent
promoter activation by AR) was used to determine the IC50 values for Hit1 and its
various derivatives as indicated, using a compound dose range of 1-10µM.
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position alone with a methoxy group abolished activity (Table 4.1). Further, methoxy
substitutions on carbons at positions 4’, 6 and 7 were tolerated although the derivatives
had sub-optimal activity (Table 4.1). Finally, methoxy substitution on the carbon at
position 3 was not tolerated (Table 4.1), predicting possible steric hindrance from any
bulky substitutions at this position.
To test the relative stability of 5,3’-dihydroxyflavone, we compared the
intracellular concentrations of 5,3’-dihydroxyflavone, 5,3’,4’-trihydroxyflavone and
5,7,3’,4’-tetrahydroxyflavone (Hit 1) following incubation at a media concentration of
2µM compound. The intracellular concentration of 5,3’-dihydroxyflavone was unchanged
between 1h and 6h in contrast to the tri- and tetra-hydroxy compounds whose
concentrations rapidly declined during this period, indicating that removal of hydroxyl
groups at the 7 and 4’ positions in Hit 1 conferred stability without compromising
effectiveness against the target (Figure 4.4).
As a secondary test of target selectivity, we examined the effect of 5,3’dihydroxyflavone on activation of ELK1 by MEK/ERK using recombinant HeLa cells
harboring the Gal4 promoter-luciferase reporter and expressing the Gal4-ELK1 fusion
protein. In these cells, activation of the luciferase reporter by transduction with a
constitutively active mutant form of MEK was completely inhibited by the MEK inhibitor
trametinib but 5,3’-dihydroxyflavone did not inhibit the promoter activation (Figure 4.5).
To conclude, 5,3’-dihydroxyflavone, which is much more stable and predictably
bioavailable than Hit 1, is the minimal structure that is fully and selectively active against
the target ELK1-AR interaction. We name this lead compound KCI807.
4.3.2 Binding of KCI807 to AR and disruption of ELK1 binding
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Figure 4.4 Cellular uptake in HeLa cells for active
compounds. HeLa cells were treated with 2 µM of each
compound and incubated for 1h or 6h. At the end of the
incubation the cells were washed 3x with cold PBS and
scraped in molecular grade H20. The compounds were
extracted and then quantified using LCMS.
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Figure 4.5 KCI807 does not inhibit ERK1/2 activation of
ELK1. HeLa cells were co-transfected with the Gal4 promoterluciferase reporter construct and the expression plasmid for the
Gal4-ELK1 fusion protein gene. In addition the cells were
transfected with an expression plasmid for a constitutively active
MEK1 protein. The cells were then treated with the MEK1
inhibitor, trametinib (1 µM ), KCI807 (20 µM), or vehicle (DMSO).
Cells were harvested 48h post transfection and luciferase activity
was measured.

111

112

Figure 4.6 KCI807 binds to purified AR and blocks ELK1 binding. (a) Surface
plasmon resonance (SPR) kinetic curves for quantitative analyses of KCI807 binding to
AR. AR was immobilized and KCI807 (analyte) was diluted in a series (0, 10, 20, 40, 80,
1600, and 320nM). (b) SPR kinetic curves for quantitative analyses inhibition of binding
of AR (used as analyte) to immobilized ELK1 by KCI807. A fixed concentration of AR
(200 nM) was combined with KCI807 diluted in a series (0, 50, 100, 200, 400, 800, and
1600 nM). (c) SPR kinetic curves for quantitative analyses of enzalutamide binding to
AR. AR was immobilized and enzalutamide (analyte) was diluted in a series (0, 6.25,
12.5, 25, 50, 100, 200nM). (d) SPR kinetic curves to test for inhibition of binding of AR
(used as analyte) to immobilized ELK1 by enzalutamide. AR (200 nM) was combined
with enzalutamide (0 uM or 1 uM). (e) and (f) Chromatin immunoprecipitation using antiAR antibody and LNCaP cells treated with R1881 (10nM), R1881 (10nM) + KCI807
(20uM), or vehicle for 2h. The target sites for the ChIP assay included previously
established sites in the chromatin at which ELK1 recruits AR (e) or the canonical ARE
enhancer sites associated with the PSA or theTMPRSS2 gene.
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It was determined by surface plasmon resonance (SPR) that KCI807 binds to purified
immobilized AR with a dissociation constant of 7x10-8 M (Figure 4.6a). In contrast,
KCI807 did not bind to immobilized ELK1 (Figure 4.6b). SPR analysis demonstrated
that KCI807 blocked binding of purified AR (used as analyte) to purified immobilized
ELK1 progressively with increasing molar ratios relative to AR (Figure 4.6b). In contrast,
although SPR analysis could demonstrate the binding of enzalutamide to AR with a
dissociation constant of 1.7x10-9 M (Figure 4.6c), enzalutamide was unable to block the
binding of AR to ELK1 (Figure 4.6d).
We then tested the ability of KCI807 to selectively block recruitment of AR by
ELK1 to chromatin in situ. Chromatin immunoprecipitation (ChIP) assays showed that in
LNCaP PC cells, KCI807 prevented association of AR with two previously (246)
established sites in the chromatin at which ELK1 recruits AR (Figure 4.6e). In contrast,
KCI807 did not affect AR recruitment at the well-established canonical ARE enhancer
sites associated with the PSA or TMPRSS2 gene (Figure 4.6f).
The set of complementary results described above establish that KCI807 directly
binds to AR and selectively blocks its physical association with ELK1, inhibiting ELK1dependent transcriptional activity of AR.
4.3.3 Narrow genotropic effects of KCI807 in AR-V7 expressing CRPC cells
KCI807 also inhibited hormone-independent promoter activation by the splice
variant AR-V7 (Figure 4.7a). The relatively higher concentrations of the compound
required for this inhibition is likely because AR-V7 was overexpressed in the assay
system.
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Figure 4.7 Transcriptional targets of KCI807. (a) HeLa cells were co-transfected with
the Gal4 promoter-luciferase reporter construct and the Gal4-ELK1 fusion protein
expression plasmid. In addition the dells were transfected with either the AR-V7
expression plasmid or the corresponding vector plasmid (pLVX). At the time of
transfection with AR-V7, the cells were also treated in parallel with KCI807 (10 uM and
20 uM) or with the vehicle control. Promoter activity was measured in terms of reporter
luciferase activity. (b) 22Rv1 cells were infected with lentivirus expressing shRNA
selective for full length AR or ELK1 shRNA or control shRNA. The cell lysates were
analyzed by western blot to confirm knockdown of full length AR (top left panel) or ELK1
(top right panel). Real time PCR was used to confirm depletion of mRNA for full length
AR (bottom left panel) or ELK1 mRNA (bottom right panel). (c) In the 22Rv1 cells in
which full length AR was depleted, the mRNAs for the indicated panel of genes were
measured by real time PCR. (d) In the 22Rv1 cells in which ELK1 was depleted, the
mRNAs for the same panel of genes were measured by real time PCR. (e) 22Rv1 cells
were treated with 10 µM of KCI807 for 72h and real time PCR was used to measure
mRNAs for the indicated panel of genes tested in c and d.
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To test the selectivity of KCI807 for ELK1-dependent gene activation by AR vs.
other target genes of the receptor, we examined 22Rv1 CRPC cells, which are
dependent on both full length AR and AR-V7 for hormone-independent growth. In these
cells, depletion of full length AR using lentiviral shRNA (Figure 4.7b, left) led to
reduction in mRNA levels of representative AR target genes previously (246) shown to
be activated by AR in either an ELK1-dependent or -independent manner (Figure
4.7c).Depletion of ELK1 using lentiviral shRNA (Figure 4.7b, right) caused reduction
only in the mRNAs for genes previously reported to be ELK1-dependent for regulation
by AR (Figure 4.7d, left of the dashed line). Treatment of the cells with KCI807
decreased expression of only the genes supported by ELK1 (Figure 4.7e). The results
demonstrate selectivity of KCI807 for AR target genes that are synergistically activated
by ELK1 and AR, which are typically strongly associated with cell cycle progression and
mitosis.
4.3.4 Selective in vitro growth inhibition by KCI807 and comparison with
enzalutamide
KCI807 inhibited both androgen-dependent and androgen-independent in vitro
growth of standard AR-dependent PC/CRPC cell line models. After initiation of colony
formation of the enzalutamide-resistant (191) 22Rv1 CRPC cells, further colony growth
was virtually completely inhibited by KCI807 beyond 125nM compound, with an IC 50 of
33.12 nM. With respect to dose response of the cell growth inhibition by the MTT
viability assay, KCI807 was more effective than enzalutamide in LNCaP (androgendependent) and 22Rv1 (androgen-independent) cells; moreover, KCI807 completely
inhibited cell growth whereas enzalutamide only showed partial effects even at a
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Figure 4.8 Inhibition of AR-dependent PC/CRPC clonogenic survival and cell
growth by KCI807 and comparison with enzalutamide. (a) 22Rv1 cells were
seeded in triplicate wells in phenol red-free growth media and treated with the indicated
concentrations of KCI807 with replenishment of the treatments every 48h. Colonies
were stained with crystal violet, 10 days later. The left panel shows representative
images of the stained wells. The colony counts were determined using a size cutoff and
average values from replicate wells are plotted in the right panel. (b) - (g) The growth
inhibitory effects of KCI807 were compared with that of enzalutamide using the MTT
assay. Twenty four hours after plating the cells, they were treated with the indicated
concentrations of each compound. (b) LNCaP Cells + KCI807 (c) LNCaP Cells +
enzalutamide (d) VCaP Cells + KCI807 (e) VCaP Cells + enzalutamide (f) 22Rv1 cells
+ KCI807 (g) 22Rv1 cells + enzalutamide.
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a.

Supplementary Figure 4.9 Effect of KCI807 on in vitro growth of ARnegative cancer cell lines was measured by the MTT assay. All values
were normalized to the Day zero value for each cell line. (a) Du145 Cells
(b) HeLa Cells (c) HEK293 Cells (d) H1650 Cells
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concentration of 20 µM (Figure 4.8). VCaP cells (androgen-dependent) were the most
sensitive to KCI807 as well as enzalutamide at comparable doses (Figure 4.8). KCI807
did not appreciably affect the growth of AR-negative cell lines including DU145 (PC
cells), HeLa (cervical cancer cells), HEK293 (adenovirus transformed kidney fibroblasts)
and H1650 (lung adenocarcinoma cells) (Figure 4.9). The growth inhibitory effect of KCI
807 is thus selective for PC cells that are dependent on AR and/or AR-V7 and further
this compound shows a better growth inhibitory profile than enzalutamide in wellestablished cell line models.
4.3.5 Suppression of CRPC growth in vivo by KCI807
The in vivo anti-tumor efficacy of KCI807 was tested using the 22Rv1 cell line
xenograft model in male SCID mice. Tumor xenografts of 22Rv1 cells were implanted
into male SCID mice in the two flanks. Following growth of implanted tumors to ~100
mg, the compound was administered (begin treatment on Day 5) intraperitoneally on
alternate days at a dose of 250 mg/kg. for 18 days, reaching a total dose of 4.5 g/Kg.
Tumor growth was completely inhibited up until the time the experiment was terminated
when the tumor burden in the placebo group reached 5-10% of body weight (Figure
4.10a). The mice treated with KCI807 did not show appreciable weight loss or obvious
physical or behavioral abnormalities (Figure 4.10b). The serum concentration of
unmetabolized KCI807 24h following the final injection was 0.56 µM.
4.4 Discussion
Current and experimental modalities of therapeutic targeting of the AR signaling
axis in prostate cancer, including inhibition of testosterone synthesis and antagonists
that bind to either the ligand binding pocket of AR or to the amino-terminal hormone-
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Figure 4.10 Inhibition of in vivo CRPC tumor growth by KCI807. Tumor xenografts
of 22Rv1 cells were implanted into male SCID mice in the two flanks. On Day 5 after
implantation, mice were administered 250mg/Kg of KCI807 or vehicle control,
intraperitoneally, every other day for 18 days, reaching a total dose of 4.5 g/Kg. (a)
Tumor volumes were measured every 3 days. (b) Changes in body weight of the mice
administered either KCI807 or the vehicle control were recorded.
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independent activation functions of AR, entail global disruption of androgen/AR actions
(337). This study was undertaken to prove the concept that a critical growth signaling
arm of AR could be selectively disrupted by small molecule drug candidates that could
also circumvent resistance to current treatments from restoration of AR function. Using
an unbiased HTS approach combined with SAR studies, we have discovered and
characterized a flavonoid molecule (KCI807) that directly binds to AR, blocks binding of
ELK1 to AR and also prevents recruitment of AR to chromatin by ELK1. As a result,
KCI807 selectively inhibits transcriptional activity of AR mediated by ELK1 binding DNA
elements vs. canonical AREs. This is reflected by selective inhibition by KCI807 of
ELK1-dependent activation of endogenous genes by AR. As target genes of ELK1dependent transcriptional activation by AR are critical for cell cycle progression and
mitosis, KCI807 selectively inhibits AR-dependent prostate cancer cell growth in vitro
and tumor growth in vivo. As ELK1 binds to the amino-terminal domain of AR, KCI807 is
also able to inhibit ELK1-dependent transcriptional activity of the major AR splice
variant, AR-V7 and to inhibit growth of AR-V7 expressing cells and tumors.
Similar to other nuclear receptors, including steroid receptors, the amino-terminal
domain of AR is intrinsically disordered (338). This is a major obstacle for structurebased design of small molecule drugs targeting functional motifs within this region of the
receptor. Nevertheless, it has been previously demonstrated by the empirical approach
of small molecule screening and structure-activity studies that small molecules including
certain bis-phenols (EPI) (237) and Sintokamide A (239) can bind selectively to this
domain of AR with profound inhibitory effects on co-activator binding. Mutational and
binding analysis indicates that for binding to ELK1, the amino-terminal domain of AR
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precisely only requires the two ERK docking sites in ELK1 (268). Based on our
structure-activity studies, the structure of KCI807 only retains the minimal features of
the initial hit from our HTS that are required for disrupting the interaction of AR with
ELK1, i.e., a flavone scaffold and two hydroxyl groups at specific positions (5 and 3’).
Notably, removal of hydroxyl groups at positions 7 and 4’ results in a more stable
molecule and also prevents rapid metabolism in vivo as observed in the mouse model.
This relatively small molecule binds to AR with a dissociation constant that is only ~ 3
times that for the binding of ELK1 to AR (268) presumably by binding to a substructure
required for the formation the recognition site for one of the two AR docking sites on
ELK1. Nevertheless, KCI807 did not interfere with the activation of ELK1 by ERK.
Indeed, it has not been possible to identify structures within the amino-terminal region of
AR that are similar to the two docking site recognition sites in ERK previously identified
using substrate peptides for hydrogen exchange mass spectrometry and X-ray
crystallography (339, 340). Therefore, there appears to be some degree of
conformational flexibility that enables AR to bind to ELK1. By extension of this principle,
it may be possible to identify other small molecules that selectively disrupt the AR-ELK1
complex by binding to other sites on AR or to either one of its two docking sites on
ELK1.
From pharmacological and clinical perspectives, the results of this study
establish that the ELK1-AR interaction is a drugable target. In the mouse tumor
xenograft model, complete suppression of CRPC tumor growth and as well a relatively
high level of unmetabolized compound were achieved. This is encouraging because
even rapidly metabolized dietary flavonoids, reach quite high (5 - 10 µM) plasma levels
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in humans after continuous dietary supplementation (341). KCI807 was generally a
better inhibitor of androgen/AR-dependent PC/CRPC cell growth in vitro when
compared with enzalutamide in the same dose range using standard cell line models.
KCI807 showed no apparent toxicity in the mouse xenograft tumor model of AR-V7
expressing CRPC while showing profound anti-tumor activity. As KCI807 did not
interfere with the classical ARE-dependent promoter and gene activation by AR, it is
clear that it does not affect co-activator recruitment by the amino-terminal domain of AR,
in contrast to current experimental drugs (237, 239) targeting the amino terminal domain
that affect a broader range of transcriptional activities of AR. However, the possibility
exists that KCI807 may interfere with binding of AR to a yet unidentified tethering
protein(s) although this would likely have a much narrower range of effects than
systemic testosterone suppression.
Disruption of ELK1-dependent gene activation by KCI807 could in turn affect the
expression of certain indirect target genes. Notably, although the PSA encoding gene
(KLK3) is regulated by AR via canonical AREs, it is also known to be activated by the
protein products of genes such as HIST1H4D (342) and H2AFX (343) which we have
found to be synergistically activated by ELK1 and AR. Therefore PSA, which is a
biomarker of prostate tumor response to conventional anti-androgen treatments, may
also serve as a biomarker of response to KCI807.
In conclusion, our studies demonstrate that the ELK1-dependent arm of
androgen/AR signaling is a drugable and functionally tumor selective target in the
spectrum of prostate tumors including CRPC and one that predictably obviates the need
for systemic testosterone suppression.
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CHAPTER 5- Hybrid Enzalutamide Derivatives with Histone Deacetylase Inhibitor
Activity Decrease HSP90 and the Androgen Receptor Levels and Inhibit Viability
in Enzalutamide Resistant C4-2 Prostate Cancer Cells
Reprinted with permission of the American Society for Pharmacology and Experimental
Therapeutics. All rights reserved.
MOLECULAR PHARMACOLOGY Mol Pharmacol 90:225–237, September 2016
Copyright ©2016 by The American Society for Pharmacology and Experimental
Therapeutics
5.1 Introduction
Prostate cancer (PCa) is the second leading cause of cancer-related deaths in
men in the United States (344). PCa is initially managed with surgery, radiation,
androgen antagonists (e.g., bicalutamide) and surgical or chemical castration. However,
the relapsed or metastatic disease post-castration (castration-recurrent prostate cancer
or CRPC) has poor prognosis with most patients dying within 2 years (345). Innovative
treatment approaches are urgently needed to treat CRPC patients.
Androgen receptor (AR) signaling is a major driving force in all stages of PCa
(114). CRPC cells evolve mechanisms to re-activate AR signaling under androgen
deprivation conditions (346); these mechanisms include overexpression and gain-offunction mutations of AR (347, 348), overexpression of AR splice variants (AR-Vs)
(210), compensatory cross-talk between AR and other signaling pathways (349) and
enhanced intra-tumoral androgen biosynthesis (350). Enzalutamide (Enz) is a newly
FDA approved AR antagonist that prolongs survival of CRPC patients (351, 352). Enz
competitively binds to AR with 5-8 fold higher affinity than bicalutamide and, in contrast
to bicalutamide, does not promote AR nuclear translocation (321). Nevertheless,
acquired resistance to Enz typically develops within months and is associated with a
relatively short-lived patient survival benefit. Indeed, in vivo generated CRPC cell line
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models that vastly overexpress AR (e.g., C4-2 cells), presumably in combination with
changes in other cellular signaling pathways, are completely resistant to Enz in
conditioned media while remaining addicted to AR (191).
A possible strategy to overcome resistance to androgen depletion is to induce
destabilization and degradation of AR and its associated proteins in CRPC cells. AR is
stabilized in the cytosol by its interaction with heat shock protein 90 (HSP90) and other
chaperone proteins. HSP90 is commonly overexpressed in many types of cancer cells
and has been explored as a drug target for cancer treatment, including PCa (353, 354).
HSP90 is an ATP-dependent molecular chaperone that aids the folding and stability of a
number of client proteins, such as steroid receptors, protein kinases, transcription
factors and proteins involved in regulating cell survival. Therefore, inhibition of HSP90
leads to degradation of its client proteins via the ubiquitin-proteasome pathway.
Association of the AR apo-protein with HSP90 is critical for stabilizing AR in a
conformation that allows androgen binding (355, 356). In PCa cells, HSP90 inhibitors
induce AR degradation and impair AR nuclear translocation while simultaneously
reducing the levels of other oncogenic client proteins, such as p-AKT/AKT, EGFR and
IGF-IR and survivin (357-360). Simultaneous disruption of AR and other aberrant
growth/survival networks via HSP90 inhibition is an advantageous treatment strategy for
CRPC as this would silence potentially mutually compensatory oncogenic signaling
pathways. Despite this attractive scientific rationale, clinical development of HSP90
inhibitors for PCa treatment were disappointing (361-364) and was also limited by
adverse toxicity to non-target tissues.
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One of the actions of histone deacetylase (HDAC) inhibitors (HDACi) is to disrupt
HSP90 activity. HDACs remove acetyl groups from lysine residues of histone and nonhistone proteins. Eighteen HDACs categorized into four classes have been identified in
mammalian cells. Among them, HDAC6 is a zinc-dependent, class-IIb HDAC and is
localized in the cytoplasm (365). HDAC6 deacetylates HSP90 (366, 367). Inhibition of
HDAC6 could result in hyper-acetylation of HSP90, loss of ATP binding and dissociation
and degradation of its client proteins, including AR. The HDACi LAQ-824 (368), PDX101 (i.e. Belinostat) (369), suberoylanilide hydroxamic acid (SAHA or vorinostat) (370,
371) and natural products sulforaphane (372) and genistein (373) have all been
reported to reduce AR protein levels in PCa cells by disrupting the HDAC6-HSP90
chaperone function.
Clinical use of HDACi is now confined to hematological malignancies. Although
nuclear HDACs (e.g., HDAC1 and HDAC3) are indispensable for AR transcriptional
activity (374) and increased HDAC levels have been reported in clinical CRPC samples
and positively correlated to Gleason scores (375, 376), they are not likely to serve as
effective drug targets to treat PCa. HDACi, such as vorinostat (SAHA) (377), romidepsin
(FK-228) (378), panobinostat (LBH-589) (379) and pracinostat (SB-939) (380) have
been tested in CRPC patients but have resulted in modest outcomes. Toxicities
associated with their pleiotropic effects could contribute to the ineffectiveness of HDACi
in PCa treatment. Moreover, recent studies have associated the pleiotropic effects of
HDACi, particularly epigenetic modifications of chromatin-associated proteins, with
induction of epithelial to mesenchymal transition (EMT) in prostate, endometrial and
nasopharyngeal cancer cells (381-384). Therefore clinical translation of the extensive
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and promising pre-clinical findings of the efficacies of HDACi in treating solid tumors
must address the issue of toxicities that prevent application of effective HDACi
treatment regimens in the clinic.
We sought to develop enzalutamide derivatives armed with HDACi activity to
antagonize AR and HSP90 actions in AR-overexpressing and enzalutamide resistant
CRPC cells with reduced pleiotropic effects typical of strong HDACis. Accordingly, we
have designed, synthesized and tested the prototype compounds 2-75 and 1005. The
2-75 and 1005 chemical scaffolds are designed to retain AR binding affinity. The
compounds are also designed to have lower intrinsic HDACi activity compared to
SAHA, thus reducing the HDACi activity against non-target proteins. Nevertheless, the
HDACi activity is expected to produce effective disruption of AR as well as other HSP90
client proteins, resulting in loss of viability in Enz-resistant CRPC cells.
5.2 Materials and Methods
5.2.1 Compound Synthesis
Detailed procedures for the synthesis of compounds 2-75, 1005, 3-52 and 1002
are described in (385). The chemical identities of the compounds were confirmed by
using 1H,

13

C-NMR and high resolution mass spectrometry. All chemical compounds (2-

75, 1005, 3-52 and 1002 ) listed were synthesized by Dr. Zhihui Qin’s laboratory.
5.2.2 HDAC activity assay
In vitro HDAC inhibition was measured by using the HDAC fluorimetric
assay/drug discovery Kit (Enzo Life Sciences, BML-AK500) and the HDAC6
fluorometric drug discovery kit (Enzo Life Sciences, BML-AK516) following the
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manufacturer’s protocols and instructions. IC50 values were calculated from nonlinear
aggression plots using GraphPad Prism5 software.
5.2.3 Cell Culture and Reagents
LNCaP and PC3 cell lines were from American Type Culture Collection
(Manassas, Va). LNCaP and C4-2 cells were routinely grown at 37°C in 5% CO2 in
RPMI 1640 medium supplemented with 10% FBS (Invitrogen); 100units/ml penicillin,
100 µg/ml streptomycin, 2mM L-glutamine mixture (Invitrogen); and sodium pyruvate
(1mM) (Invitrogen). PC3 cells were grown in RPMI 1640 medium supplemented with
10% FBS (Invitrogen); 100units/ml penicillin, 100 µg/ml streptomycin, and 2mM Lglutamine mixture (Invitrogen). Affinity-purified rabbit anti-human antibody to AR (sc816), mouse anti-human antibody to GAPDH (sc-47724) and affinity-purified mouse
anti-human antibody to alpha tubulin (sc-8035) were purchased from Santa Cruz
Biotechnology (Santa Cruz, CA). Affinity-purified rabbit anti-human antibody to HSP90
(C45G5) #4877, rabbit anti-human antibody to acetylated lysine #9441, and affinitypurified rabbit anti-human antibody to p21 Waf1/Cip1 #2947S were purchased from Cell
Signaling Technology. Affinity-purified rabbit anti-human antibody to acetyl-tubulin
(#ABT241), acetyl Histone H4 (#07-328), acetyl Histone H3 (#ABE18) were purchased
from Millipore. R1881 was kindly provided by Dr. Stephan Patrick (Karmanos Cancer
Institute). Cycloheximide was from Sigma. All experiments were conducted using
phenol-red free growth media. For hormone depletion, cells were grown in phenol-red
free RPMI 1640 medium supplemented with 10% charcoal stripped FBS (SigmaAldrich) which was heat inactivated at 56°C for thirty minutes, and a mixture of
100units/ml penicillin, 100 µg/ml streptomycin and 2 mM L-glutamine for 96 h.
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5.2.4 Cell Viability Assay
Cells were trypsinized and 6000 cells/well were seeded in 96-well plates coated
with poly-D-lysine. The cells were seeded in phenol red-free medium supplemented with
10% FBS, 100units/ml penicillin, 100 µg/ml streptomycin, 2mM L-glutamine mixture and
sodium pyruvate (1mM) for C4-2 cells and phenol red-free medium supplemented with
10% FBS, 100units/ml penicillin, 100 µg/ml streptomycin and 2mM L-glutamine mixture
for PC3 cells. The cells were grown at 37°C in 5% CO2. Twenty four hours after seeding
in the 96-well plates, the cells were treated with indicated compound or DMSO (vehicle).
The culture medium was not changed during the time course of the assay. On day zero
and on day 3, cell viability was determined using the MTT assay. MTT (10µL, 5mg/mL)
was added to each well and incubated for 2h at 37°C. The formazan crystal sediments
were dissolved in 100µL of DMSO, and the absorbance at 570nm was measured using
the BioTek Synergy 2 Microplate Reader (BioTek, Winooski, VT). The assay was
conducted in sextuplicate wells and values were normalized to day zero (386). IC50
values were calculated from nonlinear aggression plots using GraphPad Prism5
software.
5.2.5 Western Blot Analysis
Cells were washed once with phosphate buffered saline (PBS) and then lysed
with RIPA buffer (150mM NaCl, 1% Nonidet P-40, 0.5% sodium deoxycholate, 0.1%
SDS, 50mM Tris of pH 8.0) containing a protease inhibitor cocktail (Pierce, Thermo
Fisher Scientific). The cell lysates were then incubated on ice for 40 minutes. Total
protein concentrations were estimated using the Bradford Assay (Bio-Rad). Protein
samples (10-40 µg) were heated at 95°C for 5 minutes and resolved by electrophoresis
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on 8% polyacrylamide-SDS gels and electrophoretically transferred to PVDF
membranes (Millipore, Billerica, MA). The membranes were then probed overnight at
4°C with the appropriate primary antibody followed by the appropriate horseradish
peroxidase-conjugated secondary antibody. The blots were then developed to visualize
the protein bands using the HyGLO Chemiluminescent HRP Antibody Detection
Reagent (Denville Scientific, Metuchen, NI) (332).
5.2.6 RNA isolation, Reverse Transcription, and Real Time PCR
Total RNA was isolated from cells using the RNeasy Mini Kit (Qiagen). Reverse
transcription PCR was then performed using 500 ng of total RNA with random primers
and using the high-capacity complementary DNA Archive kit (Applied Biosystems). The
complementary DNA from this reaction was measured using quantitative real time PCR
using the StepONE Plus Real Time PCR system (Life Technologies Corporation,
Carlsbad, CA). All reactions were performed in triplicate and normalized to
glyceraldehyde-3-phosphate-dehydrogenase values in the same samples. All primers
and Taqman probes were purchased from the applied Biosystems inventory (Invitrogen)
(387).
5.2.7 Chromatin Immunoprecipitation (ChIP)
C4-2 cells were treated with either vehicle, R1881 (1 nM or 10 nM), or 10uM of
each indicated compound for 2 h and then subjected to ChIP using anti-AR antibody
(sc-816 from Santa Cruz, CA). The ChIP assay was performed using the EX ChIP
chromatin

immunoprecipitation

kit

(catalogue

number

17-371

from

Millipore,

Temecula,CA) according to the vendor’s protocol. The ChIP signals were measured by
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quantitative real time PCR analysis of the immunoprecipitated products. Each sample
was tested in triplicate (246).
5.2.8 Statistical Analysis
All experiments were performed in triplicate groups and repeated at least three
times. The error bars in all graphs represent the standard deviation. Statistical analysis
was performed using one-way ANOVA with post-hoc and LSD (Least Square
Differences) and/or T-test (388) using GraphPad v.6.0 software.
5.3 Results
5.3.1 Design and synthesis of compounds 2-75 and 1005 with partial chemical
scaffolds of Enz and SAHA.
Compounds 2-75 and 1005 were designed to retain partial functional scaffolds of
Enz and SAHA (Figure 5.1A). Upon binding to AR, the cyano group of Enz/Enz
derivatives forms a critical hydrogen bond with Arg752, and the conformationally
restricted thiohydantoin ring in the middle forces the rest of the molecule to the “H11
pocket”, a region near the C terminus of helix 11 and the loop connecting helices 11 and
12 (389). To design derivatives with both AR-binding and HDACi activities, different
linkers connecting Enz and a zinc binding group (ZBG) were introduced to retain the
above structural features that are required for AR binding in an antagonist-related
conformation. 1005 is a cinnamyl hydroxamic acid derivative with a three-carbon linker.
A relatively longer carbon chain in 2-75 was used to more closely mimic the chemical
structure of SAHA.

Compound 7 (3-52), a close structural analogue of 2-75 using

methyl ester to replace ZBG was synthesized as a control compound without an HDACi
functional group (Figure 5.1B). Compound 7 (3-52) and synthetic intermediate
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Figure 5.1 Compound structures and synthetic schemes. (A) Chemical structures of
Enz, SAHA, 1005, 2-75, 1002, and 3-52. (B) Synthesis of 1005, 2-75, 1002, and 3-52.
Reagents and conditions are as follows: (a) ethyl acrylate, Pd(OAc)2, P(o-tolyl)3, DIPEA,
DMF, 80°C, 75%; (b) 37% HCl (aq), acetonitrile, reflux, 91%; (c) NH2OTHP, BOP, DIPEA,
DMF, 51%; (d) HCl (4 N in dioxane), MeOH, 60% for 1005, 32% for 2-75; (e) HCOOLi,
Ac2O, Pd2(dba)3, LiCl, DMF, 80°C, 92%; (f) 7-amino-N-(tetrahydro-2H-pyran-2-yl)oxy
heptanamide, HBTU, DIPEA, DMF, 30%; and (g) methyl 7-aminoheptanoate
hydrochloride,
HBTU, DIPEA, DMF, 47%. BOP,
benzotriazol-l-yl-oxy-tris(dimethylamino)phosphonium hexa-fluorophosphate; DIPEA, N,N-Diisopropylethylamine;
DMF,
N,N-Dimethylformamide;
HBTU,
2-(1H-benzotriazol-1-yl)-1,1,3,3tetramethyluronium hexafluorophosphate; THP, tetrahydropyranyl. Reprinted with
permission of the American Society for Pharmacology and Experimental Therapeutics.
All rights reserved.
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compound 2 (i.e. 1002, an ethyl ester analogue of 1005, Figure 5.1A, B) were used to
investigate AR antagonist properties of 2-75 and 1005 scaffold, respectively.
Both 2-75 and 1005 were synthesized from a 4’-iodo substituted intermediate
(Figure 5.1B) 1. Acrylate linker of 1005 was introduced via Pd(OAc)2-catalyzed Heck
reaction to afford compound 2, followed by hydrolysis of ethyl ester, coupling to THP
(tetrahydropyranyl acetal)-protected hydroxylamine and the final acidic deprotection. To
synthesize 2-75, carboxylation of aryl iodine 1 was performed using a palladiumcatalyzed carboxylation reaction (390), the resulted carboxylic acid then coupled with
primary amines to attach the alkyl chain with protected hydroxamic acid (compound 6)
or methyl ester (compound 7). Removal of THP protecting group gave the final product
2-75. The detailed synthetic procedures are described in the Supplemental Material.
5.3.2 Compounds 2-75 and 1005 possess intrinsically weak inhibitor activity
against nuclear HDACs and cytosolic HDAC6
To measure HDAC inhibitory activities of 2-75 and 1005, cell-free enzymatic
assays were performed against a nuclear extract of Hela cells and also against human
recombinant HDAC6. HDAC1 and HDAC2 are enriched in nuclear extracts whereas
HDAC6 is a cytosolic enzyme that is the principal modulator of the acetylation status of
HSP90. The HeLa cell nuclear extract was used to evaluate inhibitory activity against
nuclear HDACs. 2-75 and 1005 dose-dependently inhibited HDACs enriched in the Hela
nuclear extract with IC50 values of 1.08 µM and 2.41 µM compared to a value of 0.30
µM for SAHA (Figure 5.2A). In contrast, compounds 3-52 and 1002, which share the
chemical scaffolds of 2-75 and 1005 respectively, but lack the HDACi functional group,
did not inhibit nuclear HDAC activity even up to a concentration of 25 µM (Figure 5.2B).

135

As expected, Enz also lacked any HDACi activity in contrast to a pan-HDACi,
trichostatin A (TSA), which was used as a positive control (Figure 5.2B). 2-75 and 1005
were also weaker inhibitors of recombinant HDAC6, with IC50 values of 2.0 µM and 6.93
µM, respectively compared with the IC50 of 0.85 µM for SAHA (Figure 5.2C). As
expected, the negative control compounds 3-52 and 1002 as well as Enz did not show
significant inhibitory activity against HDAC6 even at a concentration of 25 µM (Figure
5.2D). Again, TSA served as the positive control in Figure 5.2D.
The HDACi activities of 2-75 and 1005 were also compared with those of their
parent compounds in situ in both LNCaP and C4-2 prostate cancer cells using activation
of the DLC1 tumor suppressor gene as the readout. SAHA induces histone acetylation
at the DLC1 promoter and effectively increases DLC1 mRNA expression in prostate
cancer cells (391). Accordingly, DLC1 mRNA was strongly up-regulated by SAHA in
both LNCaP cells (Figure 5.2E) and in C4-2 cells (Figure 5.2F). As expected from the
fact that DLC1 is not an AR-regulated gene, Enz had no effect on DLC1 mRNA
expression. Consistent with the results of the cell-free HDACi assays above,
compounds 2-75 and 1005 were poor inducers of DLC1 mRNA compared with SAHA,
both in LNCaP cells and in C4-2 cells (Figure 5.2E and 5.2F). Further, similar to the
results from cell-free assays, 1005 was a much weaker HDACi than 2-75 in the in situ
assays (Figure 5.2E and 5.2F). Taken together, the results indicate that compounds 275 and, to a greater degree, 1005 have much less potent HDACi activity in the cellular
context reflecting their intrinsically weak inhibitor activities compared with SAHA.
5.3.3 The partial Enz chemical scaffold confers AR targeted antagonist activity
without ligand-induced chromatin association of AR

136

137

Figure 5.2 Measurement of intrinsic and in situ HDACI activities. (A) Dosedependent inhibition of HDACs from HeLa cell nuclear extract by 2-75, 1005, and SAHA.
HeLa cell nuclear extract was incubated with each drug at the indicated concentrations.
IC50 values were calculated from nonlinear regression plots using GraphPad Prism5
software. (B) Enz, 1002, and 3-52 were tested against HeLa cell nuclear extract at
10 µM and 25 µM and TSA (1 µM) was used as a positive control. (C) Dose-dependent
inhibition of recombinant HDAC6 by 2-75, 1005, and SAHA. Recombinant HDAC6 was
incubated with each drug at the indicated concentrations. IC50 values were calculated
from nonlinear regression plots using GraphPad Prism5 software. (D) Enz, 1002, and 352 were tested against recombinant HDAC6 at 10 µM and 25 µM and TSA (1 µM) was
used as a positive control. (E) LNCaP cells were treated with the indicated compounds
(10 µM) or vehicle (DMSO) for 48 hours. Cells were then harvested to quantify mRNA for
DLC1 and values were normalized to the values for GAPDH mRNA. (F) C4-2 cells were
treated with the indicated concentrations of Enz, SAHA, 2-75, or 1005 or vehicle (DMSO)
for 48 hours. Cells were then harvested to quantify mRNA for DLC1 and values were
normalized to the values for GAPDH mRNA. In all panels, the error bars represent the
standard deviation of experimental triplicates. Where indicated *, **, §, §§, P < 0.05.
DMSO, dimethylsulfoxide; TSA, trichostatin A. Reprinted with permission of the
American Society for Pharmacology and Experimental Therapeutics. All rights reserved.
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Although C4-2 cells are not growth-inhibited by Enz due to hormone-independent
actions of AR, the canonical androgen target genes KLK3 and TMPRSS2 are activated
by androgen and their activation is inhibited by androgen antagonists (241). HDACi are
also potent inhibitors of the androgen signaling axis as they cause degradation of AR in
the cytosol in addition to other cellular effects (368, 369, 392). To test whether the Enz
moiety could enable 2-75 and 1005 to target to AR, we tested the ability of compound 352 to inhibit activation of KLK3 and TMPRSS2 by androgen. Compound 3-52 shares the
chemical scaffold of 2-75 but lacks the HDACi functional group; therefore 3-52 should
depend on the partial Enz chemical scaffold to antagonize gene activation by androgen.
SAHA partially inhibited activation of KLK3 (Figure 5.3A) and TMPRSS2 (Figure 5.3B)
by the synthetic androgen R1881 in C4-2 cells whereas Enz showed progressive
inhibition at higher doses. Compounds 2-75 and 1005 were both better inhibitors of
gene activation by androgen compared with either Enz or SAHA (Figure 5.3A and 5.3B).
On the other hand, compound 3-52 inhibited activation of KLK3 and TMPRSS2 to a
degree that was comparable to Enz suggesting that the partial Enz chemical scaffold in
compounds 2-75 and 1005 retained an Enz-like AR binding property. The superior
androgen antagonist activities of 2-75 and 1005 compared with Enz may be explained
by their additional HDACi activities.
AR ligands including agonists and classical androgen antagonists such as
bicalutamide promote nuclear translocation of AR and the binding of AR to canonical
hormone (androgen) response elements associated with androgen-regulated genes. In
contrast, Enz does not stimulate AR nuclear translocation and DNA binding (321, 393).
To test whether the partial Enz chemical scaffold would mobilize AR to the chromatin,

139

Figure 5.3 Testing the ability of
compounds to interact with AR
and
to
induce
chromatin
association of AR. (A and B) Data
obtained using C4-2 cells are shown.
After 96 hours of hormone depletion,
cells were treated with R1881 (1 nM)
and 1 µM, 2.5 µM, 5 µM, or 10 µM of
the indicated compound or vehicle
(DMSO) for 48 hours. Cells were then
harvested to purify total RNA. The
mRNAs for KLK3 and TMPRSS2
were quantified by normalizing to the
values for GAPDH mRNA. In all
panels, the error bars represent the
standard deviation of experimental
triplicates. (C) C4-2 cells plated in
hormone-depleted medium were
treated with vehicle, R1881, or the
indicated compound for 2 hours.
Cells were harvested and subjected
to ChIP using AR antibody. TaqMan
probes targeting androgen response
element
enhancer
elements
associated with the KLK3 gene were
used
to
quantify
the
immunoprecipitated chromatin. In all
panels, the error bars represent the
standard deviation of experimental
triplicates. Where indicated, * and
§, P <
0.01.
Reprinted
with
permission of the American Society
for Pharmacology and Experimental
Therapeutics. All rights reserved.

140

we employed chromatin immunoprecipitation using C4-2 cells treated with androgen,
Enz, SAHA and compound 2-75. As a target site for the ChIP assay, we chose the wellestablished AR binding enhancer elements located 4kb upstream of the transcription
initiation site of the KLK3 gene. As seen in Figure 5.3C, androgen treatment strongly
stimulated chromatin association of AR whereas Enz, SAHA and compound 2-75 all
gave the basal ChIP signal corresponding to the vehicle treatment control. These
results suggest that the new compounds must antagonize AR in the cytosolic rather
than in the nuclear compartment.
5.3.4 Compounds 2-75 and 1005 induce enhanced degradation of AR and HSP90
and hyper-acetylation in a putative 55 KDa HSP90 fragment
Previous observations using potent non-targeted HDACi have shown that the
compounds directly affect the AR signaling axis by hyper-acetylation of the AR
chaperone complex, through inhibition of HDAC6, leading to degradation of HSP90 as
well as release and degradation of AR. We therefore hypothesized that despite their
intrinsically weak HDACi activities, the Enz moiety may enable compounds 2-75 and
1005 to more effectively target AR in its chaperone complex, leading to relatively
efficient degradation of AR. To test this possibility, we treated C4-2 cells with Enz,
SAHA, 1005 and 2-75 at doses ranging from 1µM to 10µM for 24h. Western blots of the
cell lysates were probed for AR and GAPDH (loading control) and the AR band
intensities relative to GAPDH were quantified using ImageJ software (Figure 5.4A).
Whereas Enz did not cause an appreciable change in the AR protein level, SAHA did
cause a decrease in AR level in a dose-dependent manner (Figure 5.4A). Compared to
SAHA, both 2-75 and 1005 decreased the AR level to a greater extent with 2-75 being
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Figure 5.4 Modulation of protein levels and hyperacetylation. C4-2 cells
were treated with the indicated concentrations of Enz, SAHA, 1005, or 2-75 or
with vehicle (dimethylsulfoxide) for the time indicated. Cells were then
harvested for Western blot analysis using antibody to AR (A), HSP90 (B),
acetyl lysine (C), or GAPDH (loading control). ImageJ software was used to
determine the intensities of the bands relative to the vehicle control for each
protein. The values were then divided by the values for GAPDH within the
same samples. Reprinted with permission of the American Society for
Pharmacology and Experimental Therapeutics. All rights reserved.
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more effective than 1005 at each dose (Figure 5.4A). To determine whether the
decrease in AR was due to increase in the rate of AR degradation we tested the effects
of the compounds after blocking de novo protein synthesis using cycloheximide. We
monitored degradation of p21 to confirm the activity of cycloheximide. As expected
there was a rapid decrease in p21 upon treatment with cycloheximide confirming that
the treatment efficiently blocked de novo protein synthesis (Figure 5.5). In the presence
of cycloheximide the AR protein level was decreased by approximately half at the end of
24h indicating a relatively slow turnover of the AR protein. Under these conditions
treatment with SAHA, 1005 and 2-75 all caused greater declines in the AR level with 275 showing the strongest effect (Figure 5.5). The results indicate that the decrease in
AR caused by 1005 and 2-75 is due to increased degradation of AR. The extent of
degradation of AR in C4-2 cells appeared adequate to offset the high level of
overexpression of AR that is necessary to support growth in these cells.
To explore a possible link between decreased AR levels and effects of the
compounds on the AR chaperone complex, we examined whether compounds 2-75 and
1005 decreased the level of HSP90. Probing of the lysates from the treated cells (48h
treatment) for HSP90 by western blot and quantification of HSP90 was conducted by
procedures similar to that used above for AR. Enz had no effect on the level of HSP90
whereas in the SAHA-treated cells, a decrease in HSP90 was evident at the higher
doses (5µM and 10µM) (Figure 5.4B). On the other hand, cells treated with 1005 and 275 showed more marked reduction in HSP90, with 2-75 being more efficient than 1005.
Probing identical western blots with an antibody against acetylated lysine showed that
SAHA as well as 1005 and 2-75, but not Enz, showed hyper-acetylation of a ~55 kDa

143

Figure 5.5 Induction of AR
degradation. C4-2 cells were
pretreated
with
cycloheximide
(20 µM) or with vehicle for 2 hours,
followed by the introduction of Enz
(10 µM), SAHA (10 µM), 1005
(10 µM), 2-75 (10 µM), or vehicle for
the indicated durations. Cells were
then harvested for Western blot
analysis and probed with antibody
to AR, p21, or α-tubulin (loading
control). ImageJ software was used
to determine the intensities of the
bands relative to the 0-hour time
point for each treatment. CHX,
cycloheximide.
Reprinted
with
permission of the American Society
for Pharmacology and Experimental
Therapeutics. All rights reserved.
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polypeptide (Figure 5.4C), similar to one that has previously been identified as a
fragment HSP90 produced by SAHA treatment (394).

Taken together, the above

results are consistent with the view that the ability of the compounds to induce
acetylation and reduction of HSP90, and consequently AR degradation, underlies the
ability of the compounds to attenuate AR signaling.
5.3.5 The hybrid molecules selectively inhibit cytosolic HDAC6 in situ
As HSP90 in the AR chaperone complex is a target of the cytosolic HDAC6, the
hyper-acetylation of degradation of HSP90 induced by 2-75 and 1005 is likely to occur
through inhibition of HDAC6. If this were the case, we may expect that 2-75 and 1005
would also induce hyper-acetylation of α-tubulin which is diagnostic of HDAC6 inhibition.
To test this possibility, we treated C4-2 cells with Enz, SAHA, 1005 and 2-75 at doses
ranging from 2.5µM to 10µM for 24h. Western blots of the cell lysates were probed for
acetyl-tubulin, as well as total α-tubulin. The band intensities for acetyl-tubulin relative to
total α-tubulin were quantified using ImageJ software (Figure 5.6). 2-75 induced a
greater degree of hyper-acetylation of α-tubulin (relative to total tubulin) compared to
SAHA, whereas 1005 produced a similar effect albeit to a somewhat lesser degree than
SAHA (Figure 5.6). When the same cell lysates were probed using antibodies against
acetylated histones H3 and H4, it was clear that SAHA alone induced a strong induction
of histone acetylation (Figure 5.6). The results clearly demonstrate strong and selective
in situ activity of 2-75 and 1005 on cytosolic HDAC6.
5.3.6 Compounds 2-75 and 1005 up-regulate p21 and inhibit viability of Enzresistant prostate cancer cells
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Figure 5.6 Hyperacetylation of α-tubulin and histones H3 and H4. C4-2 cells
were treated with Enz, SAHA, 1005, or 2-75 (2.5 µM, 5 µM, or 10 µM) or vehicle for
24 hours. Cells were then harvested for Western blot analysis and probed with
antibody to acetyl histone H3, acetyl histone H4, acetyl tubulin, or α-tubulin. ImageJ
software was used to determine the intensities of the bands of acetyl tubulin relative
to the total amount of tubulin for each treatment. The ratio of acetyl tubulin to total
tubulin in each sample is indicated. Reprinted with permission of the American
Society for Pharmacology and Experimental Therapeutics. All rights reserved.
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HDACis activate transcription of p21. However, as compounds 2-75 and 1005
exhibited weak intrinsic HDACi activity against nuclear HDACs and as their apparent
major cellular HDACi activity was related to targeting of the AR axis within the cytosolic
compartment, it was of interest to examine their ability to induce p21.
Enz had no effect on p21 mRNA expression in either the Enz-sensitive LNCaP
cells (Figure 5.7A) or in the Enz-insensitive C4-2 cells (Figure 5.7B), whereas SAHA
induced p21 mRNA in both cell lines (Figure 5.7A and 5.7B). Compounds 2-75 and
1005 both induced p21 to a greater extent than SAHA in the two cell lines (Figure 5.7A
and 5.7B). Moreover, combined treatment with equimolar concentrations of Enz and
SAHA did not induce p21 to a greater extent than SAHA alone, indicating the
importance of the hybrid scaffold of 2-75 and 1005 (Figure 5.7C).
To expect therapeutic effects from 2-75 and 1005, it is important to establish that,
similar to SAHA, they can induce loss of viability in Enz-resistant CRPC cells, rather
than mere growth inhibition. Therefore, the effects of 2-75, 1005 and SAHA on cell
viability were assessed in the well-established C4-2 model of Enz-resistant CRPC.
In C4-2 cells Enz could not appreciably affect viability even at a concentration of
10 µM, whereas SAHA caused loss of viability in a dose dependent manner (Figure
5.8A). Compounds 2-75 and 1005 both caused greater loss of viability compared with
SAHA with compound 2-75 being more effective than 1005 (Figure 5.8A). As a control,
compound 1002, which has a chemical scaffold similar to 1005 but lacks the HDACi
activity (Figure 5.2B and 5.2D), was unable to affect C4-2 cell viability (Figure 5.8A). As
another experimental control, at the lower drug concentration (2.5 uM) although SAHA,
2-75 and 1005 caused growth inhibition, combining Enz with SAHA (each at 2.5 uM) did
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Figure 5.7 Induction of p21 mRNA.
(A) LNCaP cells were treated with
Enz, SAHA, 1005, or 2-75 at a
concentration of 10 µM or with vehicle
(dimethylsulfoxide) for 48 hours. Cells
were then harvested to quantify p21
mRNA and the values were
normalized to those for GAPDH
mRNA. (B) C4-2 cells were treated
with Enz, SAHA, 1005, or 2-75 at the
indicated concentrations or with
vehicle (dimethylsulfoxide) for 48
hours. Cells were then harvested to
quantify p21 mRNA and the values
were normalized to those for GAPDH
mRNA. (C) C4-2 cells were treated
with either Enz (10 µM) or SAHA
(10 µM), an equimolar (10 µM each)
mixture of Enz and SAHA, 2-75
(10 µM), or 1005 (10 µM). Cells were
then harvested to quantify p21 mRNA
and the values were normalized to
those for GAPDH mRNA. In all
panels, the error bars represent the
standard deviation of experimental
triplicates. Where indicated, *, §,
○ P < 0.05. Reprinted with permission
of
the
American
Society
for
Pharmacology
and
Experimental
Therapeutics. All rights reserved.
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Figure 5.8 Effects on cell viability
in Enz-resistant CRPC cells. (A)
C4-2 cells were seeded in 96-well
plates and 24 hours later, they were
treated
with
the
indicated
compounds (2.5 µM, 5 µM, or
10 µM)
or
with
vehicle
(dimethylsulfoxide). Cell density was
measured by the MTT assay on
days 0 and 3 of treatment. Values
equal to or above that on day 0
were considered to represent 100%
viability. (B) C4-2 cells were seeded
and treated 24 hours later with Enz
(2.5 µM), SAHA (2.5 µM), an
equimolar mixture of Enz and SAHA
(each compound at 2.5 µM), 2-75
(2.5 µM), 1005 (2.5 µM), or vehicle
(dimethylsulfoxide). Cell density was
measured by the MTT assay on
days 0 and 3 of treatment. The yaxis shows percent cell growth on
day 3 relative to the cell density on
day 0. (C) PC3 cells were seeded in
96-well plates and 24 hours later,
they were treated with the indicated
compounds (2.5 µM, 5 µM, or
10 µM)
or
with
vehicle
(dimethylsulfoxide). Cell density was
measured by the MTT assay on
days 0 and 3 of treatment. Values
equal to or above that on day 0
were considered to represent 100%
viability. In all panels, the error bars
represent the standard deviation of
experimental sextuplicate samples.
Where indicated, *, §, ○ P < 0.05.
MTT,
3-(4,5-dimethylthiazol-2-yl)2,5-diphenyltetrazolium
bromide.
Reprinted with permission of the
American Society for Pharmacology
and Experimental Therapeutics. All
rights reserved.
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not enhance the ability of SAHA to inhibit cell growth (Figure 5.8B). In the AR-negative
PC3 PCa cells, SAHA induced loss of viability in a dose-dependent manner (Figure
5.8C). However, in contrast to C4-2 cells, neither 2-75 nor 1005 affected viability of PC3
cells within the duration of the assay (Figure 5.8C). As expected, the AR-positive and
hormone-dependent LNCaP cells were sensitive to SAHA, 2-75 and 1005 as well as
Enz (Figure 5.9).
The results indicate that despite the weaker inherent HDACi activities of 2-75 and
1005 compared with SAHA, the compounds could be as good or better at reducing
viability of Enz-resistant and AR-overexpressing PCa cells.
5.4 Discussion
The success of clinical interventions in prostate cancer, including surgical or
chemical castration and treatment with androgen antagonists and androgen synthesis
inhibitors support the view that the majority of prostate tumors are addicted to AR to
support PCa growth and progression (273). Nevertheless, the current interventions that
target androgen/AR signaling are circumvented by the tumors, most commonly through
mechanisms that restore functional AR (395, 396), resulting in short-lived clinical benefit
from the treatments. The goal of this study was to develop a class of compounds that
may overcome this manner of resistance to the conventional treatments by efficiently
disrupting both AR and HSP90 in the AR-HSP90 complex with minimal effects on most
other cellular targets. To accomplish this, we synthesized compounds that would
incorporate properties of two well-known drugs, an HDACi (SAHA) that efficiently
modifies and disrupts the cytosolic AR chaperone complex and an AR ligand (Enz),
which is a high affinity AR antagonist. We additionally sought to substantially weaken
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Figure 5.9: Effects on cell viability in androgen-sensitive cells.
LNCaP cells were seeded in 96-well plates and 24h later, they were treated with the
indicated compounds (10 uM) or with vehicle (DMSO). Cell density was measured by the
MTT assay on Days 0 and 3 of treatment. The error bars represent standard deviation of
experimental sextuplicate samples. Where indicated, P < 0.05 Reprinted with permission
of the American Society for Pharmacology and Experimental Therapeutics. All rights
reserved.
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the intrinsic HDACi activity of the drug to minimize its ability to affect many targets. The
studies described above suggest that compounds 2-75 and 1005 may be prototype
molecules that fit this paradigm.
The HDACi functional groups in 2-75 and 1005 conferred only weak HDACi
activity in cell-free assays using either nuclear HDACs or the cytosolic HDAC6
compared with SAHA; the shorter carbon chain in 1005 resulted in even weaker HDACi
activity than 2-75. The relative potencies of HDACi inhibition of 2-75 and 1005 was
clearly reflected in their relatively poor ability to induce DLC1, an established nuclear
target gene of HDACi (391, 397, 398), that is strongly induced by SAHA. 2-75 and 1005
were also poor modulators of histone acetylation in situ compared with SAHA.
Therefore, the new molecules may have less toxic effects than those associated with
the potent pan-HDACi activity of SAHA (377).
SAHA partially inhibited gene activation by androgen but did not produce a
further dose-dependent inhibition between 1µM and 10 µM concentrations. At this time,
we do not have a clear explanation for why this effect of SAHA was only partial except
that it may be related to the pleiotropic cellular effects of SAHA including its effects on
cross-talking molecular pathways. More important, 2-75 and 1005 produced a dosedependent inhibition of gene activation by androgen similar to Enz. The stronger
inhibition observed for the compounds compared to Enz may be attributed to their
HDACi moieties. However, the close parallel between the control compound 3-52 and
Enz in their dose-dependent antagonism of gene activation by androgen, despite the
lack of a HDACi functional group in 3-52, indicates that the Enz moiety in 2-75 and 1005
is functional in enabling binding to AR. Additionally, ChIP analysis showed that the
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modified Enz scaffold retained the inability of Enz to mobilize AR to its chromatin
binding sites in the nucleus in contrast to conventional androgen antagonists.
In the context of targeted delivery to AR via their Enz moiety, the weak intrinsic
HDACi activities of 2-75 and 1005 were adequate to mimic or surpass the effects of
SAHA on AR protein levels. The efficiency of degradation of AR by 1005 was
comparable to SAHA but 2-75 clearly induced AR degradation to a greater degree at
each dose. This difference between 2-75 and 1005 may be related to the fact that the
HDACi activity of 1005 was less than that of 2-75, despite their common Enz moiety. To
test the mechanism by which 2-75 and 1005 may cause AR degradation, we relied on
literature reports that HDACi destabilize and degrade AR by hyper-acetylating and
inducing degradation of the cytosolic AR chaperone protein, HSP90 (368, 369, 392). It
has also been reported that the hyper-acetylation and degradation of HSP90 coincides
with the appearance of a ~55 KDa HSP90 polypeptide fragment. As a diagnostic test of
this mechanism, we observed that similar to SAHA, 2-75 and 1005 did indeed cause a
decrease in HSP90, with 2-75 being more efficient than either SAHA or 1005. We were
able to observe the predicted ~55KDa fragment in cells treated with SAHA, 2-75 or
1005 using an antibody against acetylated lysine; however our antibody against HSP90
was unable to detect this fragment, possibly because the levels of the cleaved HSP90
fragment were too low to be in the detectable range of the antibody. Nevertheless, all
indications point to the AR chaperone complex in the cytosol as the mediating the action
of 2-75 and 1005. Consistent with this view HDAC6 which is associated with the ARHSP90 complex was more strongly and selectively inhibited in situ by 2-75 compared to
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SAHA. Indeed 1005 which had weaker intrinsic HDACi activity than 2-75 also strongly
inhibited HDAC6 in situ with virtually no effect on histone acetylation.
An increase in the expression of the cyclin-dependent kinase inhibitor p21 (399)
is a hall mark of the antiproliferative effects of HDACi (400, 401). Potent inhibition of the
nuclear HDAC1 at the promoter of the p21 gene is associated with induction of p21 by
HDACi (402). Inhibitors of HSP90 also increase p21 expression in PCa cells (368).
Therefore it is significant that p21 mRNA was induced by both 2-75 and 1005 more
strongly than SAHA and that combination with Enz did not further increase p21
induction by SAHA. The inability of Enz to induce p21 in the hormone-dependent
LNCaP cells despite the sensitivity of the AR signaling in these cells to Enz suggests
that induction of p21 by 2-75 and 1005 may not be directly related to disruption of AR;
rather, it may be due to their effects on additional HSP90 client proteins through ARmediated targeting of HDACi activity to HSP90. Notably, AKT and GR are also HSP90
client proteins and upregulated AKT or GR signaling were reported to result in Enz
resistance (403-406),. Therefore, these pathways could be involved in the loss of
viability induced by the compounds.
HDACi pharmacophores have previously been linked to a chemical scaffold of
cyanonilutamide, which is another nonsteroidal AR antagonist (392). However, the
antiproliferative effects of cyanonilutamide-HDACi were related to their ability to induce
AR nuclear localization, enabling elevated local concentrations of HDACi activities in the
nucleus. In contrast, our prototype drug molecules were designed to limit nuclear
HDACi activities as an approach to limiting toxicity. Our working model that would need
further testing is that in C4-2 cells, 2-75 and 1005 bind to cytosolic AR and inhibit
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HDAC6 associated with the AR chaperone complex, resulting in HSP90 acetylation and
degradation, AR degradation, suppression of ligand-insensitive gene activation by AR
and inhibition HSP90 interactions with additional client proteins (Schematic in Figure
5.10). We propose that this mechanism may address some of the limitations of strong
pan-HDAC inhibitors related to toxicity.
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Figure 5.10 Mechanistic model for the actions of compounds 1005 and 2-75. (A) In
the absence of bound ligand, AR is in a stable complex with HSP90, which is maintained
in a hypoacetylated state by HDAC6. Hypoacetylated HSP90 stabilizes AR and also
supports cell survival through regulation of its other client proteins. When 2-75 or 1005
bind to AR in the chaperone complex, their HDACI moieties inhibit HDAC6 that
associates with the complex. Despite their relatively weak intrinsic HDACI activities, the
efficiency of HDAC6 inhibition by the hybrid molecules is enhanced by their localized
effect in the chaperone complex. (B) This results in hyperacetylation of HSP90, leading
to destabilization of AR and also loss of cell survival through deregulation of other
HSP90 client proteins. Reprinted with permission of the American Society for
Pharmacology and Experimental Therapeutics. All rights reserved.
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CHAPTER 6- CONCLUSIONS
The goal of this dissertation work was to use new mechanistic concepts and
approaches for the development of small molecule drug candidates to treat prostate
cancer. Using complementary methods, we discovered that the amino-terminal domain
of AR utilizes the two ERK docking sites on ELK1 to directly bind to ELK1, inducing
constitutive activation of genes essential for prostate cancer growth even in cells that
are insensitive to androgen and resistant to enzalutamide (Chapter 3). Through the
development of a strategic cell-based screening assay and further tertiary tests and
structure-activity studies, we have identified a lead small molecule drug candidate that
binds directly to AR, disrupts its interaction with ELK1 to selectively block ELK1dependent gene activation by AR and suppresses growth of AR positive PC/CRPC cells
and tumors (Chapter 4). Finally, as an alternative approach we developed hybrid small
molecule drugs containing partial structural scaffolds derived from enzalutamide and
SAHA, two therapeutics currently in the clinic. By weakening the pan HDAC inhibitor
`activity of SAHA and using enzalutamide to direct the HDAC inhibitor activity, we could
more selectively disrupt the growth of AR overexpressing prostate cancer cells (Chapter
5).
Because of the dependence of early stage and advanced prostate tumors on AR,
testosterone suppression is a mainstay in the treatment of prostate cancer. Prostate
cancer progresses to become resistant to ADT by restoring functional AR.. ADT is also
associated with many major undesirable side effects on normal tissues. Our lab has
previouslydiscovered that tethering of AR by ELK1 in PC/CRPC cells enables
constitutive activation of a crucial set of growth genes by AR. In this study, we have
discovered a lead compound, KCI807that disrupts the ELK1-AR interaction and
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selectively suppress growth signaling by AR in PC/CRPC cells. KCI807 represents a
new functional class of potential small molecule drugs that offers the dual benefit of
obviating the need for testosterone suppression and being effective against a broader
spectrum of prostate tumors.
In our second approach, we reduced the potency of histone deacetylase activity
of SAHA while generating a hybrid molecule that would enable targeting of this activity
to the Hsp90-AR complex. These studies resulted in a prototype compound that has the
potential to circumvent the pan activity of currently used HDAC inhibiting drugs that is
associated with toxicity. Furthermore, this prototype drug should me more selective for
AR positive prostate cancer cells.
Together, these studies have addressed two separate goals to prove the
principle that small molecules can be developed for prostate cancer that 1.) can be
functionally tumor selective in both early stage and advanced disease and that do not
require androgen ablation and 2.)

that have the capability of being active in

enzalutamide-resistant prostate cancer cells.

For these reasons, such molecules

should serve as superior therapeutics compared with conventional hormonal therapies
for prostate cancer.
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APPENDIX- INTELLECUTAL PROPERTY
The information on the high throughput screening methodology and small
molecule inhibitors of ELK1-AR interactions described in chapter

four comprise

intellectual property of Wayne State University and is covered by provisional patents
filed by the university.
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ABSTRACT
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Prostate cancer (PC) is generally dependent on the androgen signaling axis for
tumor growth. PC is managed by androgen deprivation therapy (ADT). The tumors then
frequently progress by restoring ADT-resistant AR signaling through mechanisms such
as intratumoral androgen synthesis, overexpression of AR, expression of splice variants
of AR and alteration in the balance of AR co-regulators. This stage of progression is
termed castrate recurrent prostate cancer (CRPC). Moreover, ADT has many major
undesirable acute and chronic side effects on various normal tissues. Therefore a more
strategic therapy approach is one that would disrupt a functional arm of AR signaling
critical for PC/CRPC growth but not for the essential physiological roles of AR in normal
adult tissues. This thesis describes two different mechanism-based approaches to
develop small molecule drugs that address the above problems.
The transcription factor ELK1 tethers the androgen receptor (AR) to chromatin,
enabling sustained activation of genes critical for growth in prostate cancer cell lines.
The N-terminal A/B domain of AR [AR(A/B)], which excludes the ligand binding pocket
of AR, is adequate for interaction with ELK1. This is significant because the major splice
variants of AR (AR-V7) that lack the ligand binding domain, as well as overexpressed
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full length AR, are known to strongly support growth of castration resistant prostate
cancer (CRPC). In our first approach to develop small molecule drugs for prostate
cancer, we showed that both wtAR and AR-V7 synergize with ELK1 by coopting the two
ERK docking sites on ELK1, independent of the classical mechanism of (transient)
activation of ELK1 via phosphorylation by ERK. As the association of ELK1 and AR is
only required for prostate tumor growth, disrupting this interaction should selectively
inhibit the growth of CRPC cells without interfering with the physiological role of
androgen in normal tissues. Therefore, small molecules that disrupt binding of AR to
ELK1 should inhibit the growth of a broader spectrum of advanced prostate tumors than
androgen ablation or conventional anti-androgen therapies without the many acute and
chronic side effects associated with those treatments. We have developed and
conducted a stringent in situ high throughput screen for small molecules that selectively
disrupt the ELK1-AR synergy. We initially screened over 18,000 compounds from
diversity sets that follow the Lipinski guidelines for “drug-likeliness”. Our top hit from the
screen inhibited ELK1-dependent promoter activation by androgen in a dose-dependent
manner but did not inhibit promoter activation via canonical androgen response
elements. Follow up structure-activity studies identified a lead compound that was much
more stable than the initial hit. We report discovery of this small molecule (KCI807) that
selectively disrupts ELK1-dependent promoter activation by wild-type and variant forms
of AR without interfering with ELK1 activation by ERK. KCI807 has an obligatory flavone
scaffold and functional hydroxyl groups on C5 and C3'. KCI807 binds to purified AR,
blocking ELK1 binding, and selectively blocks recruitment of AR to chromatin by ELK1.
KCI807 narrowly affects a subset AR target growth genes and selectively inhibits AR-
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dependent growth of PCa cell lines and Enzalutamide-resistant PCa tumor xenografts.
The results offer a mechanism-based therapeutic paradigm for disrupting the AR growth
signaling axis in the spectrum of prostate tumors while avoiding global attenuation of
testosterone actions.
The second approach to developing new small molecule drugs against prostate
cancer involved the development of hybrid molecules. Histone deacetylase inhibitors
(HDACis) can disrupt androgen signaling through the down regulation of heat shock
protein 90 (HSP90). However despite their ineffectiveness in prostate cancer (PCa)
cells non-selective toxicities are associated with these molecules. We designed hybrid
molecules containing partial scaffolds of the AR targeted drug, enzalutamide, and the
HDAC inhibitor, suberoylanilide hydroxamic acid (SAHA), to weaken the intrinsic panHDACi activity of the molecule and to selectively target the cytosolic AR-HSP90
complex in AR overexpressing and enzalutamide-resistant PCa cells. These new
molecules, 2-75 and 1005, showed reduced potency in intrinsic HDAC inhibitor activity,
degraded the HSP90 chaperone protein, induced hyper acetylation of the HDAC6
substrate α tubulin, induced p21, and caused loss of viability of the enz-resistant C4-2
cells all to a greater extent compared to either parent compound alone. These results
suggested that these new molecules could be used as prototypes for the development
of hybrid HDAC inhibiting drugs with reduced pan HDAC inhibitor activity and increased
selectivity for AR overexpressing PC cells.
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